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Background: Children with juvenile idiopathic arthritis (JIA) are at risk of uveitis. The role of adalimumab
(Humira®; AbbVie Inc., Ludwigshafen, Germany) in the management of uveitis in children needs to be
determined.
Objective: To compare the efficacy, safety and cost-effectiveness of adalimumab in combination with
methotrexate (MTX) versus placebo with MTX alone, with regard to controlling disease activity in refractory
uveitis associated with JIA.
Design: This was a randomised (applying a ratio of 2 : 1 in favour of adalimumab), double-blind, placebo-
controlled, multicentre parallel-group trial with an integrated economic evaluation. A central web-based
system used computer-generated tables to allocate treatments. A cost–utility analysis based on visual acuity
was conducted and a 10-year extrapolation by Markov modelling was also carried out.
Setting: The setting was tertiary care centres throughout the UK.
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Participants: Patients aged 2–18 years inclusive, with persistently active JIA-associated uveitis (despite
optimised MTX treatment for at least 12 weeks).
Interventions: All participants received a stable dose of MTX and either adalimumab (20 mg/0.8 ml for
patients weighing < 30 kg or 40 mg/0.8 ml for patients weighing ≥ 30 kg by subcutaneous injection every
2 weeks based on body weight) or a placebo (0.8 ml as appropriate according to body weight by subcutaneous
injection every 2 weeks) for up to 18 months. A follow-up appointment was arranged at 6 months.
Main outcome measures: Primary outcome – time to treatment failure [multicomponent score as defined
by set criteria based on the Standardisation of Uveitis Nomenclature (SUN) criteria]. Economic outcome –
incremental cost per quality-adjusted life-year (QALY) gained from the perspective of the NHS in England
and Personal Social Services providers. Full details of secondary outcomes are provided in the
study protocol.
Results: A total of 90 participants were randomised (adalimumab, n = 60; placebo, n = 30). There were
14 (23%) treatment failures in the adalimumab group and 17 (57%) in the placebo group. The analysis
of the data from the double-blind phase of the trial showed that the hazard risk (HR) of treatment failure
was significantly reduced, by 75%, for participants in the adalimumab group (HR 0.25, 95% confidence
interval 0.12 to 0.51; p < 0.0001 from log-rank test). The cost-effectiveness of adalimumab plus MTX was
£129,025 per QALY gained. Adalimumab-treated participants had a much higher incidence of adverse
and serious adverse events.
Conclusions: Adalimumab in combination with MTX is safe and effective in the management of
JIA-associated uveitis. However, the likelihood of cost-effectiveness is < 1% at the £30,000-per-QALY
threshold.
Future work: A clinical trial is required to define the most effective time to stop therapy. Prognostic
biomarkers of early and complete response should also be identified.
Trial registration: Current Controlled Trials ISRCTN10065623 and European Clinical Trials Database
number 2010-021141-41.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 15.
See the NIHR Journals Library website for further project information. This trial was also funded by Arthritis
Research UK (grant reference number 19612). Two strengths of adalimumab (20 mg/0.8 ml and 40 mg/0.8ml)
and a matching placebo were manufactured by AbbVie Inc. (the Marketing Authorisation holder) and supplied
in bulk to the contracted distributor (Sharp Clinical Services, Crickhowell, UK) for distribution to trial centres.
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Plain English summary
Juvenile idiopathic arthritis (JIA) is one of the most common rheumatic diseases in children and youngpeople, who are at risk of developing inflammation in an area of the eye called the uvea (called uveitis).
The purpose of the study was to look at how effective the use of adalimumab in combination with
methotrexate (MTX) is compared with using MTX alone to treat JIA-associated uveitis.
A total of 90 children (aged 2–18 years) taking MTX with JIA-associated uveitis took part in the study.
If the inflammation in a patient’s eye or eyes was not getting better during the 18 months, the patient was
told to stop taking the study drug.
It was found that those patients who were taking placebo and MTX in the trial stopped taking the study
drug sooner than those who were taking adalimumab and MTX. This means that adalimumab and MTX
was better at treating uveitis than MTX alone.
It was found that more patients taking adalimumab and MTX together either reduced or stopped taking
topical steroids than the patients taking placebo and MTX.
It was found that patients taking adalimumab and MTX together experienced more side effects than
those taking placebo with MTX. However, these were expected based on what was already known about
adalimumab’s side effects.
An economic evaluation was conducted to estimate whether or not adalimumab would represent value for
money for the NHS for this condition. This included long-term effects based on information about patients’
clarity of vision. The analysis showed that adalimumab may not be cost-effective, as the additional costs
of treatment may not be justified by the benefits.
The final results show that although adalimumab used in combination with MTX does help to treat
patients with JIA and uveitis, it may not represent good value for the NHS.
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Scientific summary
Background
Juvenile idiopathic arthritis (JIA) is the most common paediatric rheumatic disease. Children with JIA are at
significant risk of inflammation of the uvea (uveitis). Approximately 12–38% of patients with JIA develop
uveitis within 7 years following the onset of arthritis. Despite current screening and therapeutic options,
up to 15% of children with JIA-associated uveitis may develop bilateral visual impairment and be certified
legally blind.
Experimental models of autoimmune uveitis demonstrate that tumour necrosis factor alpha (TNF-α) plays a
pivotal role in pathogenesis, which is borne out in the treatment of adult uveitis and paediatric case series.
Adalimumab (Humira®; AbbVie Inc., Ludwigshafen, Germany) is a fully human anti-TNF-α monoclonal
antibody. A multicentre randomised, double-blind, parallel-group trial has shown significant benefit in
children with active rheumatoid arthritis.
The randomised controlled trial of the clinical effectiveness, SafetY and Cost-effectiveness of Adalimumab
in Combination with MethOtRExate for the treatment of juvenile idiopathic arthritis associated uveitis
(SYCAMORE) was conducted to assess the role of adalimumab in the treatment of methotrexate
(MTX)-refractory JIA-associated uveitis.
Aims and objectives
The primary objective of the trial was to compare the clinical effectiveness of adalimumab in combination
with MTX versus placebo with MTX alone, with regard to controlling disease activity in refractory uveitis
associated with JIA.
The secondary objectives of the trial were to:
l evaluate short-term safety and tolerability of adalimumab in combination with MTX versus MTX alone,
with regard to ocular complications of treatment, adverse events (AEs) and laboratory assessments
l determine quality of life and cost-effectiveness of adalimumab in combination with MTX versus MTX
alone in severe uveitis associated with JIA
l determine the clinical effectiveness of adalimumab in combination with MTX versus MTX alone,
with regard to underlying JIA disease activity
l determine the durability and magnitude of adalimumab efficacy response in sustaining inactive disease
and achieving complete clinical remission
l determine the long-term safety of adalimumab in combination with MTX versus MTX alone
l assess the efficacy of treatment with adalimumab to permit concomitant medication reduction,
in particular regional and parenteral steroids
l develop a fully consented, trial-related tissue bank for subsequent investigation.
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Methods
Study design
This was a randomised, parallel-group, double-blind, placebo-controlled, multicentre clinical trial that
compared the effects of adalimumab in combination with MTX with placebo in combination with MTX in
participants with active uveitis in association with JIA refractory to MTX monotherapy.
Participants were randomised in a ratio of 2 : 1 (in favour of adalimumab) to receive up to 18 months
of the randomised treatment. Once treatment had stopped, participants were followed up for a further
6 months. The primary outcome (treatment failure) was assessed by a blinded assessor at each scheduled
or unscheduled visit.
The trial also included an economic evaluation to estimate the incremental cost per quality-adjusted
life-year (QALY) with adalimumab in addition to MTX, versus MTX alone.
Eligibility criteria
Children and adolescents aged 2–18 years with active JIA-associated uveitis, despite stable MTX treatment
for at least 12 weeks, were eligible for randomisation.
Exclusion criteria were previous exposure to adalimumab, previous exposure to another biologic (within
five half-lives), receipt of more than six topical glucocorticoid drops per eye per day and receipt of prednisone
(or equivalent) at a dose exceeding 0.2 mg/kg of body weight per day.
Recruitment
The trial took place in 17 centres throughout the UK, 14 of which randomised at least one participant.
Randomisation and blinding
Participants were randomised in a 2 : 1 ratio (in favour of adalimumab); randomisation sequences were
computer-generated, stratified by centre.
Participants, investigators and study personnel were all blinded to the study medication that the participant
received. Pharmacy department staff were not blinded to the study medication that the participant received.
Outcome measures
Primary outcome
The primary end point of the study was ‘time to treatment failure’. ‘Treatment failure’ was defined by the
presence of one or more of the following factors:
l Anterior segment inflammatory score grade [Standardisation of Uveitis Nomenclature (SUN) criteria] –
¢ two-step increase from baseline in SUN cell activity score (anterior chamber cells) over two
consecutive readings
¢ sustained non-improvement with entry grade of ≥ 3 for two consecutive readings
¢ only partial improvement (1+ grade) or no improvement from baseline, with development of other
ocular comorbidities (defined below) that are sustained
¢ worsening of existing (on enrolment) ocular comorbidities (defined below) after 3 months
¢ sustained scores recorded at entry grade, measured over two consecutive readings (grade 1 or 2)
and still present after 6 months of therapy.
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In addition, following at least 3 months of therapy, treatment failure was met if any of the following
factors were met:
l Use of concomitant medications – at any time, requirement for concomitant medications in a manner
outside the predefined acceptable criteria or for any of the concomitant medications not allowed.
l Intermittent or continuous suspension of study treatment (adalimumab or placebo) for a cumulative
period of longer than 4 weeks.
l Ocular comorbidities, defined as:
i. disc swelling and/or cystoid macular oedema (as gauged clinically and when possible by optical
coherence tomography evidence)
ii. raised intraocular pressure (IOP) (> 25 mmHg) sustained over two consecutive visits (not responding
to a single ocular hypotensive agent)
iii. hypotony (< 6 mmHg) sustained over two consecutive visits
iv. development of an unexplained reduction in vision over two consecutive visits of 0.3 logarithm of
the minimum angle of resolution (logMAR) units (in the event of cataracts, participants will remain
in the trial; if cataract surgery is required, failure will still remain as described in end points above)
Please note that an IOP of ≥ 25 mmHg or < 6 mmHg was an exclusion criterion at baseline. Ocular
comorbidities (i)–(iv) could be developed during follow-up only; (i) may worsen based on the existing
(on enrolment) ocular comorbidity.
Secondary outcomes
l Number of participants failing treatment.
l Incremental cost-effectiveness of adalimumab added to MTX, compared with MTX alone.
l Health status according to the multiattribute Health Utility Index Mark 3 (HUI3).
l Safety, tolerability and compliance defined as follows:
¢ AEs and serious adverse events (SAEs)
¢ laboratory parameters (haematological and biochemical analysis and urinalysis)
¢ participant diaries and dosing records determined tolerability and compliance throughout the trial
treatment period.
l Use of corticosteroids over the duration of the study period and throughout follow-up, including
the following:
¢ total oral corticosteroid dose
¢ reduction and reduction rate of systemic corticosteroid dose from entry dose
¢ topical corticosteroid use (frequency) compared with use at time of entry
¢ need for pulsed corticosteroid.
l Optic and ocular outcomes, defined as follows:
¢ number of participants with disease flares (defined by worsening based on SUN criteria) following a
minimum of 3 months of disease control
¢ number of participants with disease flares within the first 3 months of the study
¢ visual acuity as measured by age-appropriate logMAR assessment
¢ number of participants with resolution of associated optic nerve or macular oedema [as assessed by
slit lamp biomicroscopy or optical coherence tomography (when available)]
¢ number of participants with disease control (defined as zero cells with topical treatment for 3 and 6 months)
¢ number of participants entering disease remission (defined as zero cells without topical treatment
for 3 and 6 months)
¢ duration of sustaining inactive disease (zero cells with or without topical treatment).
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l Quality-of-life assessments [as assessed via the Childhood Health Questionnaire (CHQ) and Childhood
Health Assessment Questionnaire (CHAQ)].
l American College of Rheumatology (ACR) Pedi core set criteria at ACR 30, 50, 70, 90 and 100 levels.
l Number of participants with disease flares, in remission on and/or off medication, related to their JIA
and with minimum disease activity.
l Number of participants requiring change in biological and/or disease-modifying antirheumatic drug
therapy for arthritis due to failure to respond.
l Juvenile Arthritis Disease Activity Score.
Sample size
The total target number of participants was 114 (adalimumab, n = 76; placebo with MTX, n = 38).
Statistical methods
Primary and secondary outcome data were analysed following the intention-to-treat (ITT) principle. Safety
analyses included participants’ data if they had received at least one dose of the randomised treatment.
The statistical analysis plans were developed prior to the analyses being conducted.
The primary outcome was ‘time to treatment failure’ and was analysed at two planned interim analyses;
the final analysis used Kaplan–Meier curves and the log-rank test. Nine predefined sensitivity analyses were
conducted to test the robustness of the primary analyses to different assumptions.
The secondary outcomes were analysed using the following methods: binary outcomes were analysed
using the chi-squared test, time-to-event data and longitudinal data were analysed using joint modelling,
time-to-event data with competing risks were analysed using a competing risk model, continuous data were
analysed using t-tests or random intercept models and count data were analysed using Poisson regression.
Economic analysis
The economic analysis adopted the perspective of the NHS in England and Personal Social Services providers.
Resource use was estimated using questionnaires and via medical records, and utilities were estimated via
the HUI3 multiattribute utility scoring system. Costs were based on 2016 prices, and both costs and QALYs
were discounted at 3.5% after the first year. Missing utility data were handled using multiple imputation.
Costs and QALYs were analysed using an instrumental variable regression approach to account for patients
having access to adalimumab during the open-label phase of the trial. A trial-based evaluation, based on the
ITT population, was extrapolated by 10 years using a Markov model in order to assess the long-term costs
and consequences of adalimumab treatment. The primary outcome of the economic evaluation was the
incremental cost per QALY with adalimumab in addition to MTX versus MTX alone. Probabilistic sensitivity
analyses assessed the impact of parameter uncertainty, and scenario analyses were conducted to assess the
impact of varying (1) the proportion of patients continuing adalimumab after the end of the study; (2) the
duration of post-study access to adalimumab; (3) patient adherence to adalimumab and MTX; (4) the time
horizon of analysis; (5) the unit price of adalimumab; (6) visual impairment rates, using the most and least
favourable combinations; and (7) the discount rate of future costs and benefits.
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Results
Recruitment to the trial was halted based on the results of the second interim analysis of the trial data.
These data showed that there was significant evidence that adalimumab was more effective than placebo.
The Independent Data and Safety Monitoring Committee (IDSMC) made the recommendation to stop
recruitment and unblind the participants who were on trial treatment at that time. Participants who were
on placebo stopped taking their randomised treatment and entered the follow-up period of the trial;
participants who were on adalimumab continued with their treatment as per the protocol.
The trial had three distinct phases: the double-blind phase of the trial refers to the period of time that
participants were on treatment prior to the IDSMC recommending that unblinding of allocations should
take place; the open-label phase of the trial refers to the period of time that participants were on treatment
following the IDSMC recommendation to unblind treatment allocations (this phase of the trial only contained
participants who were on adalimumab); and the follow-up phase of the trial is the period of time that
followed discontinuation of treatment.
The total number of participants analysed was 90 (adalimumab, n = 60; placebo, n = 30).
The analysis of the data from the double-blind phase of the trial showed that the hazard of treatment
failure was significantly reduced by 75% for participants in the adalimumab group [hazard ratio (HR)
0.25, 95% confidence intervals (CI) 0.12 to 0.51; p < 0.0001 from log-rank test]. Additional data collected
during the open-label phase of the trial continued to support this conclusion for the integrated analysis of
the double-blind and open-label data. The results of the sensitivity analyses showed that the conclusions
of the primary analysis were robust to changes that were made. These results all remained highly
statistically significant.
The results of the analysis of the secondary outcomes strengthen the evidence to support the effectiveness
of adalimumab over placebo.
Adalimumab-treated patients had a much higher incidence of AEs and SAEs. However, this difference was
not deemed to be clinically significant and the differences observed between the adalimumab and placebo
groups in terms of the frequency of AEs and SAEs, or for the laboratory parameters, were as expected for
this population. Data collected during the follow-up period for laboratory parameters continued to show no
clinically significant differences between the two treatment groups.
The total costs associated with adalimumab treatment over the time horizon of the 18-month trial plus
10-year extrapolation were £70,951 [95% credible range (CR) £45,204 to £123,764] The corresponding
costs of the placebo arm were £31,587 (95% CR £5308 to £83,320). Total mean QALYs were 8.60
(95% CR 8.00 to 9.19) and 8.29 (95% CR 7.42 to 9.17) for the adalimumab and placebo arms, respectively.
The incremental cost-effectiveness ratio (ICER) was £129,025 per QALY gained. In 96% of simulations,
adalimumab was both more costly and more effective; however, the probability of cost-effectiveness at the
£30,000 per QALY threshold was < 1%.
Conclusions
Adalimumab significantly controlled inflammation and reduced the rate of treatment failure in patients
with active uveitis on a stable dose of MTX. Adalimumab-treated patients had a much higher incidence of
AEs and SAEs, and the treatment is not cost-effective at the £30,000-per-QALY threshold.
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Recommendations for future research
This trial demonstrated effective achievement of inactive disease using a combination of adalimumab
and MTX. A clinical trial is now needed to determine which treatment regimen (continuing or stopping
adalimumab) will result in shorter time to recurrence of ocular inflammation in patients with quiescent
JIA-associated uveitis.
There is also a need to identify effective clinical biomarkers of early and complete response.
Trial registration
This trial is registered as ISRCTN10065623 and European Clinical Trials Database EudraCT number
2010-021141-41.
Funding
Funding for this study was provided by the National Institute for Health Research Health Technology
Assessment programme and Arthritis Research UK (grant reference 19612). Two strengths of adalimumab
(20 mg/0.8 ml and 40 mg/0.8 ml) and a matching placebo were manufactured by AbbVie Inc. (the Marketing
Authorisation holder) and supplied in bulk to the contracted distributor (Sharp Clinical Services, Crickhowell, UK)
for distribution to trial centres.
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Chapter 1 Introduction
Scientific background
Children with juvenile idiopathic arthritis (JIA), the most common rheumatic disease in children, are at risk
of inflammation of the uvea in the eye (uveitis). Overall, 20–25% of all paediatric uveitis is associated with
JIA.1,2 Several major risk factors are known for the development of uveitis in JIA, including oligoarticular
pattern of arthritis, onset of arthritis at < 7 years of age and antinuclear antibody positivity.3 Generally, in
the initial stages of mild to moderate inflammation, the uveitis is entirely asymptomatic; therefore, current
practice is to screen all children with JIA regularly for uveitis. Between 12% and 38% of patients with
JIA will develop uveitis in the initial 7 years following the onset of arthritis.4,5 Structural complications are
present in 30–50% of children with JIA-associated uveitis at diagnosis.6 Importantly, 50–75% of those
children with severe uveitis will eventually develop visual impairment secondary to ocular complications
including cataracts, glaucoma, band keratopathy and macular pathology.7–9 Defining the severity of
inflammation and structural complications in uveitis patients can now be more consistently described
following Standardisation of Uveitis Nomenclature (SUN) guidelines.10 These guidelines allow incorporation
into randomised controlled trials and cohort studies.10
Poor prognosticators of poor visual acuity include structural changes at presentation, need for intraocular
surgery, posterior segment inflammation, abnormal intraocular pressure (IOP) and the failure to maintain
long-term disease control as marked by persistent anterior chamber (AC) cell scores of ≥ 1+.6–8,11 Despite
current screening and therapeutic options (pre biologics), some 10–15% of children with JIA-associated
uveitis may eventually develop bilateral visual impairment and will be certified legally blind.12,13 It is,
therefore, critical to find more effective therapeutic interventions.
Rationale for research
Methotrexate (MTX) is well established as the first-line disease-modifying agent in the management of
JIA.14,15 Topical corticosteroids are among the current approaches to treatment of mild JIA-associated
uveitis. In children with moderate to severe JIA-associated uveitis, MTX is also effective.16–18 However,
there have been no prospective randomised placebo-controlled trials of MTX or corticosteroid regimens
for JIA-associated uveitis.
A systematic review of the evidence of the use of MTX in JIA is restricted to joint involvement14 and does
not include paediatric uveitis. Despite the scarce evidence, MTX has become the mainstay of treatment
for JIA-uveitis.19 However, up to 15–50% of children will have refractory uveitis in spite of optimal therapy
with MTX.16–18 In a small study,20 some 30% of patients started on MTX for JIA-associated uveitis did
not achieve disease control during the first year of therapy and, even when remission was achieved with
MTX, nearly 70% of patients will later relapse, suggesting that only 4 out of 22 (18%) patients achieved
total remission.13 In a Dutch study, only 12% were found to be in total remission 5 years after starting
MTX.20 In small, retrospective case series, other agents including ciclosporin and mycophenolate mofetil
have been shown to be of partial benefit in controlling JIA-uveitis.21,22 However, there is little evidence
that they rescue MTX-refractory patients and their use is restricted because of intolerability and adverse
reactions. Neither ciclosporin nor mycophenolate mofetil is very effective in controlling joint manifestations
of JIA in children.19
More recently, animal models and corroborative human evidence23 support the role of tumour necrosis
factor alpha (TNF-α) in the aetiopathogenesis of uveitis and, moreover, the potential value of its inhibition
as a therapeutic intervention.24 Studies on experimental models of autoimmune uveitis have demonstrated
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that TNF-α plays a pivotal role in pathogenesis of intraocular inflammation,23 which has been borne out in
treatment of adult uveitis.24 In mouse models of anterior uveitis, deleting the TNF p55 receptor alone is as
effective as combined tumour necrosis factor p55 and p75 knockout animal in demonstrating reduced
ocular inflammation,25 equivalent to the effect of tumour necrosis factor p55 fusion protein.26 In an animal
model of uveitis, infliximab reduced disease severity,27 albeit at doses of 20 mg/kg.
Translating this to humans, several case series have been published demonstrating the efficacy of infliximab
and adalimumab (Humira®; AbbVie Inc., Ludwigshafen, Germany) in the treatment of severe refractory
uveitis in adults and children.28–33 In contrast, etanercept has been reported not to halt the onset of uveitis or
be more effective than placebo,34,35 and is less effective than infliximab in treating JIA-uveitis.31,36,37 There are
a number of reports of new-onset uveitis associated with etanercept use in JIA.38 An adverse events (AEs)
register-based study examining these cases determined that, although the frequency was greater for
etanercept than for infliximab or adalimumab (n = 20, 4 and 2 cases, respectively), causality could not
be established.39 Etanercept is not considered to be effective in treating intraocular inflammation.31
Intervention
Adalimumab is a fully human monoclonal antibody, engineered by gene technology that uses site-directed
mutagenesis to enhance its binding efficiency to TNF-α. It does not contain non-human or artificial protein
sequences. Adalimumab binds only to TNF-α and has an elimination half-life of approximately 2 weeks.
The antibody has been studied extensively in vitro as well as in vivo and in animal toxicology experiments.
A clinical trial of adalimumab as monotherapy or in combination with MTX in adult subjects with
rheumatoid arthritis showed a significant clinical response.40 In children with JIA, a multicentre randomised,
double-blind stratified parallel-group trial has shown a significant benefit in children with active arthritis:
disease flares (the primary end point) occurred in a significantly lower percentage of those receiving
adalimumab than of those receiving placebo [13 of 30 (43%) vs. 20 of 28 (71%); p = 0.03].41
Studies in paediatric non-infectious uveitis have shown very promising results with adalimumab, with
21 out of 26 eyes from 14 children with JIA- or idiopathic-uveitis showing improvement in inflammation.42
In another retrospective case series of 18 paediatric patients with uveitis, 88% had a substantial decrease
in ocular inflammation and adalimumab showed corticosteroid-sparing potential.28
At the time of starting the randomised controlled trial of the clinical effectiveness, SafetY and Cost-effectiveness
of Adalimumab in Combination with MethOtRExate for the treatment of juvenile idiopathic arthritis
associated uveitis (SYCAMORE), there were no prospective studies of efficacy and safety of anti-TNF-α agents
in JIA-associated uveitis, or of their cost-effectiveness. In the randomised controlled trial of adalimumab in
JIA that demonstrated efficacy and supported its safety, the most commonly reported AEs were infections
and injection-site reactions.41 Serious adverse events (SAEs) that were considered to be possibly related to the
study drug by the investigator occurred in 14 patients. Seven of these included one case of bronchopneumonia,
one of herpes simplex infection, one of pharyngitis and one of pneumonia, and two cases of herpes zoster
infection. In this trial, there were no deaths, malignant conditions, opportunistic infections, cases of tuberculosis,
demyelinating diseases or lupus-like reactions.41 The fixed-dose model of fortnightly 20 mg of adalimumab
(for 16 weeks) for children weighing < 30 kg and 40mg for children weighing ≥ 30 kg selected for this trial is
based on the data generated in the previously mentioned trial using the same dosing regimen.41
Although there are no published economic evaluations of JIA-associated uveitis, there are a number of
economic evaluations of anti-TNF-α agents (including adalimumab) in JIA. These are of interest but limited
applicability, because they are not directly transferable for estimating the cost-effectiveness of treatment
in the context of uveitis management. The only study to adopt a costing perspective of the NHS in the
UK is Shepherd et al.,43 who constructed a cost–utility Markov model to compare abatacept, adalimumab,
etanercept and tocilizumab44–47 in JIA using disease flare as the measure of efficacy. The analysis was
based on four economic evaluations of biological disease-modifying antirheumatic drugs (DMARDs) in JIA.
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Utility values were sourced from the Prince et al. study.47 The incremental cost-effectiveness ratios (ICERs)
for adalimumab, etanercept, tocilizumab and abatacept, versus MTX, were £38,127, £32,256, £38,656
and £39,536 per quality-adjusted life-year (QALY), respectively. The model results were found to be most
sensitive to changes in utility values and the differences in cost-effectiveness of the biological DMARDs
were primarily due to differences in drug acquisition cost. A limitation common to economic analyses in
JIA is the challenge of obtaining valid utility scores and extrapolation of effects over a longer time period,
both of which can significantly influence cost-effectiveness. A recent economic evaluation of adalimumab
and dexamethasone intravitreal implant (Ozurdex®; Allergan Ltd, Marlow, UK) for treating non-infectious
intermediate uveitis, posterior uveitis or panuveitis in adults indicated that adalimumab was not cost-
effective at £94,523 per QALY gained in active uveitis,48 but these findings may not be generalisable to
children with active JIA-associated uveitis. The aim of the economic evaluation as part of the SYCAMORE
trial was to assess the cost-effectiveness of adalimumab, based on utility and cost data acquired directly
within the trial, and extrapolated using data on representative patients from routine care.
Objectives
The primary objective of the trial was to compare the clinical effectiveness of adalimumab in combination
with MTX versus placebo with MTX alone, with regard to controlling disease activity in refractory uveitis
associated with JIA.
The secondary objectives of the trial were to:
l evaluate short-term safety and tolerability of adalimumab in combination with MTX versus MTX alone,
with regard to ocular complications of treatment, AEs and laboratory assessments
l determine quality of life and cost-effectiveness of adalimumab in combination with MTX versus MTX
alone in severe uveitis associated with JIA
l determine the clinical effectiveness of adalimumab in combination with MTX versus MTX alone, with
regard to underlying JIA disease activity
l determine the durability and magnitude of adalimumab efficacy response in sustaining inactive disease
and achieving complete clinical remission
l determine the long-term safety of adalimumab in combination with MTX versus MTX alone
l assess the efficacy of treatment with adalimumab to permit concomitant medication reduction, in
particular regional and parenteral steroids
l develop a fully consented, trial-related tissue bank for subsequent investigation.
DOI: 10.3310/hta23150 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 15
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Ramanan et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
3

Chapter 2 Trial design and methods
Study design
This was a randomised, parallel-group, double-blind, placebo-controlled, multicentre clinical trial that
compared the effects of adalimumab in combination with MTX versus placebo in combination with MTX
in participants with active uveitis in association with JIA refractory to MTX monotherapy. Participants were
randomised applying a ratio of 2 : 1 (in favour of adalimumab), stratified by centre.
Patients with persistently active JIA-associated uveitis (despite optimised MTX treatment for at least
12 weeks) were recruited from tertiary care centres throughout the UK.
A schematic of the study design can be seen in Figure 1.
No
Participant fulfilling eligibility criteria and
providing fully informed written consent
Randomise
Fortnightly subcutaneous injections of adalimumab
plus MTX 
Fortnightly subcutaneous injections of placebo
plus MTX 
Treatment months 1 – 3
Monthly OPD review: completion of QoL and health 
economic questionnaires, AE review, and ophthalmology 
and rheumatology review
Treatment months 4 – 18
3-monthly OPD review: completion of QoL and
health economic questionnaires, AE review, and
ophthalmology and rheumatology review
No
Post-treatment follow-up, months 19 – 24
3-monthly OPD review: completion of QoL
and health economic questionnaires, AE review, 
and ophthalmology and rheumatology review
Yes
Cease trial
treatment
FIGURE 1 The SYCAMORE study design. OPD, outpatient department; QoL, quality of life.
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The trial protocol has previously been published in an open access journal.49
Trial registration and ethics
The trial was registered on EudraCT on 1 June 2010 (EudraCT number 2010-021141-41) and received
Clinical Trials Authorisation from The Medicines and Healthcare products Regulatory Agency on 9 May
2011 (Clinical Trials Authorisation reference number 12893/0228/001). The trial, and all subsequent
protocol amendments, were reviewed and authorised by the Medicines and Healthcare products
Regulatory Agency.
The trial protocol was not initiated until it had received the favourable opinion of the Main Research Ethics
Committee (London – Hampstead Research Ethics Committee 11/LO/0425) on 24 June 2011. It was then
reviewed at the research and development offices at participating sites.
The trial and any subsequent amendments were reviewed and approved by the National Research Ethics
Service Committee London – Hampstead.
The trial was listed on the International Standard Randomised Controlled Trials Number (ISRCTN) register
on the 2 September 2011 (ISRCTN10065623) and adopted onto the Medicines for Children Research
Network and co-adopted onto the Ophthalmology portfolio on the 10 May 2011.
Participant inclusion and exclusion criteria
Patients who met the following eligibility criteria were considered for the trial.
Inclusion criteria
l Children and young people aged ≥ 2 and < 18 years who fulfilled the International League of
Associations for Rheumatology (ILAR) diagnostic criteria for JIA (all subgroups that had uveitis).
l At the time of trial screening, the participant must have had active anterior uveitis, defined as a
‘sustained grade of cellular infiltrate in AC of the SUN criteria10 grade > 1+ during the preceding
12 weeks of therapy despite MTX and corticosteroid (both systemic and topical) therapy’.10 The latest
date of SUN grade score must have been the date of the screening visit.
l Participants must have failed MTX (minimum dose of 10–20 mg/m2 once per week, with a maximum
dose of 25 mg per participant). The participant must have been on MTX for at least 12 weeks and have
been on a stable dose for 4 weeks prior to screening visit. (Omission of a maximum of 2 weeks’ MTX
treatment within the 12 weeks was acceptable and did not render the patient ineligible, unless they
were missed in the 4 weeks prior to the screening visit.)
l No disease-modifying immunosuppressive drugs, other than MTX, in the 4 weeks prior to screening
were allowed.
l Written informed consent of adult participant or parent/legal guardian of minor, and assent, when
appropriate, must have been received.
l Participant and parent/legal guardian must have been willing and able to comply with
protocol requirements.
l Participants of reproductive potential (males and females) must have been willing to use a reliable
means of contraception throughout their trial participation. Post-pubertal females must have had a
negative serum pregnancy test within 10 days before the first dose of the trial drug.
l Participant must have been able to be randomised and commence trial treatment within 2 weeks of the
screening visit.
Exclusion criteria
l Uveitis without a diagnosis of JIA.
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l Currently on adalimumab or had previously received adalimumab.
l Have been on other biological agent within previous five half-lives of agent.
l More than six topical steroid drops per eye per day prior to screening (this dose must have been stable
for at least 4 weeks prior to screening visit).
l For patients on prednisone or prednisone equivalent, change of dose within 30 days prior to screening.
l For patients on prednisone or prednisone equivalent with a dose > 0.2 mg/kg per day.
l Intra-articular joint injections within 4 weeks prior to screening.
l Any ongoing chronic or active infection (including infective uveitis) or any major episode of infection
requiring hospitalisation or treatment with intravenous antibiotics within 30 days or oral antibiotics
within 14 days prior to the screening evaluation.
l History of active tuberculosis of < 6 months treatment or untreated latent tuberculosis.
l Participant has history of central nervous system neoplasm, active infection, demyelinating disease,
or any progressive or degenerative neurological disease.
l Poorly controlled diabetes or persistently poorly controlled severe hypertension (> 95th percentile for
height/age), as deemed by the treating physician.
l Previous history of malignancy.
l Intraocular surgery within the 3 months prior to screening (cataract/glaucoma/vitrectomy).
l Intraocular or periocular corticosteroids within 30 days prior to screening.
l History of ocular herpetic disease.
l Pregnant or nursing female.
l Demonstrations of clinically significant deviations in any of the following laboratory parameters:
¢ a platelet count of < 100,000/mm3
¢ a total white cell count of < 4000 cells/mm3
¢ a neutrophil count of < 1000 cells/mm3
¢ aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels of > 2× the upper limit of
normal or serum bilirubin > 2× the upper limit of normal
¢ a glomerular filtration rate (GFR) of < 90 ml/minute/1.73 m2 [GFR (ml.minimum/1.73 m2 body
surface area)] = 0.55 × height (cm)/plasma creatinine (mg/dl)
¢ a haematocrit of < 24%.
l Having been administered a live or attenuated vaccine within 3 months prior to screening.
l Previous randomisation into SYCAMORE to either arm of the trial.
l An intraocular pressure of < 6 mmHg or > 25 mmHg.
l Intraocular pressure control requiring more than one topical pressure-lowering therapy or requiring
systemic acetazolamide.
Recruitment
Recruitment took place in 14 tertiary care centres throughout the UK. Participants were identified through
rheumatology and ophthalmology outpatient clinics. Most tertiary care centres also set up referral links
with local district general hospitals.
Informed consent
This trial recruited minors and young people aged < 16 years. Informed consent procedures reflected the legal
and ethics requirements to obtain valid informed consent for this population. Prior written informed consent
was required for all trial participants. In obtaining and documenting informed consent, the investigator
complied with applicable regulatory requirements and adhered to good clinical practice and to the ethics
principles that have their origin in the Declaration of Helsinki.50
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Information was provided to potential participants and their families verbally and in writing. All participants
had the opportunity to discuss the project with the responsible investigator at site and/or a designated
member of the research team. Discussions were supported with detailed written, ethics-approved patient
information sheets and consent forms, provided directly to young people able to consent for themselves
(defined in statutory instrument 2004 number 1031 as aged ≥ 16 years51) and parents/legal guardian of
minors (aged < 16 years). Information leaflets appropriate to age and stage of development were provided
to minors and their assent was obtained, when appropriate. Careful presentation was made of the known
risks of the disease and trial medications and the possible benefits, as well as a detailed explanation of the
trial procedures and protocol.
All participants were given the opportunity to ask any questions that may arise and to discuss the study
with their surrogates and were given the time to consider the information prior to agreeing to participate.
All of the recruiting investigators were experienced rheumatologists and/or ophthalmologists familiar with
imparting information to families and young people. All investigators obtaining consent had attended
good clinical practice courses. When potentially eligible minors and young people were identified, they/
their parent/the person with parental responsibility were approached by the investigator, or a designated
member of the investigating team, and an opportunity was given to understand the objectives of the trial.
The treatment schedule and trial visits were in line with standard clinical care, although they were made
aware that additional travel may be needed if the trial assessments required they be reviewed at their
tertiary centre rather than their local hospital. The potential risks and benefits of the anti-TNF-α agent were
discussed, as were treatment failure criteria and what would happen if they chose not to enter the trial or
had to withdraw from the trial for any reason. In addition, the rationale for the use of a placebo and the
applied randomisation ratio was explained.
The right of the patient (non-minors) or parent/legal guardian (for minors) to refuse consent to participate in
the trial without giving reasons was respected. After the patient had entered the trial, the clinician remained
free to give alternative treatment to that specified in the protocol, at any stage, if they felt that it was in the
best interest of the patient. However, the reason for doing so was recorded and the patient remained within
the trial for the purpose of follow-up and data analysis in accordance with the treatment option to which
they had been allocated. Similarly, the patient remained free to withdraw at any time from the protocol
treatment and trial follow-up without giving reasons and without prejudicing their further treatment.
Adequate time to consider trial entry (generally 24 hours, although it was acknowledged that some
patients/families came to a decision sooner) was allowed before written consent of the participant/parent/
legal representative was obtained by the responsible clinician or other designated team member (recorded
on the signature and delegation log).
Randomisation
Randomisation was undertaken during normal working hours (Monday to Friday, 09.00 to 17.00) by the
pharmacy departments of participating centres on receipt of a randomisation request form and prescription
from authorised clinicians. Pharmacy personnel verified that these documents were appropriately completed
before proceeding.
It was the responsibility of the principal investigator or delegated research staff to:
l notify the pharmacy of potential randomisations so that the pharmacy could ensure that adequate drug
supplies were at site
l complete the appropriate trial documents and deliver these to the pharmacy department at their centre
in order that the pharmacy could proceed with a randomisation.
TRIAL DESIGN AND METHODS
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Participants were randomised using a secure (24-hour) web-based randomisation system, which was
controlled centrally by the Clinical Trials Research Centre (CTRC). Randomisation lists were generated in a
2 : 1 ratio in favour of the active therapy. The lists were produced by an independent statistician (based
at CTRC, but otherwise not involved in the trial) in Stata® version 9.2 (StataCorp LP, College Station, TX,
USA) using the ralloc command. The randomisation lists were stratified by centre but in order to reduce the
predictability of the randomisation sequence, the randomisation numbers were sequential across all sites
(rather than within each site) to make it appear that there was no stratification by centre. For smaller sites
(i.e. expected recruitment of < 10), a block size of three was used. For larger sites (i.e. expected recruitment
of at least 10), random block sizes of three and six were used.
Participant treatment allocation was displayed on a secure webpage and an automated e-mail
confirmation was sent to the authorised randomiser.
Description of interventions
All participants received a stable dose of MTX and either adalimumab (20 mg/0.8 ml for participants
weighing < 30 kg or 40 mg/0.8 ml for participants weighing ≥ 30 kg) or placebo (0.8 ml, based on body
weight) via a subcutaneous injection every 2 weeks for a maximum period of 18 months.
All participants in both arms continued to receive a stable dose of MTX at a minimum dose of 10–20 mg/m2
and a maximum dose of 25 mg as a non-IMP throughout the 18-month treatment period.
Clinical trial supplies were to be delivered to an investigator site only once the site had been initiated by
the CTRC, acting on behalf of the sponsor to ensure full ethics and regulatory approvals had been granted.
The size of the shipments to each site were predetermined, based on the participant recruitment target for
that individual site. Recruitment was monitored centrally and drug shipment dates tailored accordingly, to
ensure that pharmacies held adequate supplies of trial treatment. Pharmacies documented all shipment
receipts and provided copies of this documentation to the CTRC. IMP stock was to be received by a designated
member of the pharmacy department and stored at 2–8 °C, with temperature monitoring and in accordance
with IMP regulations. Records of all shipments were to be kept in the pharmacy site file. All temperature
excursions or damage to stock was reported to CTRC, which liaised with AbbVie Inc. for assessment.
The dose of adalimumab or placebo remained the same as at trial entry, regardless of minor fluctuations
in weight that may cause a participant to cross the 30-kg threshold for the upper and lower doses.
The first dose was administered by the research/clinical team looking after the participant. Participants, or a
family member, were invited to self-administer the study treatment after the first dose and taught how to
do this, following the procedures in place within each participating centre. The first self-administered dose
was carried out under the supervision of the clinical team, which would ensure that the participant was
confident and able to carry out all parts of the procedure appropriately and accurately. The trial provided
validated cooler bags for participants to transport their trial medication home. If participants did not want
to self-administer the trial medication, then arrangements were put in place, on an individual basis, to
ensure that trial medication was administered as prescribed.
Investigational medicinal products were labelled in accordance with regulation 46 SI2004/1031 and the
detailed guidance provided in annex 13 of the EU Good Manufacturing Practice (GMP) guide.51
Blinding
Participants, investigators, study personnel, the trial co-ordinator, statisticians and data management
personnel were all blinded to the trial medication that the participant received. Pharmacy department staff
were not blinded to the trial medication that the participant received.
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This trial was placebo controlled and all trial assessments were carried out by health professionals, parents/
carers and participants without knowledge of treatment allocation. The placebo solution for subcutaneous
injection was a clear, colourless solution (matching the adalimumab vial) presented in a single-use vial for
subcutaneous injection in volumes of 0.8 ml.
The packaging of the kit for adalimumab and placebo was identical. Each kit consisted of two vials of
adalimumab or placebo in an outer carton. The vials of adalimumab and placebo were also identical
in appearance.
Treatment allocation was concealed unless knowledge was essential for the ongoing care of the
participant. If knowledge of treatment allocation was required by the responsible investigator, the process
was to obtain it via the pharmacy department at the respective hospital, which would then complete an
unblinding case report form (CRF) and submit this to the CTRC.
All children participating in this study during the active treatment phase of the study were immunosuppressed,
in view of their concomitant MTX therapy and/or potential corticosteroid therapy, irrespective of whether
they were on adalimumab or placebo. In addition, for the purpose of out-of-hours management of the
patient, all participants were presumed to be on anti-TNF-α therapy and managed as such. In this way,
in the event of an AE or SAE, such as an intercurrent infection, the treating clinician managed patients
presuming them to be on anti-TNF-α therapy. For this reason, if unblinding was deemed necessary, this was
carried out via the local pharmacy department following the procedure described below. If out-of-hours
unblinding was required, this was accessed via the local pharmacy department’s on-call service.
Unblinding of individual participants during trial conduct
Procedures regarding potential unblinding were available for a number of relevant clinical scenarios.
On completion of 18 months of treatment
Although discouraged, it was acceptable to unblind participants on completion of their trial treatment
(at 18 months) if this was necessary to enable appropriate ongoing treatment decisions by the
participant’s clinician.
Early withdrawal from treatment
On early withdrawal from trial therapy, breaking the statistical blind was considered only when knowledge
of the treatment assignment was deemed essential for the participant’s care by the participant’s physician,
or a regulatory body. It was considered that it may not always be necessary to know the allocation of
these participants.
Investigators were instructed that if simply ceasing trial treatment was a viable option for the participant’s
care, then it was not necessary for unblinding to occur.
The procedure for unblinding during the course of the trial is set out below. The decision to unblind a
single case was made when knowledge of an individual’s allocated treatment was essential to enable:
l treatment of SAEs
l administration of another therapy that is contraindicated by the trial treatment
l appropriate ongoing care on cessation of allocated trial therapy.
When possible (during office hours), consent for individual unblinding was made via the trial co-ordinator
at CTRC who would seek agreement of one of the lead co-chief investigators (Athimalaipet V Ramanan
and Michael W Beresford).
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Pharmacy departments were unblinded to the treatment allocations of participants within their centre.
It was the principal investigator’s responsibility to ensure that all research personnel were aware of contact
details for obtaining details of treatment allocation, if this was necessary.
The request for the allocated treatment was made to the local pharmacy department. Only the individual
participant was to be unblinded and the following was documented by the pharmacy on the unblinding CRF:
l date the information was needed
l detailed reason for unblinding
l identity of recipients of the unblinding information.
The local investigator ensured that all necessary CRFs to time of unblinding were completed and submitted
to CTRC (if possible, completed before unblinding was performed).
All instances of unblinding were recorded and reported in writing to the CTRC by the local investigator,
including the identities of all recipients of the unblinding information.
Allocation was not routinely revealed to CTRC personnel.
All instances of inadvertent unblinding were recorded and reported in writing to the CTRC by the local
investigator. Reports included:
l date of unblinding
l detailed explanation of circumstances
l recipients of the unblinding information
l action to prevent further occurrence.
Data collection and management
For SYCAMORE, a paper CRF was used to collect participant data at each study visit. The paper CRF was
designed by the Trial Management Group (TMG) and CTRC specifically for the study, in line with the trial
protocol. Completed paper CRFs were transferred from the trial sites to the CTRC; data were then entered
in to a Good Clinical Practice-compliant database (MACRO; Elsevier, Amsterdam, the Netherlands) by
trial staff.
The configuration of the database was specific to SYCAMORE: there were built-in validations on certain
aspects of the trial data. Any missing or inconsistent data were queried with the site using paper data
query forms: query responses were completed by site staff and returned to the CTRC for entry into the
database. A full audit trail of changes to the data was maintained.
Outcome measures
Primary outcome
The primary outcome for the trial was ‘treatment failure’. This was assessed at each scheduled or
unscheduled visit and was defined by one or more of the following:
l Anterior segment inflammatory score grade (SUN criteria10). Following at least 3 months of therapy –
¢ two-step increase from baseline in SUN cell activity score (AC cells) over two consecutive readings
¢ sustained non-improvement with entry grade of ≥ 3 for two consecutive readings
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¢ only partial improvement (1 grade) or no improvement, from baseline, with development of other
ocular comorbidity that is sustained
¢ worsening of existing (on enrolment) ocular comorbidity after 3 months
¢ sustained scores, as recorded at entry grade, measured over two consecutive readings
(grades 1 or 2) still present after 6 months of therapy.
l Use of ineligible concomitant medications: these include medications that are not listed in the prespecified
acceptable criteria or those that were not allowed.
l Intermittent or continuous suspension of study treatment (adalimumab/placebo) for a cumulative period
of no longer than 4 weeks.
Ocular comorbidities were defined as:
i. disc swelling and/or cystoid macular oedema as gauged clinically, and when possible, by optical
coherence tomography evidence
ii. a raised IOP (of > 25 mmHg) sustained over two consecutive visits, not responding to single ocular
hypotensive agent
iii. hypotony (of < 6 mmHg) sustained over two consecutive visits
iv. development of unexplained reduction in vision [logarithm of the minimum angle of resolution (logMAR)]
over two consecutive visits of 0.3 logMAR units (in the event of cataracts, participants remained in the
trial, also if cataract surgery is required. Failure will still remain as described in end points above).
Note that an IOP of ≥ 25 mmHg or < 6 mmHg was an exclusion criterion at baseline and ocular
comorbidities (i)–(iv) could be developed during follow-up only; (i) may worsen based on the existing
(on enrolment) ocular comorbidity.
When a reading was required to be sustained over two consecutive visits to define treatment failure,
the time of treatment failure was taken as the second of these readings.
Secondary outcomes
The following secondary outcomes were also recorded during the course of the trial:
l Number of participants failing treatment.
l Incremental cost-effectiveness of adalimumab added to MTX compared with MTX alone, based on:
¢ health status according to the multiattribute Health Utility Index Mark 3 (HUI3)
¢ resource use, estimated from participant diaries, questionnaires and routine data from patient-level
information and costing systems (PLICS).
l Safety, tolerability and compliance, defined as follows:
¢ AEs and SAEs
¢ laboratory parameters (haematological and biochemical analysis and urinalysis)
¢ participant diaries and dosing records determined tolerability and compliance throughout the trial
treatment period.
l Use of corticosteroids over the duration of the study period and throughout follow-up, including
the following:
¢ total oral corticosteroid dose
¢ reduction and reduction rate of systemic corticosteroid dose from entry dose
¢ topical corticosteroid use (frequency) compared with use at time of entry
¢ need for pulsed corticosteroid.
TRIAL DESIGN AND METHODS
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l Optic and ocular outcomes, defined as follows:
¢ number of participants with disease flares (defined by worsening based on SUN criteria) following
a minimum of 3 months of disease control
¢ number of participants with disease flares within the first 3 months of the study
¢ visual acuity as measured by age-appropriate logMAR assessment
¢ number of participants with resolution of associated optic nerve or macular oedema (as assessed by
slit-lamp biomicroscopy or optical coherence tomography, where available)
¢ number of participants with disease control (defined as zero cells with topical treatment for 3 and
6 months)
¢ number of participants entering disease remission (defined as zero cells without topical treatment
for 3 and 6 months)
¢ duration of sustaining inactive disease (zero cells with or without topical treatment).
l Quality-of-life assessments [as assessed by the Childhood Health Questionnaire (CHQ)52 and Childhood
Health Assessment Questionnaire (CHAQ)53].
l American College of Rheumatology (ACR) Pedi core set criteria54 at ACR 30, 50, 70, 90 and 100 levels
l Number of participants with disease flares,55 in remission on and/or off medication,56 related to their JIA
and with minimum disease activity.57
l Number of participants requiring change in biological and/or DMARD therapy for arthritis because of
failure to respond.
l Participants’ score on the Juvenile Arthritis Disease Activity Score (JADAS).58 The JADAS comprises four
components: a physician’s global assessment of disease activity, parent/patient global assessment of
well-being, active joint count (in 27, 71 or 10 joints) and erythrocyte sedimentation rate.
The outcome ‘development of human antihuman antibody to adalimumab determined with samples collected
at 1, 6 and 18 months’ was removed in version 4.0 of the trial protocol (in substantial amendment 10), because
during the trial it was not possible to collect human antihuman antibody samples.
Data collection tools
Quality of life
Quality of life was measured by the use of CHQ52 and CHAQ.53 Data collection took place on a monthly
basis for the first 3 months, and then 3-monthly until withdrawal from the active phase of trial treatment.
Child Health Assessment Questionnaire
The CHAQ53 is the most widely used functional measure of disability in JIA, both in routine clinical practice
throughout the UK and in clinical trials. Translated into many languages and validated in respective cultures
and countries, it is easily completed and scored. It consists of eight domains, enquiring about the child/
young person’s ability to manage a range of activities of daily living on a 5-point scale. Completion of the
questionnaire was checked by staff.
Childhood Health Questionnaire
The CHQ52 is a generic measure of quality of life used in JIA. It explores a number of important domains
including self-esteem, emotional and behavioural difficulties, and family impact. Completion of the
questionnaire was checked by staff.
Sample size
Sample size calculations were undertaken using nQuery Advisor software version 4.0 (Statistical Solutions,
Saugus, MA, USA).
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Details of the original and revised sample size calculations are given below. Sample size revisions were
necessary as a result of lower patient availability than expected.
Original trial sample size calculation
The original sample size calculation was based on data on failure rates from 62 patients on MTX in a
comparable population provided by Clive Edelsten from Great Ormond Street Hospital for Children NHS
Trust (2008). After 3 months, 11 patients had disease control based on grade 0 SUN criteria (18%) and,
therefore, based on the trial inclusion criteria, would not be eligible for the trial. At 15 months following
the start of treatment with MTX, 23 out of the 51 patients who had failed at 3 months had achieved
disease control (45%), leaving 28 patients (55%) who had not. A total of 140 participants (adalimumab,
n = 93; placebo, n = 47) were required to detect a relative reduction of 50% between a failure rate of
60% and 30% with 90% power (to optimise the detection of a significant difference between treatment
regimens if one truly exists) at a 5% significance level, using a 2 : 1 randomisation.
The advent of biological therapies in JIA has led international investigators to a paradigm shift in the
treatment of JIA and related complications, leading to significantly more ambitious outcomes in clinical
trials, including elimination of inflammation and normalisation of short- and long-term function.15,59
To this end, in JIA, instead of previously accepted clinical outcomes of 30% absolute difference in outcome
between active agent and placebo,60 increasingly significant differences are being expected, with new
definitions of response being established for use in clinical trials, such as clinical remission and minimal
disease activity.56,57 Indeed, 40% of patients in the adalimumab-JIA trial were reported as showing an
ACR Pedi 100% response (100% response rate) at 2 years.41
The clinically relevant outcomes of JIA-uveitis may take years to develop and the relationship between
isolated measures of clinical activity and long-term outcomes remains ill-defined. Recent studies do suggest
that the length of continuously controlled activity is likely to be of more clinical relevance than short-term
improvements in levels of activity.
In view of these factors, as well as the expectation expressed unanimously through consultation with parent
representatives in the development of the trial protocol, a minimum of 50% relative difference in failure rate
between interventions was set. Based on the nature of the disease (potentially resulting in loss of vision) and
a meeting of investigators representing participating centres as well as consumer representatives, and their
experience of compliance from current usage of biological therapies in JIA-uveitis, it was estimated that loss
to follow-up would be approximately 10%. Therefore, the sample size was increased by approximately 10%
to allow for this, giving a total number of 154 participants (adalimumab, n = 102; placebo, n = 52).
The null hypothesis underlying this trial was that there is no significant difference between adalimumab
and placebo in controlling disease activity of JIA-associated uveitis that is unresponsive to MTX therapy.
TRIAL DESIGN AND METHODS
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Revised sample size calculation for the primary outcome
The original sample size calculation had a power of 90%, but given a series of challenges arising, including
those that were faced during recruitment, it was proposed by the TMG, and agreed on by the Trial Steering
Committee (TSC) and Independent Data and Safety Monitoring Committee (IDSMC), as well as the sponsor
and trial funders, to revise this. Reducing power to what is a universally accepted convention of 80% power
maintained the status of this trial as an internationally relevant and robust contribution to the evidence
base for the safety of this intervention, and was felt to be clinically acceptable. This was both acceptable to
patients/families and clinicians, and would enable the sample size to be markedly reduced, and, therefore,
more feasible within a reasonable period.
Furthermore, as of September 2013, there had only been one participant who had withdrawn and refused
to provide primary outcome data. Therefore, it was reasonable to assume that the original assumption of
adding 10% to the sample size calculation to account for missing data could be reduced to 5%.
The total sample size (including 5% drop out) that was required to detect the difference between a placebo
proportion of 60% and treatment group proportion of 30% (with 0.05 two-sided significance level) was
114 participants.
Tissue bank
A blood sample collection system was developed, in accordance with Arthritis Research UK’s guidelines61
on detailed clinical and related material banks.
Written information was provided to families for this part of the study and written informed consent
(with assent when appropriate) obtained for those who wished to provide blood samples. Participants
who did not give consent to provide samples were eligible to take part in the main part of the trial.
Samples have been collected for future analysis and could be used as a resource to investigate the
pharmacogenetics, aetiopathogenesis and identification of biomarkers of JIA-associated uveitis, for
example. Understanding the genetic basis of age-specific disease processes allows consideration of the
unique and rapid period of human development through to adulthood. Pharmacologic modulation of
developing gene networks may have unintended and unanticipated consequences that do not become
apparent or relevant until later in life. Early predictors of response allow future personalised treatment
prescription in children.
Blood samples were collected pre treatment (0 months) and at two time points post treatment (at 3 months
and 18 months).
Patient and public involvement
Patient and public involvement (PPI) representatives have been an integral part of SYCAMORE since the
initial prioritisation, design stage and funding applications. PPI representatives provided detailed input into
all aspects of the protocol design and all subsequent amendments and patient information sheets and
consent forms and amendments. The patient information sheets, consent forms and assent forms were
reviewed and feedback was given by the Medicine for Children Research Network young person’s advisory
group. PPI representatives also provided input into any information sent to patients, such as letters to
explain the closure of recruitment and the frequently asked questions section on the SYCAMORE website.
DOI: 10.3310/hta23150 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 15
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Ramanan et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
15
Changes to the protocol
Over the course of the whole trial, eight amendments were made to the protocol. These consisted of six
non-substantial and 15 substantial amendments. A summary of amendments follows and the full list is
reported in the trial protocol.
Version 1.0 (25 February 2011) amended to version 1.1 (8 September 2011)
The first amendment to the protocol made corrections to typographical errors in the original protocol.
Version 1.1 (8 September 2011) amended to version 2.0 (30 September 2011)
The second amendment added clarification to the tissue bank section; added clarification to the primary end
point section and introduced an end point for the intermittent or continuous suspension of adalimumab/
placebo; added clarification that patients cannot have previously received adalimumab; added two further
exclusion criteria points relating to IOP; removed the limit on how many times patients can be screened;
added a window for adalimumab/placebo injections; added clarification of topical treatment after 3 months
of trial treatment; changed the dose range of allowed MTX to 10–20 mg/m2; and added clarification of
treatment timelines and visit windows.
Version 2.0 (30 September 2011) amended to version 3.0 (25 April 2013)
The third amendment to the protocol made changes to the monthly visit windows to allow a window of
7 days; clarified in the table of assessments that the Clinical Service Receipt Inventory (CSRI) questionnaire
is completed at baseline only; changed the timeline for tuberculosis assessment from 4 weeks to 12 weeks
prior to baseline; and clarified that haematological and biochemical samples taken at screening can be
used for the baseline visit.
Version 3.0 (25 April 2013) amended to version 4.0 (25 September 2013)
The fourth amendment to the protocol reduced the sample size from 154 to 114 participants and the
duration of follow-up post treatment from 18 months to 6 months; changed the assessment of reduction of
vision from number of letters to logMAR units; added clarification to inclusion and exclusion criteria; added
systemic acetazolamide to the list of medication not permitted; removed the requirement for collection of
human antihuman antibody samples; window for MTX administration added change to the collection of
routine PLICS data; and added clarification on the definition of ‘end of trial’.
Version 4.0 (25 September 2013) amended to version 4.1 (11 August 2014)
The fifth amendment to the protocol added text to say that the IDSMC may request an interim analysis of
the primary outcome.
Version 4.1 (11 August 2014) amended to version 5.0 (11 August 2014)
The sixth change to the protocol clarified that patients are classed as withdrawals and not treatment
failures if they miss > 4 weeks of MTX treatment; added further clarification that haematological and
biochemical blood results can be used for baseline (if taken at screening) only if assessment was completed
within the previous 15 days; added clarification to tissue bank samples to state that the 3-month samples
should be taken at the very next opportunity if not taken at 3 months and that the 18-month samples
should be taken if patient ends treatment early.
Version 5.0 (11 August 2014) amended to version 6.0 (17 April 2015)
The seventh change to the protocol stated that the blinded phase of the trial had been stopped and that
all patients on adalimumab would continue to be treated but that patients on placebo would stop
treatment and proceed to follow-up.
Version 6.0 (17 April 2015) amended to version 6.1 (14 July 2016)
The eighth change to the protocol clarified that JADAS was a secondary outcome and clarified SAE
reporting procedures.
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Compliance with intervention
Participant diaries and dosing records determined tolerability and compliance throughout the trial period.
The parent/guardian of a participant maintained a diary for all trial and other medications that were
administered outside the trial visit (i.e. at home). In the diary, the date and time that the drug was
administered were recorded. The dosing records were reviewed and verified for compliance at each visit by
the research personnel at the trial centre.
Trial management and oversight
Trial Management Group
The TMG was a multidisciplinary team comprising the co-chief investigators, several co-investigators, PPI
representatives, a sponsor representative, health economists and members of the CTRC (see Appendix 1).
The TMG was responsible for the day-to-day clinical and practical aspects of the trial.
Independent Data and Safety Monitoring Committee
The IDSMC comprised two independent ophthalmologists, a statistician and a paediatric rheumatologist
(see Appendix 1). The main responsibilities of the IDSMC were to safeguard the interests of the SYCAMORE
participants, assess the safety and efficacy of the interventions during the course of the trial and monitor the
overall progress and conduct of the trial. The IDSMC met at least annually during the course of the trial and
provided recommendations to the TSC. The statistical team at the CTRC produced reports for the IDSMC.
Trial Steering Committee
The membership of the TSC included an independent rheumatologist, an independent ophthalmologist
and an independent statistician, as well as representatives from the TMG (see Appendix 1). An observer
from the sponsor and from the funder(s) were also invited to meetings. The TSC met at least annually,
shortly after the IDSMC meeting. Its main role was to provide overall oversight of the trial.
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Chapter 3 Statistical methods
Interim analysis
Interim monitoring reports of the accumulating data were performed at regular intervals (at least annually)
for review by the IDSMC. In addition to the interim monitoring reports, the IDSMC requested that an
interim analysis of the primary outcome was to be undertaken. The Peto–Heybittle stopping rule was
applied to both interim analyses of the primary outcome. This required an extreme p-value of p < 0.001 as
evidence to indicate potentially stopping for benefit. This approach was used to allow the IDSMC flexibility
with the number and timing of further analyses, based on current safety and efficacy data, as it has the
added benefit of preserving an overall two-sided type I error of 0.05 for the final analysis62 (see Chapter 4).
Final analysis
The results of this report are based on the data collected during three phases of the trial. Chapter 5
presents the results from the double-blind phase of the trial, Chapter 6 presents the results from the
integrated analysis of the double-blind phase and the open-label phase, and Chapter 7 presents the results
of the integrated analysis of the double-blind phase, open-label phase and the follow-up phase of the trial.
The data presented in this report are based on data at the final database lock that occurred on 2 August 2017.
The results from the blinded phase of the trial that were presented in the published manuscript of
SYCAMORE were based on data snapshots taken on 11 September 2015 (primary outcome and AE data)
and 24 May 2016 (secondary outcomes).
Because data were still being received from sites during this period, there were minor ongoing updates
and changes to the database. The differences between the results in the New England Journal of Medicine
manuscript63 and Chapter 5 in this report are documented in Appendix 2.
There were three statistical analysis plans (SAPs) written for the final analysis of study results. The first SAP
was written by the trial statistician and contained detail only of the analyses for the primary outcome and the
safety data of the blinded phase of the trial. The second and third SAPs were written after the completion
of the primary analysis (after the blind had been broken to treatment allocation) and, therefore, written by
independent statisticians who were blinded to the allocation of the trial. The second SAP described the
analysis that was conducted on the secondary outcomes for the blinded phase of the trial and the third SAP
described the analyses that were conducted for the open-label and follow-up phases of the trial. All three
SAPs are available at www.journalslibrary.nihr.ac.uk/programmes/hta/095101 (accessed 4 February 2019).
General statistical considerations
The primary and secondary outcomes were all analysed using the (two-sided) 5% level of significance and
95% confidence intervals (CIs) are presented throughout. There were no adjustments for multiple testing;
rather, all secondary analyses were treated as hypothesis generating.
The primary and secondary analyses used the principle of intention to treat (ITT) based on all the randomised
participants, meaning that participants who consented and were randomised were analysed on the basis
of the treatment they were randomised to, regardless of whether or not they received it. If consent for
treatment was withdrawn but the participant was happy to remain in the study for follow-up, they were
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followed up until completion. However, if they decided to withdraw consent completely, then the reasons
for withdrawal of consent were collected (if possible) and reported for both groups.
All statistical analyses were conducted using SAS® V9.3 (SAS Institute, Cary, NC, USA), except for the joint
modelling and competing risk analyses, which were conducted in R (R Foundation for Statistical Computing,
Vienna, Austria).
Analysis of baseline data
Demographic and baseline characteristics were summarised for each treatment group and overall, using
descriptive statistics. No formal statistical testing was performed on these data. Descriptive statistics,
including the number of observations; mean; standard deviation (SD); median, minimum and maximum
for continuous variables; and counts and percentages for discrete variables, are presented as appropriate.
Analysis of the primary outcome
The primary outcome of ‘treatment failure’ was a time-to-event outcome. For those patients who entered
the trial and whose eyes (both) met the entry criteria, the time to the first eye to fail treatment was used.
This was not observed in all participants; those participants who did not experience an event were classed
as censored. The event time or censoring was calculated by subtracting the randomisation date from one
of the following scenarios:
l Participants who failed treatment – date of the visit at which they failed treatment.
l Participants who completed the trial treatment phase without failing treatment – censored at date of
18-month treatment visit.
l Participants who discontinued treatment early and agreed to follow-up –
¢ if they were assessed to be a treatment failure during a follow-up visit within 18 months following
randomisation: date of follow-up visit
¢ if they were not assessed to be a treatment failure during their follow-up visits: censored at date of
last follow-up visit within 18 months following randomisation.
l Participants that were lost to follow-up – censored date of last treatment visit.
Survival estimates were calculated using the method of Kaplan and Meier, with curves for each treatment
group presented graphically with numbers at risk.
The p-value obtained from the log-rank test and the hazard ratios (HRs) with 95% CIs were used to assess
differences in failure estimates across treatment groups. The statistical test for the primary end point was
performed at a two-sided significance level of 0.05.
Participants who withdrew from trial treatment (providing they did not withdraw from the entire study or
withdraw consent) moved to the follow-up phase of the trial, were assessed for the primary outcome and
could still contribute to the ITT analysis.
Any participants who withdrew from follow-up contributed primary outcome data until the point at which
they withdrew from the trial.
Missing data were monitored and strategies developed to minimise this occurrence. Missing data were
handled by considering the robustness of the complete-case analysis to sensitivity analyses using various
imputation assumptions; this was informed by data collected on the reasons for missing data.
STATISTICAL METHODS
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Nine sensitivity analyses were carried out to determine the robustness of the results from the primary analysis:
1. Best case – all participants who withdrew from treatment were treated as censored at time of
treatment withdrawal.
2. Worst case – all participants who withdrew from treatment were treated as treatment failures
(i.e. events at time of treatment withdrawal).
3. Methotrexate – any participants who withdrew from treatment because of MTX intolerance were
classified as treatment failures at the time of treatment withdrawal.
4. Component 1 of primary outcome – all participants who failed for component 1 at a treatment failure
assessment had their event date as the mid-point between this visit and the previous visit instead of the
date of this visit.
5. Component 2 of primary outcome – all participants who failed for component 2 at a treatment failure
assessment had their event date as the date that they commenced concomitant medications (a) used
against predefined acceptable criteria (see SYCAMORE protocol49) or (b) any of the concomitant
medications not allowed. The event date was determined by the co-chief investigators making a clinical
decision following review of the participants’ concomitant medications taken since their previous visit.
6. Component 3 – all participants who failed for component 3 at a treatment failure assessment had their
event date as the exact date that they qualified as ‘intermittent or continuous suspension of study
treatment (adalimumab/placebo) for a cumulative period longer than 4 weeks’.28 The event date was
determined by the chief investigator making a clinical decision following review of a participant’s trial
treatment dose recordings in the treatment diaries.
7. Any missing primary outcome data – any cases of missing data for any of the primary outcome
components (except for unscheduled visits) had data imputed on a worst-case basis, because the
missing data could have meant that a participant failed earlier than recorded. All participants were
treated the same, regardless of whether or not they had a treatment failure.
8. Loss to follow-up – in the primary analysis of the primary outcome, participants who were lost to
follow-up were treated as withdrawals, assuming that they were non-informative. The reasons for loss
to follow-up, when available, were blindly reviewed by Michael W Beresford (co-chief investigator) and
Andrew Dick (ophthalmology expert on the TMG) to see whether or not any might be related to the
prognosis. If any were deemed to be related, a sensitivity analysis would be undertaken, assuming these
participants to be a treatment failure at the time of last recorded visit.
9. Incorrectly identified to be a treatment failure – once a participant was deemed to have failed
treatment, treatment was stopped and they entered the follow-up phase of the study, providing that
they still wished to be followed up. Any participants wrongly identified as treatment failures by the
assessing physician would be classed as a withdrawal at their time of ‘treatment failure’.
Analysis of secondary outcomes
The secondary continuous outcomes were analysed using the following methods:
l Chi-squared test, relative risk (RR) and 95% CI for the number of participants –
¢ failing treatment
¢ needing pulsed corticosteroids
¢ having uveitis disease flares
¢ having resolution of associated optic nerve or macular oedema
¢ with uveitis disease control
¢ entering disease remission for uveitis
¢ undergoing JIA disease flare
¢ with minimum disease activity of JIA
¢ having remission of their JIA on and off medication
¢ requiring a change in biologics due to failure to respond from arthritis.
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l Change from baseline –
¢ laboratory parameters (haematological and biochemical assessments).
l Poisson regression –
¢ total oral corticosteroid dose
¢ systemic corticosteroid dose.
l Competing risks –
¢ reduction in systemic corticosteroid dose
¢ topical corticosteroid use.
l Joint modelling of longitudinal and time-to-treatment failure data –
¢ visual acuity
¢ CHAQ and CHQ
¢ ACR 30, 50, 70, 90 and 100
¢ JADAS.
l Random intercept model –
¢ duration of sustaining inactive disease.
No between-group statistical analyses were conducted for compliance data or urinalysis data; instead,
summary data are presented for these outcomes.
Adverse events were tabulated by the Medical Dictionary for Regulatory Activities (MedDRA) version 18.0
system by organ class and preferred term. In addition, summaries by severity and relationship to study drug
were completed. SAEs and events that led to premature withdrawal were listed in detail. No formal testing
of AE or SAE data was planned.
STATISTICAL METHODS
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Chapter 4 Interim analysis results
Initial meeting
The first meeting of the IDSMC took place on 2 August 2011. During this meeting, the IDSMC reviewed
the study protocol, was updated on study progress and agreed the IDSMC charter and also the expedited
safety reports that it wished to receive.
Future meetings
The IDSMC met at regular intervals following the initial meeting (11 April 2012, 18 December 2012,
3 July 2013 and 18 February 2014). During these meetings, the committee was updated on the progress
of the trial and was also presented with a report that contained data on recruitment, data completeness
and safety.
There were two sessions held during the meetings, an open and closed session. Present at the open
session were the independent members of the IDSMC and also relevant members of the TMG (i.e. co-chief
investigators, lead trial ophthalmologist, trial co-ordinator, statistical team). During the open session, data
were presented overall and not split by treatment group. The open session was then followed by a closed
session, which was attended only by the independent members of the IDSMC and the statistical team
responsible for the production of the report.
On 18 February 2014, the IDSMC decided that the recruited sample was approaching a size at which an
interim analysis was needed in order to allow them to protect participants from potential harm or to stop
the trial early if there was a clear benefit. This allowed for avoidance of delay by bringing the benefits to
patients once the question that had been posed in the trial had been answered with sufficient statistical
certainty.
The IDSMC, therefore, requested that an interim analysis be conducted and the results be presented at the
next IDSMC meeting, which was to be held on 29 September 2015.
Statistical methods
A full SAP was written prior to conducting the interim analysis.
The Peto–Haybittle stopping rule was applied to the interim analysis of the primary outcome. This required
an extreme p-value of < 0.001 as evidence to stop for benefit. This approach was used to allow the IDSMC
flexibility with the number and timings of further analyses, based on current safety and efficacy data, as it
had the added benefit of preserving an overall two-sided type I error of 0.05 for the final analysis.
Survival estimates were calculated using the method of Kaplan and Meier, with curves for each treatment
group presented graphically along with numbers at risk.
The log-rank test was used to assess differences in failure estimates across treatment groups.
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Interim analysis 1
The first interim analysis report was based on follow-up data from 71 participants who had been randomised
(adalimumab, n = 48; placebo, n = 23). Safety data (SAE/AE) were based on data from 64 participants
(adalimumab, n = 43; placebo, n = 21).
There was a total of nine treatment failures recorded in 48 participants in the adalimumab group (19%)
and 13 treatment failures recorded in 21 participants in the placebo group (62%), and five withdrawals
from 48 participants recorded in the adalimumab group (10%) and four withdrawals from 23 participants
recorded in the placebo group (17%).
The Kaplan–Meier plot is shown in Figure 2. The log-rank chi-squared statistic was 15.77 and the associated
log-rank p-value was < 0.0001.
At the time of the first interim analysis, 353 AEs had been reported in 34 of the 43 participants in the
adalimumab group who qualified for the safety analysis set (i.e. received at least one dose of treatment).
There had been 89 AEs reported in 14 out of the 21 participants in the placebo group who qualified for
the safety analysis set (i.e. received at least one dose of treatment).
There had been 10 SAEs reported in 9 participants from a total of 43 participants in the adalimumab
group (21%). There had been one SAE reported from a total of 21 participants in the placebo group (5%).
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FIGURE 2 Interim analysis 1: Kaplan–Meier plot.
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The IDSMC considered the report and made the recommendation that the trial should continue with
recruitment. However, it did make three observations with regard to the trial based on the report that
it received:
1. We (the IDSMC) have been much reassured over recent months, and in the current report, that the
recruitment rate is now running just ahead of the amended estimated rate. We would like to commend
the TMG on overcoming significant difficulties to achieve this favourable situation.
2. We do, however, remain concerned that some centres are performing exceptionally badly; there is, for
example, a marked contrast between the performance of Bristol, where ≈50% of those screened are
recruited, and Birmingham, where < 1% of those screened are being recruited. While these two are at
the extreme ends, there are several other poorly recruiting centres – this appears as a weakness with
potential implications for the representativeness of the trial sample. An investigation into the problems
in these centres, with a view to resolving their issues, would be time well spent.
3. We are also concerned about the levels of missing data, which seem high for certain variables. For
example, in table 10.2 [referring to the meeting report], in 14% the relationship between the AE and
the trial medication is missing and in 5% the severity of the AE is missing. Whilst we appreciate that
you are taking steps to reduce these rates of missing data, we would like to register our concern in
regard to this problem of missing data, which is evident in other parts of the report. Please take all
steps to recover missing data and reduce the levels going forward.
The TMG provided further information with regards to missing data for both the primary outcome and the
safety data. The response contained a more detailed breakdown of missing and unobtainable data for
each component of the primary outcome and safety data, by site and overall.
This thorough investigation of the missing and unobtainable data reassured the IDSMC that the
monitoring procedures being implemented by the TMG and the engagement of sites with the data
manager were ensuring that these figures were kept to a minimum.
The IDSMC requested that a further interim analysis be conducted at their next meeting in March 2015.
Interim analysis 2
The IDSMC met on the 25 March 2015 to discuss the results of the second interim analysis of the
SYCAMORE data.
At the time of the report, there were a total of 85 participants who had been randomised (adalimumab,
n = 57; placebo, n = 28). From these 85 participants:
l 80 were included in the analysis (adalimumab, n = 54; placebo, n = 26).
l Five were excluded –
¢ four had no randomisation CRF input on the trial database
¢ one had their randomisation CRF input on the trial database but had not had any further follow-up
visits input to the trial database.
There were a total of 10 withdrawals from the trial: five withdrawals from the adalimumab group (n = 57)
(9%) and five withdrawals from the placebo group (n = 28) (18%). There were a total of 27 treatment
failures in the trial: 12 treatment failures on adalimumab (21%) and 15 on placebo (54%).
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The Kaplan–Meier plot is shown in Figure 3. The log-rank chi-square statistic was 14.63 and the associated
log-rank p-value was 0.0001.
The safety data set was based on 80 participants (adalimumab, n = 54; placebo, n = 26).
There were a total of 10 withdrawals from the trial: five withdrawals from the adalimumab (n = 57) (9%)
and five withdrawals from the placebo group (n = 28) (18%). There were a total of 27 treatment failures in
the trial: 12 treatment failures on adalimumab (21%) and 15 on placebo (54%).
Following the review of the second interim analysis, the IDSMC carefully considered evidence from the first
interim analysis, the subsequent satisfactory conclusion of the vast majority of missing data, and also the
continued presence of such a strong treatment effect. The IDSMC subsequently agreed unanimously that:
l The levels of missing data were acceptable with all reasonable efforts being made to collect
outstanding missing data items where feasible, or to confirm the fact that the data were unobtainable.
l The AEs and SAEs were in keeping with expectations for the medications in use, based on clinical
experience and previous published reports.
l The statistical significance of the beneficial effect of the investigational medicinal product (IMP) in the
interim analysis substantially exceeded the predetermined requirement for consideration of stopping
the trial on the basis of a powerful positive treatment effect.
l The IDSMC should obtain guidance on procedure prior to making any stopping recommendation.
Options for stopping included either to immediately stop and fully close the trial or to stop recruitment
and continue collecting data until all current participants had completed their passage through
the protocol.
It was decided by the IDSMC that no immediate recommendation should be made, but that the IDSMC
chairperson should take advice in a timely manner, following which the IDSMC would communicate
further among themselves before arriving at a final recommendation.
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Summary of Independent Data and Safety Monitoring Committee and
Trial Steering Committee meetings following interim analysis 2
The IDSMC and TSC met on 8 April 2015 in a combined meeting that involved all of the independent
members of both committees, as well as both co-chief investigators and the lead statistician (non-independent
members). The IDSMC advised the TSC that the trial should stop recruiting with immediate effect. They
further recommended that all participants currently in the trial should continue in their randomly allocated
treatment regimen, blinded, and follow treatment scheduling as per protocol. The IDSMC did not unblind
the TSC (or co-chief investigators) to the results of the trial during the meeting. The TSC decided to consider
the recommendations of the IDSMC overnight and meet again on 9 April 2015.
The independent members of the TSC met with the co-chief investigators and lead statistician
(non-independent members of the TSC) again on 9 April 2015. The chairperson of the TSC contacted the
chairperson of the IDSMC, requesting that the IDSMC make formal recommendations to the TSC in a
formal document; they agreed to meet again on 10 April 2015.
The same independent members of the TSC, the co-chief investigators and lead statistician met on
10 April 2015 and discussed the formal recommendations that had been made by the IDSMC.
The voting members of the TSC (the three independent members and one non-independent member) then
voted unanimously in favour of the following specific IDSMC recommendations:
l Recruitment to SYCAMORE should not be reinstated. This was based on a positive signal of efficacy of
the IMP (adalimumab) versus placebo, which exceeded the prespecified level.
l All participants in the trial should be invited to attend a final blinded assessment visit. On completion of
assessments, their treatment allocation should then be unblinded.
l All participants in the active arm of the trial (adalimumab) should continue follow-up in an open-label
fashion, as this long-term follow-up would contribute important additional data on quality of life,
utilities and long-term efficacy. Subsequent changes in therapy would be at the discretion of the
treating clinical team.
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Chapter 5 Clinical effectiveness results: blinded
phase of study
The results presented in this chapter are from the blinded period of the trial only.
Participant recruitment
The first participant was randomised into SYCAMORE on 27 October 2011 and the last participant was
randomised on 31 March 2015. The last blinded visit took place on 16 June 2015.
Fourteen of the 17 sites randomised at least one participant and five centres randomised five or more
participants. The flow of participants through the trial is represented in the Consolidated Standards of
Reporting Trials (CONSORT)64 flow diagram in Figure 4.
A total of 332 patients were assessed for eligibility from 519 screenings (patients could be screened on
multiple occasions).
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FIGURE 4 The CONSORT flow diagram for all trial participants.
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The number of participants enrolled overall by month is provided in Appendix 3 (see Figure 13); the
screening overview by centre is also given in Appendix 3 (see Table 40). The main reasons for ineligibility
included the following: the patient did not have active uveitis (49%), the patient had not failed on MTX or
been on MTX for at least 12 weeks with a stable dose (19%), the patient had been on another biological
agent within the previous five half-lives of the agent (6%), the patient had more than six topical steroid
eye drops per day at randomisation (6%) or other reasons (11%). For five patients, it was not clear
whether or not they were eligible.
A total of 130 patients were eligible to participate in the trial from 139 screening visits; 90 patients were
randomised. The reasons for the 45 patients (49 screening visits) not providing consent are given in
Appendix 3 (see Table 41).
Recruitment rates
The original target sample size of 154 participants was expected to be achieved within 30 months of
recruitment. This original target was based on feasibility data provided by each of the centres that took part
in the trial. The actual rates of recruitment during the trial were lower than anticipated (see Appendix 3,
Figure 13) and, therefore, the recruitment period of the trial was extended by 36 months on 16 June 2014,
to allow for additional time to recruit the necessary number of participants.
The sample size of the trial was also revised, which meant that the target sample size was reduced from
154 to 114 participants. Other strategies were used to improve recruitment, including the aligning of the
rheumatology and ophthalmology clinics in any sites that did not already have this service and holding a
series of regional investigator meetings and local investigator meetings each month via teleconference,
which included members of the CTRC and the co-chief investigators and lead SYCAMORE ophthalmologists.
Regular newsletters were sent to sites to keep sites aware of recruitment and to maintain interest in the trial.
All sites were also encouraged to build referral links with district general hospitals to allow referrals of
potential patients for screening.
Comparison of interventions
The ITT analysis population included all 90 participants who were randomised (see Figure 4). There were
no exclusions from either the safety or the ITT population.
All participants who withdrew consent for trial continuation contributed outcome data up until the point
of withdrawal.
The memberships of the analysis set for the primary outcome and safety data set were determined and
documented prior to the blinding being broken and the treatment allocations being requested.
Trial completion and trial exit
There were 19 participants who withdrew prematurely during the blinded treatment phase of the trial
(Table 1). There were a total of 11 (18%) withdrawals in the adalimumab group (nine continued into the
follow-up phase of the trial and two withdrew complete consent) and eight (23%) in the placebo group
(seven continued into the follow-up phase of the trial and one withdrew complete consent). The majority
of premature withdrawals were for non-safety reasons (see Table 1). The most common reason for
withdrawal in the adalimumab group was because of MTX intolerance and in the placebo group it was the
worsening of uveitis (that did not meet the exit criteria).
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Baseline characteristics
The demographic baseline data of the 90 participants randomised across all centres were comparable
between the two groups (Table 2). The mean age in the placebo group was slightly lower than that in the
adalimumab group and the proportion of females and males was approximately the same in the two
treatment groups, with more females than males.
The distribution in weight was similar in both groups, as was physical global assessment of disease activity,
antinuclear antibody and double-stranded deoxyribonucleic acid.
A total of 65 (72%) participants entered the trial with one eye that was eligible for evaluation (i.e. they
met the inclusion criteria for active uveitis in one eye only) and 25 (28%) participants entered the study
with two eyes that were eligible (i.e. they met the inclusion criteria for active uveitis in both eyes).
Therefore, a total of 115 eligible eyes entered into the study.
Table 3 shows ocular data collected at baseline, presented at the eye level rather than the individual level
for ease of reading. The overall mean for logMAR score was 0.05; this was slightly higher in the placebo
group than in the treatment group. Of the eligible eyes, 76 (66%) had a score of 1+ for the AC score;
the numbers in each of these categories were similar in both groups, as were the flare score and vitreous
haze grading. The mean IOP in each group was similar, with an overall mean of 14.54 mmHg.
When the best and worst scores were entered for those with two eligible eyes, the baseline results were
very similar to those when the eyes were looked at independently.
TABLE 1 Participants withdrawn from trial treatment, by treatment group
Reasons
Treatment group, n (%)
Total, n (%)Adalimumab Placebo
Safety 2 (3.3) 1 (3.3) 3 (3.3)
AE 2 (3.3) 0 (0) 2 (2.2)
SAE 0 (0) 1 (3.3) 1 (1.1)
Non-safety 9 (15) 7 (23.3) 16 (17.8)
Consultant discretion owing to disease activity 0 (0) 1 (3.3) 1 (1.1)
Family circumstances 0 (0) 1 (3.3) 1 (1.1)
Flare of JIA 0 (0) 1 (3.3) 1 (1.1)
MTX intolerance 4 (6.7) 0 (0) 4 (4.4)
Needle phobia 1 (1.7) 0 (0) 1 (1.1)
Participant felt no benefit 0 (0) 1 (3.3) 1 (1.1)
Recurrent infections 1 (1.7) 0 (0) 1 (1.1)
Refused injections 1 (1.7) 0 (0) 1 (1.1)
Unable to tolerate adalimumab/placebo 0 (0) 1 (3.3) 1 (1.1)
Use of medication that was not permitted 1 (1.7) 0 (0) 1 (1.1)
Withdrawal of consent – no reason 1 (1.7) 0 (0) 1 (1.1)
Worsening of uveitis (not meeting exit criteria) 0 (0) 2 (6.7) 2 (2.2)
Overall 11 (18.3) 8 (26.7) 19 (21.1)
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TABLE 2 Demographic baseline data: individual patient level
Variable
Treatment group
Total (N= 90)Adalimumab (N= 60) Placebo (N= 30)
Number of study eyes, n (%)
Unilateral 43 (72) 22 (73) 65 (72)
Bilateral 17 (28) 8 (27) 25 (28)
Age at randomisation (years)
Mean (SD) 9.07 (3.94) 8.56 (3.79) 8.90 (3.88)
Sex, n (%)
Female 47 (78) 23 (77) 70 (78)
Male 13 (22) 7 (23) 20 (22)
Weighta (kg), n (%)
< 30kg 33 (60) 17 (57) 50 (56)
≥ 30kg 26 (44) 13 (43) 39 (44)
a One unobtainable value from the adalimumab group.
TABLE 3 Ocular baseline data: eye level
Variable
Treatment group
Total (N= 115)Adalimumab (N= 77) Placebo (N= 38)
Topical steroid drops scorea
Mean (SD) 2.04 (1.38) 2.20 (1.57) 2.09 (1.44)
LogMAR scoreb
Mean (SD) 0.04 (0.15) 0.07 (0.12) 0.05 (0.14)
AC cells (SUN) (%)
1+ 52 (68) 24 (63) 76 (66)
2+ 18 (23) 11 (29) 29 (25)
3+ 6 (8) 3 (8) 9 (8)
4+ 1 (1) 0 (0) 1 (1)
Flare score (SUN), n (%)
0 18 (23) 12 (32) 30 (26)
1+ 49 (64) 23 (61) 72 (63)
2+ 10 (13) 3 (8) 13 (11)
LOCS III grading: pseudophakic, n (%)
No 77 (100) 38 (100) 115 (100)
LOCS III grading: nuclear,c n (%)
N0 69 (96) 36 (97) 105 (96)
NI 3 (4) 1 (3) 4 (4)
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TABLE 3 Ocular baseline data: eye level (continued )
Variable
Treatment group
Total (N= 115)Adalimumab (N= 77) Placebo (N= 38)
LOCS III grading: cortical,d n (%)
No cortical cataract 56 (88) 29 (94) 85 (90)
Control 3 (5) 0 (0) 3 (3)
CI 4 (6) 2 (7) 6 (6)
CII 1 (1) 0 (0) 1 (1)
LOCS III grading: posterior,e n (%)
0 68 (92) 29 (81) 97 (88)
PI 5 (7) 4 (11) 9 (8)
PII 1 (1) 3 (8) 4 (4)
Other structural changes: central band keratopathy covering visual axis, n (%)
No 75 (97) 38 (100) 113 (98)
Yes 2 (3) 0 (0) 2 (2)
Other structural changes: synchiae, n (%)
No 59 (77) 32 (84) 91 (79)
Yes 18 (23) 6 (16) 24 (21)
Other structural changes: iris bombe, n (%)
No 77 (100) 38 (100) 115 (100)
Other structural changes: membrane formation, n (%)
No 75 (97) 38 (100) 113 (98)
Yes 2 (3) 0 (0) 2 (2)
Other structural changes: neovascularisation, n (%)
No 77 (100) 38 (100) 115 (100)
IOP (mmHg)
Mean (SD) 14.76 (3.85) 14.11 (4.27) 14.54 (3.99)
Vitreous haze grading, n (%)
0 65 (84) 32 (84) 97 (84)
0.5+ 8 (10) 4 (11) 12 (10)
1+ 3 (4) 2 (5) 5 (4)
2+ 1 (1) 0 (0) 1 (1)
LOCS, Lens Opacities Classification System.
a Two adalimumab and 3 placebo unobtainable.
b One adalimumab unobtainable.
c Five adalimumab and 1 placebo unobtainable.
d Thirteen adalimumab and 7 placebo unobtainable.
e Three adalimumab and 2 placebo unobtainable.
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Table 4 shows the baseline data describing the classification by disease subtype of the participants’ JIA
status. A total of 53 (59%) participants had persistent oligoarticular JIA and 21 (23%) had extended
oligoarticular JIA. The proportions for each of the subcategories were similar for both groups. The mean
overall JIA disease duration was 5.33 years, with the duration being slightly longer in the treatment group.
A total of 66 (73%) participants had a negative rheumatoid factor (RF); this was slightly higher in the
adalimumab group.
Unblinding of randomised treatment
There were 57 (63%) participants who were unblinded during the course of the trial: 38 (67%) in the
adalimumab group and 19 (33%) in the placebo group. A breakdown of the stage of the trial that the
participants were in at the time of unblinding is given in Table 5.
TABLE 4 Rheumatology baseline data: individual patient level
Variable
Treatment group
Total (N= 90)Adalimumab (N= 60) Placebo (N= 30)
Type of JIA (ILAR classification), n (%)
Extended oligoarthritis 14 (23) 7 (23) 21 (23)
Persistent oligoarthritis 36 (60) 17 (57) 53 (59)
Polyarthritis RF negative 8 (13) 4 (13) 12 (13)
Polyarthritis RF positive 1 (2) 1 (3) 2 (2)
Psoriatic arthritis 1 (2) 1 (3) 2 (2)
Disease durationa (years)
Mean (SD) 5.58 (3.69) 4.81 (3.19) 5.33 (3.53)
Physician global assessment of disease activityb
Mean (SD) 0.76 (1.48) 0.83 (1.09) 0.78 (1.36)
Active joint count (all joints)
Mean (SD) 0.57 (2.03) 1.1 (2.23) 0.74 (2.10)
Swollen joint count (all joints)
Mean (SD) 0.55 (1.66) 1.0 (1.55) 0.70 (1.63)
Antinuclear antibody,c n (%)
Negative 24 (42) 10 (40) 34 (42)
Positive 33 (58) 15 (60) 48 (58)
Double-stranded deoxyribonucleic acid,d n (%)
Negative 47 (94) 22 (92) 69 (93)
Positive 3 (6) 2 (8) 5 (7)
RF,e n (%)
Negative 46 (98) 20 (87) 66 (94)
Positive 1 (2) 3 (13) 4 (6)
ILAR, International League of Associations for Rheumatology; RA, rheumatoid factor.
a Six adalimumab and 4 placebo unobtainable.
b Two adalimumab and 1 placebo unobtainable.
c Three adalimumab and 5 placebo not carried out.
d Ten adalimumab and 6 placebo not carried out.
e Thirteen adalimumab and 7 placebo not carried out.
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Protocol deviations
Protocol deviations were monitored centrally via evaluation of inclusion/exclusion criteria at trial entry and
throughout the course of the trial. During the course of the blinded phase of the trial, a total of 74 (82%)
participants had at least one major protocol deviation (Table 6). All protocol deviations were agreed with
the co-chief investigators before the final treatment allocations were requested on 11 September 2015.
TABLE 5 Trial status of unblinded participants
Reason
Treatment group, n (%)
Adalimumab Placebo
Completed 18 months of treatment 12 (32) 1 (5)
Based on recommendation of IDSMC 10 (26) 4 (21)
Treatment failure 11 (29) 8 (42)
Withdrawal 5 (13) 6 (32)
Total 38 19
TABLE 6 Important major protocol deviations
Institution Total, n
Any protocol
deviation, n (%)
At least one protocol deviation related to, n (%)
Inclusion
criteria
Exclusion
criteria
Treatment
regimen
Study
assessment
The Leeds Teaching Hospitals
NHS Trust
2 2 (100) 0 (0) 0 (0) 1 (50) 2 (100)
University Hospitals of Leicester
NHS Trust
3 3 (100) 2 (67) 0 (0) 2 (67) 2 (67)
Norfolk and Norwich University
Hospitals NHS Foundation Trust
5 5 (100) 0 (0) 0 (0) 3 (60) 4 (80)
The Newcastle upon Tyne
Hospitals NHS Foundation Trust
5 4 (80) 1 (20) 0 (0) 3 (60) 4 (80)
Hull and East Yorkshire
Hospitals NHS Trust
1 1 (100) 0 (0) 0 (0) 1 (100) 1 (100)
University Hospital Southampton
NHS Foundation Trust
4 4 (100) 2 (50) 1 (25) 2 (50) 4 (100)
University Hospitals Bristol NHS
Foundation Trust
28 23 (82) 2 (7) 1 (4) 15 (54) 20 (71)
Birmingham Children’s Hospital
NHS Foundation Trust
1 1 (100) 0 (0) 0 (0) 0 (0) 1 (100)
Alder Hey Children’s NHS
Foundation Trust Hospital
7 6 (85) 1 (14) 0 (0) 4 (57) 6 (856)
Central Manchester University
Hospitals NHS Foundation Trust
4 4 (100) 1 (25) 0 (0) 3 (75) 4 (100)
Sheffield Children’s NHS
Foundation Trust
4 4 (100) 0 (0) 0 (0) 2 (50) 4 (100)
Great Ormond Street Hospital
for Children NHS Trust
22 13 (59) 2 (9) 0 (0) 9 (41) 12 (55)
Royal Hospital for Sick Children
Edinburgh – NHS Lothian
1 1 (100) 0 (0) 0 (0) 1 (100) 1 (100)
Royal Belfast Hospital for Sick
Children
3 3 (100) 0 (0) 0 (0) 2 (67) 3 (100)
Total 90 74 (82) 11 (12) 2 (2) 48 (53) 68 (76)
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Primary outcome
Adalimumab plus MTX significantly delayed the time to treatment failure compared with placebo and
MTX. There were a total of 14 (23%) treatment failures for the 60 participants in the adalimumab group
and 17 (57%) failures for the 30 participants in the placebo group. The median time to treatment failure
was 24.10 weeks (95% CI 14.70 weeks to 81.00 weeks) in the placebo group and was not reached in
the adalimumab group within the 18-month treatment period because fewer than half of the subjects
experienced treatment failure at the conclusion of the trial (Figure 5).
Reasons for the treatment failure of each participant can be found in Appendix 3 (see Table 42).
In the adalimumab group, five participants (trial numbers 0114011, 0116006, 0116026, 0249024 and
0030073) were classified as treatment failures because they had taken permitted concomitant medications
against the acceptable criteria, three participants (trial numbers 0243023, 0249043 and 0133058) were
given non-permitted concomitant medications, three participants (trial numbers 0069039, 0116062 and
0116066) had missed doses that met the failure criteria, two participants (trial numbers 0246055 and
0069076) had sustained SUN scores (as recorded at entry grade) that were still present after 6 months of
therapy and one participant (trial number 0030035) had both taken permitted concomitant medications
against the acceptable criteria and missed doses that met the failure criteria.
In the placebo group, two participants (trial numbers 0114033 and 0116067) received permitted
concomitant medications against the acceptable criteria, seven participants (trial numbers 0249019,
0249025, 0246030, 0243032, 0540037, 0393075 and 0249086) were given non-permitted concomitant
medications, one participant (trial number 0116003) missed doses that met the failure criteria and seven
participants (trial numbers 0116008, 0036018, 0116005, 0249029, 0249047, 0116051 and 0249059)
had sustained SUN scores (as recorded at entry grade) that were still present after 6 months of therapy.
Four participants who were classified as treatment failures did not subsequently enter the follow-up phase
of the trial and withdrew completely from the trial with no further follow-up. One of these was in the
adalimumab group (2%) and three were in the placebo group (10%).
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FIGURE 5 Primary outcome ITT Kaplan–Meier plot.
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The HR indicated that treatment with adalimumab significantly decreased the hazard of treatment failure
by 75% (HR 0.25, 95% CI 0.12 to 0.51). The results of the log-rank test offered strong statistical evidence
that the placebo group and adalimumab group differed with respect to time to treatment failure (p < 0.0001),
relative to placebo. The HR was derived using Statistical Analysis Systems Procedure (SAS PROC) proportional
hazards regression methods with no stratification factors.
Test of proportional hazards assumption
The assumption of proportional hazards was tested by including an interaction between time and
treatment group in the Cox proportional hazards model. There was no evidence (p = 0.15) that the
interaction was not zero and, therefore, no evidence that the HR was not constant over time.
Sensitivity analyses
The results of the nine sensitivity analyses can be seen in Table 7, which contains information on the
number of participants analysed in each group, the number of treatment failures, the number of
participants censored, the log-rank chi-squared statistic, the log-rank p-value, the HR and the 95% CIs.
There were no losses to follow-up and no incorrect treatment failures; therefore, sensitivity analyses eight
and nine were not conducted. The results of the other sensitivity analyses indicate that the original
conclusion from the primary analysis was robust with regard to the assumptions that were made.
The overall statistical significance in the sensitivity analyses did not change.
Additional analyses
Development of uveitis in non-study eye
There were 43 (72%) participants who had unilateral vision in the adalimumab group and 22 (73%)
participants who had unilateral vision in the placebo group. Those participants who had bilateral vision
[17 (28%) in the adalimumab group and 8 (27%) in the placebo group] were not eligible for this analysis
as they had uveitis in both eyes at baseline.
There were five (17%) participants in the placebo group who developed uveitis (defined as sustained
AC cell scores of ≥ 1+ over two consecutive visits) in the non-study eye and one (2%) participant in the
adalimumab group who developed uveitis in the non-study eye [the participant in the adalimumab group
had a baseline AC cell score of 1+ in their non-eligible eye, but they were taking too many drops in this
eye (left) for it to be eligible].
There were two participants (one in the adalimumab group and one in the placebo group) who had a
single AC cell score of ≥ 1+ and had a treatment failure in their study eye at the same visit.
Time-to-treatment failure in both eyes
This analysis was not possible because only one participant (in the placebo group) failed in both eyes at
different times.
Development of comorbidity on treatment failure
One participant developed cataract in the adalimumab group; none in the placebo group developed
cataract. Three participants developed IOP in the adalimumab group, whereas none in the placebo group
developed IOP.
There were so few participants in either of the two treatment groups who developed a comorbidity that
any modelling, including the development of a comorbidity, was not possible.
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TABLE 7 Primary outcome ITT analysis and sensitivity analyses results
Analysis Participants, N
Treatment group
Log-rank
chi-squared
statistic
Log-rank
p-value HR 95% CI
Adalimumab Placebo
Participants, n
Treatment
failures, n Censored, n Participants, n
Treatment
failures, n Censored, n
ITT 90 60 14 46 30 17 13 16.72 < 0.0001 0.25 0.12 to 0.51
1: best case 90 60 13 47 30 15 15 19.98 < 0.0001 0.21 0.10 to 0.44
2: worst case 90 60 24 36 30 23 7 24.17 < 0.0001 0.25 0.14 to 0.46
3: MTX 90 60 19 41 30 17 13 10.45 0.001 0.34 0.18 to 0.68
4: component 1 90 60 14 46 30 17 13 17.67 < 0.0001 0.24 0.12 to 0.49
5: component 2 90 60 14 46 30 17 13 16.93 < 0.0001 0.24 0.12 to 0.50
6: component 3 90 60 14 46 30 17 13 16.77 < 0.0001 0.25 0.12 to 0.51
7: missing PO 90 60 14 46 30 17 13 16.72 < 0.0001 0.25 0.12 to 0.51
8: loss to follow-upa – – – – – – – – – – –
9: incorrect TFb – – – – – – – – – – –
PO, primary outcome; TF, treatment failure.
a No losses to follow-up observed; therefore, this sensitivity analysis is not applicable.
b No incorrect treatment failures observed; therefore, this sensitivity analysis is not applicable.
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Post hoc analyses
Time to treatment response
There were 44 participants in the adalimumab group and eight participants in the placebo group who were
classified as having a treatment response; the difference between the two groups was statistically significant
(log-rank p-value = 0.002). The HR indicated that those participants on adalimumab were over three times
more likely to achieve a treatment response than those on placebo (HR 3.01, 95% CI 1.41 to 6.41).
Proportion of responders/failures/no change
Proportion of responders/failures/no change at 3 months
There were 20 (35%) participants in the adalimumab group and three (10%) participants in the placebo
group who were classified as having a treatment response before 3 months. The Cochran–Armitage trend
test showed a significant difference between the treatment groups at 3 months (p = 0.004).
There were three patients excluded from the analyses because they had not reached the 3-month time point.
Proportion of responders/failures/no change at 6 months
There was a total of 20 (37%) patients in the adalimumab group and three (11%) patients in the placebo
group who were classified as having a treatment response prior to 6 months. The Cochran–Armitage trend
test showed a significant difference between the treatment groups at 6 months (p = 0.004).
Nine participants were excluded from the analyses because they had not reached the 6-month time point.
Area under the curve of anterior chamber cells in eligible eye
There was a significant difference in the median number of AC cells between the two groups (median
number of AC cells –0.79, 95% CI –0.96 to –0.63; p < 0.0001) in favour of the adalimumab group. Similar
results were obtained when the best or worst score was used for participants with two eligible eyes.
Secondary outcomes
Number of participants failing treatment
Fourteen (23%) participants in the adalimumab group and 17 (57%) participants in the placebo group
were classified as having treatment failures. The risk of having a treatment failure was statistically
significantly reduced by 60% (RR 0.40, 95% CI 0.23 to 0.72; p = 0.002) in the adalimumab group
compared with placebo.
Safety, tolerability and compliance
Adverse events and serious adverse events
Throughout the course of the trial, 733 (non-serious, n = 713; serious, n = 20) AEs were recorded. A total
of 85 participants (out of 90) experienced at least one AE. There were 619 AEs reported in 59 (98%)
participants in the adalimumab group and 114 AEs reported in 26 (87%) participants in the placebo
group. The rate of AEs in the adalimumab group (10.60 per patient-year, 95% CI 9.77 per patient-year to
11.44 per patient-year) was greater than that in the placebo group (7.21 per patient-year, 95% CI 5.89
per patient-year to 8.53 per patient-year).
The commonest AEs in the adalimumab group were classified as infections and infestations (83%),
respiratory, thoracic and mediastinal disorders (55%), general disorders and administration-site conditions
(52%), gastrointestinal disorders (47%), investigations (32%), musculoskeletal and connective tissue
disorders (27%), nervous system disorders (27%) and eye disorders (25%). Aside from eye disorders
(27%), common AEs reported in the placebo group were consistently lower [infections and infestations
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(47%), respiratory (20%), thoracic and mediastinal disorders (27%), general disorders and administration-
site conditions (30%), gastrointestinal disorders (13%), investigations (23%), musculoskeletal and
connective tissue disorders (13%) and nervous system disorders (27%) (Table 8)].
The majority of AEs in both treatment groups were deemed to be mild or moderate in intensity.
Overall, 8% (five events in five participants) of the adalimumab group had at least one severe AE and 7%
(three events in two participants) of the placebo group had one severe AE. The five severe AEs in the
adalimumab group were cataract, injection-site reaction, glaucoma, arthralgia and arthritis; the three
severe AEs in the placebo group were AC flare (two events in the same participant) and uveitis.
TABLE 8 Adverse events, by treatment group
System Organ Class
Treatment group
TotalAdalimumab Placebo
Events
(n)
Patients
(n)
% of
patients
Events
(n)
Patients
(n)
% of
patients
Events
(n)
Patients
(n)
% of
patients
Blood and lymphatic
system disorders
5 5 8 0 0 0 5 5 6
Eye disorders 19 15 25 9 8 27 28 23 26
Gastrointestinal disorders 79 28 47 14 9 30 93 37 41
General disorders and
administration-site
conditions
130 31 52 15 8 27 145 39 43
Immune system disorders 3 3 5 1 1 3 4 4 4
Infections and
infestations
149 50 83 30 14 47 179 64 71
Injury, poisoning and
procedural complications
15 12 20 5 3 10 20 15 17
Investigations 39 19 32 6 4 13 45 23 26
Metabolism and nutrition
disorders
3 3 5 0 0 0 3 3 3
Musculoskeletal and
connective tissue
disorders
31 16 27 8 7 23 39 23 26
Neoplasms benign,
malignant and
unspecified (including
cysts and polyps)
5 5 8 0 0 0 5 5 6
Nervous system disorders 31 16 27 10 4 13 41 20 22
Psychiatric disorders 5 2 3 2 1 3 7 3 3
Reproductive system and
breast disorders
6 2 3 0 0 0 6 2 2
Respiratory, thoracic and
mediastinal disorders
84 33 55 9 6 20 93 39 43
Skin and subcutaneous
tissue disorders
13 8 13 5 4 13 18 12 13
Surgical and medical
procedures
2 2 3 0 0 0 2 2 2
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A total of 17 SAEs were reported in 13 (22%) participants in the adalimumab group and three SAEs in
two (7%) participants in the placebo group during the course of the blinded phase of the trial. The rate of
SAEs was greater in the adalimumab group (0.29 per patient-year) than in the placebo group (0.19 per
patient-year).
A participant listing of SAEs for adalimumab and placebo can be found in Appendix 3 (see Table 43). All
but one of the SAEs were classified as mild to moderate. This SAE was reported in a participant on placebo
whose vision had deteriorated while on medication; the participant’s treatment allocation was revealed
and, consequently, they commenced on dexamethasone drops and anti-TNF-α.
Laboratory parameters
Haematological
The data relating to haematological parameters are summarised below.
Table 9 gives the mean difference [standard error (SE)] of change in haematological laboratory parameters
from baseline to each treatment visit of adalimumab compared with placebo. Differences marked by an
asterisk were significant at the 5% level. None of the mean changes in haematological assessments was
considered to be clinically significant.
There was evidence of a greater change in lymphocytes from baseline to months 1 and 2 and in
eosinophils from baseline to 3 months in the adalimumab group than in the placebo group. The placebo
group experienced a greater change in mean red blood cell count from baseline to 6 months than the
adalimumab group.
Biochemical
The data relating to biochemical parameters are summarised below.
Table 10 gives the mean difference (SE) of change in biochemical laboratory parameters from baseline to
each treatment visit of adalimumab compared with placebo. Differences marked by an asterisk were
significant at the 5% level.
There was evidence of a greater change in urea from baseline to months 1, 2, 3 and 18; in potassium
from baseline to 6 months; and in creatinine from baseline to 18 months in the placebo group than in
the adalimumab group. None of the mean changes in biochemical assessments was considered to be
clinically significant.
Urinalysis
Table 11 shows the number of abnormal urinalysis assessments in each treatment group over time.
Details on the microscopic analysis are presented in Table 12. Overall, the results from the urinalysis were
not clinically significant.
Participant diaries and dosing records
Participant diaries and dosing records determined tolerability and compliance throughout the trial treatment
period. Treatment compliance was estimated using participant treatment diaries and accountability logs.
Treatment diaries were used to estimate participant compliance by dividing the number of doses recorded
as taken in the treatment diary by the expected number of doses the participant should have taken (on the
basis of the time the participant was on treatment). According to the treatment diaries, compliance of
adalimumab was 84% and compliance of placebo was 74%. MTX compliance was estimated to be 62% for
the adalimumab group and 50% for the placebo group (see Appendix 3, Tables 44 and 45, respectively).
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TABLE 9 Mean difference in haematological variables from baseline to each treatment visit of adalimumab compared with placebo
Variable
Month, mean difference (SE)
1 2 3 6 9 12 15 18
Haematocrit (%) 0.44 (0.60) 0.27 (0.56) –0.73 (0.67) –1.23 (0.76) –0.81 (1.24) –1.93 (1.54) 0.12 (1.69) 1.62 (1.88)
Haemoglobin (g/dl) 0.08 (0.17) 0.02 (0.17) –0.12 (0.18) –0.41 (0.25) –0.38 (0.37) –0.52 (0.41) –0.37 (0.44) –0.09 (0.68)
Red blood cell count ( × 1012/l) 0.00 (0.06) –0.00 (0.06) –0.06 (0.06) –0.20 (0.08)a* –0.18 (0.11) –0.18 (0.14) –0.25 (0.14) –0.17 (0.17)
White blood cell count ( × 1012/l) 0.33 (0.53) 0.09 (0.66) –0.22 (1.17) 1.17 (0.69) 0.06 (0.99) 0.90 (1.36) 1.36 (1.32) 0.75 (1.63)
Neutrophils ( × 109/l) –0.07 (0.45) –0.66 (0.52) –0.83 (1.10) 0.64 (0.58) –0.45 (0.70) 0.04 (0.95) 0.40 (1.08) 0.03 (1.29)
Lymphocytes ( × 109/l) 0.39 (0.15)* 0.52 (0.20)* 0.42 (0.23) 0.32 (0.19) 0.53 (0.38) 0.72 (0.42) 0.61 (0.63) 0.34 (0.32)
Monocytes ( × 109/l) 0.04 (0.04) 0.07 (0.05) 0.07 (0.06) 0.12 (0.06) 0.09 (0.09) 0.10 (0.10) 0.20 (0.11) 0.10 (0.13)
Basophils ( × 109/l) 0.01 (0.01) 0.00 (0.01) –0.00 (0.01) –0.00 (0.01) –0.01 (0.01) –0.01 (0.01) 0.01 (0.01) –0.01 (0.01)
Eosinophils ( × 109/l) 0.04 (0.06) 0.06 (0.05) 0.14 (0.05)* 0.11 (0.08) –0.02 (0.06) –0.02 (0.26) 0.06 (0.10) 0.17 (0.13)
Platelet count ( × 109/l) –3.34 (12.80) –6.79 (11.60) –21.86 (13.48) –17.27 (13.30) –14.41 (20.23) –6.78 (30.89) –15.56 (37.23) –15.05 (29.94)
ESR (mm/hour) 0.09 (3.49) –0.85 (2.71) –0.03 (2.43) –1.84 (4.25) –2.49 (3.40) 3.40 (5.34) –1.50 (6.25) 5.39 (8.31)
Plasma viscositya N/A N/A N/A N/A N/A N/A N/A N/A
*p < 0.05.
ESR, erythrocyte sedimentation rate; N/A, not applicable.
a In the placebo arm, only one assessment was carried out at baseline and at months 1, 2, 3 and 6; none was carried out at months 9, 12, 15 and 18; therefore, no mean difference could
be calculated between the two groups.
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TABLE 10 Mean difference (SE) in biochemical variables from baseline to each treatment visit of adalimumab compared with placebo
Variable
Month, mean difference (SE)
1 2 3 6 9 12 15 18
CRP (mg/l) 1.15 (2.43) 0.19 (1.43) 0.06 (3.09) –0.99 (1.78) –1.82 (2.16) –0.25 (2.22) 1.26 (3.69) 6.06 (12.90)
Urea (mmol/l) –0.43 (0.21)* –0.55 (0.25)* –0.57 (0.27)* –0.38 (0.36) –0.69 (0.49) –1.02 (0.54) –1.45 (0.86) –1.57 (0.72)*
Creatinine (mmol/l) –1.19 (1.86) –2.22 (2.27) 0.51 (2.29) 0.45 (1.86) –0.94 (5.36) 0.88 (3.09) 0.15 (3.89) –23.64 (8.68)*
Sodium (mmol/lL) 1.07 (0.61) 1.14 (0.64) –0.05 (0.55) 0.19 (0.96) 0.05 (1.11) 0.39 (1.29) –0.59 (1.88) 0.57 (2.04)
Potassium (mmol/l) –0.05 (0.10) 0.01 (0.11) 0.00 (0.13) –0.29 (0.14)* 0.15 (0.33) 0.18 (0.32) 0.07 (0.21) –0.09 (0.19)
Calcium (mmol/l) 0.02 (0.02) 0.01 (0.03) 0.04 (0.03) 0.01 (0.03) –0.03 (0.05) 0.03 (0.05) 0.02 (0.06) –0.06 (0.08)
Inorganic phosphate (mmol/l) 0.05 (0.06) 0.05 (0.06) –0.03 (0.06) 0.02 (0.07) 0.08 (0.12) –0.11 (0.10) –0.06 (0.14) –0.09 (0.14)
Glucose (mmol/l) –0.06 (0.30) –0.33 (0.30) 0.15 (0.30) 0.43 (0.40) 0.11 (0.77) 0.10 (0.77) 0.69 (0.74) 0.17 (0.84)
Chloride (mmol/l) 0.86 (0.63) 0.31 (0.68) 1.19 (0.76) 1.24 (0.98) 0.41 (1.23) 0.45 (1.33) –1.25 (1.78) –0.38 (1.96)
Bicarbonate (mmol/l) 0.28 (1.08) –0.41 (1.00) –1.34 (1.01) 0.02 (1.53) –3.70 (2.42) 1.52 (2.00) 0.39 (3.36) 0.20 (2.90)
Total bilirubin (mmol/l) 1.08 (0.89) 1.25 (0.93) –0.35 (0.96) 0.84 (1.50) 2.11 (1.69) 2.74 (1.75) 0.06 (3.43) –3.40 (2.13)
ALT (IU/l) 2.67 (8.05) 6.80 (7.31) –0.86 (6.11) 1.51 (9.53) 25.83 (41.90) 0.66 (10.92) 9.19 (14.94) 4.29 (13.68)
AST (IU/l) –3.32 (2.47) –3.63 (2.72) –1.02 (4.31) –4.41 (4.89) 6.03 (26.32) –11.75 (6.85) –12.00 (13.41) 8.76 (13.63)
*p < 0.05.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein.
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The accountability logs were used to provide another estimate of adalimumab and placebo compliance
by dividing the sum of the number of used vials returned (and the number of missing vials) by the number
of vials issued. Estimated compliance for the adalimumab group was 94% and for the placebo group
was 90%.
Four participants in the adalimumab group (0069039, 0030035, 0116062 and 0116066) had their
medication stopped. Participant 0030035 failed treatment because of missed doses that met failure criteria
and taking permitted concomitant medications against acceptable criteria, and one participant (0116003)
in the placebo group failed treatment because they missed more than the required number of doses while
on treatment.
Four participants had their study medication stopped because of missed doses of MTX: 0116052, 0248064,
0540060 and 0246055. These participants were all receiving adalimumab at the time that they met the
threshold for missed doses of MTX.
Use of corticosteroids over duration of study period
Total oral corticosteroid dose
One participant in the placebo group and five participants in the adalimumab group received oral
corticosteroids during the course of the blinded treatment phase. The five participants in the adalimumab
group were on study treatment for a total of 5.28 years and the placebo participant was on study
treatment for 0.17 years.
TABLE 11 Number of abnormal urinalysis assessments at each visit
Visit Allocation
Number of abnormal assessments
(number of participants)
Baseline Adalimumab 19 (17)
Placebo 15 (13)
Month 1 Adalimumab 20 (15)
Placebo 12 (8)
Month 2 Adalimumab 23 (18)
Placebo 9 (7)
Month 3 Adalimumab 15 (13)
Placebo 9 (7)
Month 6 Adalimumab 17 (11)
Placebo 4 (4)
Month 9 Adalimumab 15 (12)
Placebo 5 (4)
Month 12 Adalimumab 12 (11)
Placebo 4 (3)
Month 15 Adalimumab 8 (8)
Placebo 1 (1)
Month 18 Adalimumab 6 (6)
Placebo 1 (1)
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The total oral dose for the placebo group was 640 mg (standardised per patient-year, was 3767.74 mg)
and 4248.5 mg for the adalimumab group (standardised per patient-year 804.31 mg). A rate ratio of 0.21
(95% CI 0.20 to 0.23; p < 0.0001) indicated that participants on placebo required more oral corticosteroids
per patient-year than those randomised to adalimumab and there was evidence at the 5% level of a
statistically significant difference between the two groups.
Reduction in and rate of systemic corticosteroid dose from entry dose
Reduction in systemic corticosteroid dose from entry dose
Reduction in systemic corticosteroid dose from entry dose to 0 mg
At the beginning of the study, there were six participants (adalimumab group, n = 5; placebo group,
n = 1) who were prescribed systemic corticosteroids (permitted dose < 0.2 mg/kg/day; median dose
0.14 mg/kg/day). Three adalimumab-treated participants stopped systemic corticosteroids (median duration
18.14 weeks). The placebo group participant stopped systemic corticosteroids after 5.57 weeks.
No comparative analysis could be performed because the statistical algorithm did not converge.
Reduction in systemic corticosteroid dose from entry dose to < 5 mg
At the beginning of the study, there were three participants (adalimumab group, n = 2; placebo group,
n = 1) who were on ≥ 5 mg of systemic corticosteroids.
TABLE 12 Microscopic urinalysis results
Time
point Allocation Assessments, n
Normal
assessments,
n (%)
Abnormal
assessments,
n (%)
If abnormal,
clinically
significant,
n (%)
Assessment
recorded
as not
applicable,
n (%)
Missing,
n (%)
Baseline Adalimumab 17 9 (53) 7 (41) 1 (14) 1 (6) 0 (0)
Placebo 13 7 (54) 4 (31) 0 (0) 2 (15) 0 (0)
1
month
Adalimumab 15 8 (53) 3 (20) 0 (0) 4 (27) 0 (0)
Placebo 8 4 (50) 3 (38) 0 (0) 1 (13) 0 (0)
2
months
Adalimumab 18 11 (61) 3 (17) 1 (33) 3 (17) 1 (6)
Placebo 7 3 (43) 3 (43) 0 (0) 0 (0) 1 (14)
3
months
Adalimumab 13 9 (69) 3 (23) 0 (0) 1 (8) 0 (0)
Placebo 7 4 (57) 2 (29) 0 (0) 0 (0) 1 (14)
6
months
Adalimumab 11 6 (55) 3 (28) 2 (67) 2 (18) 0 (0)
Placebo 4 4 (100) 0 (0) N/A 0 (0) 0 (0)
9
months
Adalimumab 12 6 (50) 6 (50) 2 (33) 0 (0) 0 (0)
Placebo 4 3 (75) 0 (0) N/A 0 (0) 1 (25)
12
months
Adalimumab 11 7 (64) 3 (27) 2 (67) 1 (9) 0 (0)
Placebo 3 1 (33) 2 (67) 0 (0) 0 (0) 0 (0)
15
months
Adalimumab 8 5 (63) 2 (25) 0 (0) 1 (13) 0 (0)
Placebo 1 0 (0) 0 (0) N/A 1 (100) 0 (0)
18
months
Adalimumab 6 2 (40) 1 (20) 1 (100) 2 (40) 0 (0)
Placebo 1 0 (0) 1 (100) 0 (0) 0 (0) 0 (0)
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No comparative analysis could be performed because the statistical algorithm did not converge.
One participant on adalimumab had a reduction to < 5 mg of systemic corticosteroids and one participant
ended treatment before having a reduction to < 5 mg. The participant on placebo had a reduction to < 5 mg.
Rate of systemic corticosteroid dose from entry dose
The result of this analysis was the same as that of the total oral corticosteroid analysis.
Topical corticosteroid use (frequency) compared with entry use
Time to reduction to fewer than two drops in topical corticosteroid
The outcome was time to reduction to fewer than two drops per day for those participants already at
more than two drops per day at baseline. There were 63 participants who were on more than two drops
per day at baseline [18 (60%) in the placebo group and 45 (75%) in the adalimumab group] and who
were, therefore, included in the analysis.
Twenty-four (53.3%) of the 45 participants on adalimumab and three (16.70%) of the 18 participants on
placebo reached fewer than two drops per day before treatment failure (or the 18-month treatment visit).
Five participants (11.10%) on adalimumab and one (5.60%) participants on placebo reached the 18-month
visit before reaching fewer than two drops per day and 16 (35.6%) of the adalimumab group and 14 (77.8%)
of the placebo group had a treatment failure/withdrawal before reaching fewer than two drops per day.
The time to reduction to fewer than two drops per day was statistically significant in favour of adalimumab
(HR 3.99, 95% CI 1.18 to 13.48; p = 0.03); the incidence plot is shown in Figure 6.
Time to reduction to zero drops in topical steroid (post hoc analysis)
The outcome was time to reduction to zero drops for those participants already at more than zero drops
at randomisation. There were 74 participants [25 (34%) on placebo and 49 (66%) on adalimumab] who
were on more than zero drops at randomisation and who were, therefore, included in the analysis.
Twenty-five (51%) of the 49 participants on adalimumab and four (16%) of the 25 participants on placebo
reached zero drops before treatment failure (or the 18-month treatment visit). Six participants (12%) on
adalimumab and two participants (8%) on placebo reached the 18-month visit before reaching zero drops
and 18 (37%) of the adalimumab group and 19 (76%) of the placebo group had a treatment failure/
withdrawal before reaching zero drops.
The time to reduction to zero drops was statistically significant in favour of adalimumab (HR 4.01, 95% CI
1.40 to 11.51; p = 0.01); the incidence plot is shown in Figure 7.
Need for pulsed corticosteroid
One participant in the placebo group (3%) and two participants in the adalimumab group (3%) required
pulsed corticosteroids during the course of the blinded phase. There was no evidence of a difference
in the risk of requiring pulsed corticosteroids between the two treatment groups (RR 1.00, 95% CI
0.09 to 10.59; p > 0.99).
Optic and ocular
Number of participants having disease flares (as defined by worsening on standardised
uveitis nomenclature criteria) following 3 months of disease control
One of the 30 participants in the placebo group (3%) and 5 of the 60 participants in the adalimumab
group (8%) experienced 3 months of disease control with a subsequent disease flare; there was no
statistically significant difference between the two groups (RR 2.50, 95% CI 0.31 to 20.45; p = 0.66).
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The inference from the analysis of participants who had disease control in both eligible eyes followed by a
flare in at least one eye was the same as the analysis of disease control in one eye.
Number of participants having disease flare within the first 3 months
Three participants in the placebo group (10%) and no participants in the adalimumab group had a disease
flare in the first 3 months of treatment. There was statistically significant evidence at the 5% level (p = 0.03)
of a difference (RR 0.07, 95% CI 0.004 to 1.36) between the two groups.
No participants in the placebo group who had a flare within the first 3 months entered the study with two
eligible eyes; therefore, the analysis on both eyes was not possible.
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FIGURE 6 Incidence plot of time to reduction to fewer than two drops per day.
0
0.0
0.2
0.4
0.6
0.8
1.0
100 200 300
Days
400 500
Pr
o
b
ab
ili
ty
Reduction to zero drops,
placebo
Reduction to zero drops,
adalimumab
Treatment failure,
placebo
Treatment failure,
adalimumab
FIGURE 7 Incidence plot for time to reduction to zero drops.
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Visual acuity measured by age-appropriate logarithm of the minimum angle of
resolution assessment
Two analyses were conducted using joint modelling. In each analysis, when only one eye was involved,
the single logMAR value was used. When there were two eyes involved, the two analyses were:
l analysis 1 – taking the best logMAR measurement (the minimum of the two values)
l analysis 2 – taking the worst logMAR measurement (the maximum of the two values).
The parameter estimates for analyses 1 and 2 are presented in Table 13. For analyses 1 and 2, the results
of the joint modelling showed that the treatment effects (adalimumab) on the longitudinal logMAR are
–0.01 (95% CI –0.07 to 0.02) and –0.02 (95% CI –0.07 to 0.02), respectively, implying that there is no
significant difference between the treatments on logMAR. These estimates are adjusted for failure because
of treatment dropout from the trial.
Appendix 3 presents data on the logMAR score for participants in the trial, split by treatment group and
time point (see Table 46, and Figures 14 and 15).
Sensitivity analysis
The residuals from the separate fitted linear missed models (LMMs) for the logMAR indicated slight
departures from the normality assumption. In general, fixed-effects estimates are robust to non-normal
errors in LMMs.65 The histograms of baseline logMAR scores (for analyses 1 and 2) appeared approximately
normal (not shown) and, therefore, no further analysis from log-transformed data was considered.
In the primary analysis, a random-intercepts model for the longitudinal submodel was fitted. The second
sensitivity analysis investigated fitting a random-intercepts and random-slopes model. This showed that
inferences remained similar. For analyses 1 and 2, the treatment effect on the longitudinal outcome was
–0.01 (95% CI –0.05 to 0.03) and for the random-intercepts and random-slopes model the treatment
effect was –0.01 (95% CI –0.05 to 0.03); these were not statistically significant.
TABLE 13 Model parameters for joint modelling of logMAR analyses 1 and 2
Analysis Component Parameter Estimate 95% CI p-value
1 Longitudinal Intercept 0.01 –0.02 to 0.04 0.76
Baseline 0.71 0.51 to 0.93 < 0.0001
Time –0.001 –0.01 to 0.001 0.22
Adalimumab –0.01 –0.07 to 0.02 0.51
Survival Adalimumab –1.37 –2.26 to –0.70 0.001
HR 0.25 0.10 to 0.50 0.001
Association γ0 3.29 –2.42 to 12.15 0.39
2 Longitudinal Intercept 0.02 –0.02 to 0.05 0.36
Baseline 0.82 0.61 to 1.07 < 0.0001
Time –0.002 –0.01 to 0.0004 0.21
Adalimumab –0.02 –0.07 to 0.02 0.36
Survival Adalimumab –1.36 –2.35 to –0.69 0.001
HR 0.26 0.10 to 0.50 0.001
Association γ0 3.52 –3.09 to 9.44 0.29
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Number of participants with resolution of associated optic nerve or macular oedema
(as assessed by slit lamp biomicroscopy or optical coherence tomography, where available)
Four participants in the adalimumab group (6.67%) had associated optic nerve at baseline or developed it
at some point during the study, two (50%) of these cases were resolved during the study. There were no
participants who had associated optic nerve at baseline or developed this during the course of the study in
the placebo group. It was, therefore, not possible to carry out the planned statistical test of these data.
Two participants in the placebo group (7%) had macular oedema at baseline or developed it during the
course of the study, compared with four participants in the adalimumab group (7%).
Three participants in the adalimumab group (75%) and no participants in the placebo group had
resolution of the macular oedema (RR 5.00, 95% CI 0.34 to 74.52). This was based on the assumption
that, if the macular oedema occurred in both eligible study eyes, then resolution only had to occur in at
least one of these eyes.
Two of the three participants who had resolution of macular oedema were eligible in both eyes. Because
both of these participants experienced resolution in both eyes, there was no difference in results when
considering the assumption that the resolution must occur in both eligible eyes.
Number of participants with disease control (defined as zero cells, with topical
treatment for 3 and 6 months)
Three months
Two participants in the placebo group (7%) and 23 in the adalimumab group (38%) had disease control
for at least 3 months (RR 5.75, 95% CI 1.45 to 22.78; p = 0.001).
One (50%) of the two participants with disease control in the placebo group had both eyes eligible at
baseline and did not have disease control in both eyes. Of the 23 participants in the adalimumab group,
five participants (22%) had both eyes eligible at baseline and all five participants had disease control in
both study eyes for at least 3 months. The inference of the analysis when both eligible eyes had to have
disease control was the same as that for at least one eligible eye.
Six months
At 6 months, one participant (3%) in the placebo group and 17 participants in the adalimumab group
(28%) had disease control in at least one of their eligible eyes (RR 8.50, 95% CI 1.19 to 60.87; p = 0.005).
Four of the 17 participants (24%) had two eyes eligible at the beginning of the study.
All four participants in the adalimumab group, who were eligible in both eyes at the beginning of the
study, had disease control in both eyes for at least 6 months. The inference of the analysis when both
eligible eyes had to have disease control was the same as that for at least one eligible eye.
Number of participants entering disease remission (defined as zero cells, without topical
treatment for 3 and 6 months)
Three months
At 3 months, one participant in the placebo group (3.33%) and 15 in the adalimumab group (25%) had
entered disease remission in any of their eligible eyes (RR 7.50, 95% CI 1.04 to 54.12; p = 0.02).
One participant in the placebo group was eligible in both eyes at the beginning of the study, but had
disease remission in only one eye; four participants in the adalimumab group were eligible in both eyes at
the beginning of the study and all four had disease remission in both eyes. The inference of the analysis
when both eligible eyes had to be in remission was the same as that for at least one eligible eye.
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Six months
At 6 months, no participants in the placebo group and 13 in the adalimumab group (23%) had entered
disease remission in both of their eligible eyes (RR 13.72, 95% CI 0.84 to 223.26, p = 0.004).
Four participants in the adalimumab group (29%) were eligible in both eyes at the beginning of the study.
After 6 months, three of these four participants had entered remission in both of their eligible eyes and
one had not. The inference of the analysis when both eligible eyes had to be in remission was the same as
that for at least one eligible eye.
Duration of sustaining inactive disease (zero cells in the anterior chamber, with or
without topical treatment)
The difference in the total amount of time that participants sustained inactive disease was statistically
significant between the two treatment groups. The estimated mean days of sustained inactive disease was
16.36 days (SE 23.79 days) for the placebo group and 180.91 days (SE 16.81 days) for the adalimumab
group, with participants in the adalimumab group spending 164.55 more days (95% CI 104.41 days to
224.69 days; p < 0.0001) with inactive disease than those in the placebo group.
Quality-of-life assessment
Childhood Health Questionnaire
Overall, the mean scores for the CHQ psychosocial subscale (PsS) were very similar in both treatment
groups, with the adalimumab group having slightly higher scores (see Appendix 3, Table 47, and Figure 16).
The treatment effect on the longitudinal CHQ PsS score was 2.31 (95% CI –0.44 to 5.40), implying that
there is no difference between the treatments on the score; however, the p-value (0.06) is close to the
margin of statistical significance (Table 14).
TABLE 14 Joint modelling results (random intercepts only) for PsS and PhS summary scores
Outcome Component Parameter Estimate 95% CI p-value
PsS Longitudinal Intercept 15.84 7.49 to 23.13 0.0002
Baseline 0.68 0.54 to 0.83 < 0.0001
Time 0.05 –0.17 to 0.23 0.66
Adalimumab 2.31 –0.44 to 5.40 0.15
Survival Adalimumab –1.66 –2.55 to –0.89 0.0002
HR 0.19 0.08 to 0.41 0.0002
Association γ0 –0.14 –0.28 to –0.01 0.04
PhS Longitudinal Intercept 20.85 12.32 to 30.54 < 0.0001
Baseline 0.57 0.39 to 0.75 < 0.0001
Time –0.02 –0.21 to 0.12 0.83
Adalimumab 1.16 –2.41 to 5.05 0.55
Survival Adalimumab –1.40 –2.35 to –0.67 0.001
HR 0.25 0.10 to 0.51 0.001
Association γ0 –0.06 –0.17 to 0.03 0.18
PhS, physical subscale.
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The summary statistics for each time point for CHQ physical subscale (PhS) and the mean profile plots are
presented in Appendix 3 (see Table 48 and Figure 17). The treatment effect on the longitudinal CHQ-PhS
score was 1.16 (95% CI –2.41 to 5.05), which implies that there is no difference between the treatments
on this score (see Table 14). This estimate is adjusted for failure because of dropout from the trial.
Sensitivity analysis
The normality assumption was considered for each CHQ score. The log-transform of baseline CHQ scores
resulted in distributions that were more normal (not shown), although they still remained somewhat
skewed. The residuals from the separate fitted LMMs for the CHQ scores indicated departures from the
normality assumption. The log-transformations did not lead to an improvement in model fit according to
the Q–Q plot of the residuals (not shown). In general, fixed-effects estimates are robust to non-normal
errors in LMMs; therefore, the inferences from the untransformed (raw) CHQ scores are used.
The log-likelihood values for the primary analysis (random-intercepts only) and the sensitivity analysis
model (random-intercepts and random-slopes) were calculated. Although the likelihood is increased
for the random-intercepts and random-slopes model, it estimates two additional parameters: a variance
component for the random slope and a correlation term. Trading off the improvement in goodness of fit
against model complexity, only marginal model improvement for PhS was found. However, for PsS, there
was greater evidence in favour of the random-intercepts and random-slopes models. The inference on the
PhS score remained the same: 1.49 (95% CI –1.87 to 5.45). The treatment effect on the longitudinal PsS
score was 2.09 (95% CI –0.74 to 5.21), implying that there was no difference between the treatments on
this score too.
As a sensitivity analysis, the missing baseline values (n = 15) were imputed with the mean observed values for
the other participants and the 57 intermediate missing measurements; the approach was used as per the
predefined methodology in the SAP. After imputing the data, the joint model was refitted. The treatment
effect on PhS is halved for the imputation analysis; however, both the primary and the imputation analysis
treatment effects remain statistically non-significant. The treatment effect on the CHQ-PsS also remained
non-significant.
Childhood Health Assessment Questionnaire
The treatment effect on the longitudinal CHAQ is –0.14 (95% CI –0.31 to 0.02) and implies that there is
no difference between the treatments on CHAQ (Table 15). This estimate is adjusted for failure because of
dropout from the trial. However, the p-value (0.08) is close to the margin of statistical significance.
TABLE 15 Random-intercepts model: CHAQ
Component Parameter Estimate 95% CI p-value
Longitudinal Intercept 0.20 0.05 to 0.35 0.01
Baseline 0.65 0.49 to 0.75 < 0.0001
Time –0.01 –0.01 to 0.001 0.06
Adalimumab –0.14 –0.31 to 0.02 0.09
Survival Adalimumab –1.46 –2.23 to –0.80 0.0001
HR 0.23 0.11 to 0.45 0.0001
Association γ0 0.64 –0.89 to 2.04 0.35
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The summary statistics for the CHAQ are shown for each treatment group for each scheduled study visit.
The mean profile plots for each treatment group are given in Appendix 3 (see Table 49 and Figure 18).
Sensitivity analysis
The distribution of baseline CHAQ scores is non-normal. This is predominantly because of the large
proportion of zero baseline scores (n = 12 out of 87 remaining participants). However, the effect of the
log-transformation had little effect on the normality assumption of the residuals; therefore, no further
analysis was carried out.
In the first sensitivity analysis that considered the model specification, the model included a treatment-to-time
interaction term, as the treatment effect in the longitudinal submodel in the primary analysis, it was significant
at a 10% level. The interaction term in the fitted model was statistically significant. Furthermore, the fixed
effects for time and treatment were both significant at the 5% level under this model. The joint log-likelihood
values for the model with and without the interaction term indicated an improvement in model fit.
The treatment effects on the longitudinal outcome CHAQ were –0.20 (95% CI –0.37 to –0.06) and
implied that CHAQ was significantly lower in the adalimumab group.
The second sensitivity analysis considered a random-intercepts and random-slopes model. There was no
apparent increase in likelihood for the random-intercepts and random-slopes model. In addition, the
random-intercepts and random-slopes model estimates two additional parameters: a variance component
for the random slope and a correlation term. Trading off the improvement in goodness of fit against
model complexity, there was no model improvement. The sensitivity analysis that examined missing data
used imputation; the joint model was refitted and the inferences remained statistically significant.
American College of Rheumatology Pedi core set criteria at ACR 30, 50, 70, 90 and 100
The results for the joint model of the ACR Pedi and time-to-treatment failure can be seen in Table 16.
None of the improvements on ACRs is significantly different between treatments. The treatment effect on
ACR30 is 0.04 (95% CI –1.37 to 1.59), ACR50 is –0.70 (95% CI –2.15 to 0.77), ACR70 is –1.08 (95% CI
–2.70 to 0.46), ACR90 is –0.33 (95% CI –2.22 to 1.39) and ACR100 is –0.32 (95% CI –1.85 to 1.17).
These estimates are adjusted for an informatively missing outcome because of treatment failure.
Sensitivity analysis
The time effect was significant at the 10% level for all ACRs except for ACR 30 and 100. Models
(estimates not shown in this report) were assessed with time-by-treatment interaction term, but resulted in
non-significant effects for time, treatment and time–treatment.
For each model, the deviance information criterion (DIC) statistic was extracted, which can be thought of
as the Bayesian analogue of the Akaike information criterion (AIC).
For ACR 90 and 100, the separate longitudinal submodels did not fit or appear to converge. Model fit and
convergence problems were not unexpected, because the event (ACR = 1) rates were relatively low for
ACR 90 and 100. The event rates were:
l ACR30 – 35.5% (n = 125)
l ACR50 – 28.7% (n = 101)
l ACR70 – 18.5% (n = 65)
l ACR90 – 13.4% (n = 47)
l ACR100 – 5.4% (n = 19).
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For ACR 70, 90 and 100, the event rates had decreased immensely, from 35.5% for ACR30 to 18.5% for
ACR70, 13.4% for ACR90 and 5.4% for ACR100. The primary models for ACR 30, 50 and 70 (compared
with the model in sensitivity analysis 1) had overwhelmingly smaller DIC values; therefore, no further
models were considered. Note that owing to the problems outlined above, it was not possible to assess
whether or not there was an improvement between the primary model and all additional models fitted
for ACR 70, 90 and 100.
TABLE 16 Parameter estimates for ACR 30, 50, 70, 90 and 100
Outcome Component Parameter Estimate 95% CI p-value
ACR30 Longitudinal Intercept –1.35 –2.65 to –0.23 0.02
Time 0.03 –0.03 to 0.09 0.36
Adalimumab 0.04 –1.37 to 1.59 0.98
Survival Adalimumab –2.13 –3.10 to –1.22 < 0.001
HR 0.12 0.05 to 0.29 < 0.001
Association γ0 –0.23 –0.51 to 0.01 0.07
ACR50 Longitudinal Intercept –1.68 –2.98 to –0.53 0.003
Time 0.06 –0.003 to 0.13 0.06
Adalimumab –0.70 –2.15 to 0.77 0.37
Survival Adalimumab –2.22 –3.30 to –1.23 < 0.001
HR 0.11 0.037 to 0.29 < 0.001
Association γ0 –0.27 –0.58 to –0.02 0.04
ACR70 Longitudinal Intercept –2.67 –3.93 to –1.46 < 0.001
Time 0.07 –0.001 to 0.14 0.06
Adalimumab –1.08 –2.70 to 0.46 0.16
Survival Adalimumab –2.29 –3.58 to –1.28 < 0.001
HR 0.10 0.03 to 0.28 < 0.001
Association γ0 –0.32 –0.79 to 0.003 0.05
ACR90 Longitudinal Intercept –4.48 –6.03 to –3.06 < 0.001
Time 0.09 0.01 to 0.17 0.04
Adalimumab –0.33 –2.22 to 1.39 0.72
Survival Adalimumab –2.59 –4.40 to –1.37 < 0.001
HR 0.07 0.01 to 0.26 < 0.001
Association γ0 –0.41 –0.93 to –0.04 0.03
ACR100 Longitudinal Intercept –4.98 –6.25 to –3.88 < 0.001
Time 0.05 –0.05 to 0.15 0.30
Adalimumab –0.32 –1.85 to 1.17 0.65
Survival Adalimumab –2.17 –3.55 to –1.22 < 0.001
HR 0.11 0.03 to 0.29 < 0.001
Association γ0 –0.28 –1.08 to 0.22 0.34
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Number of participants undergoing disease flare, in remission on and/or
off medication for their juvenile idiopathic arthritis, and with minimum
disease activity
Number of participants undergoing disease flare
Three participants (10%) in the placebo group and no participants in the adalimumab group had at least
one case of disease flare of their JIA. In total, there were three episodes of disease flare in the three
participants in the placebo group.
The RR for disease flare was 0.07 (95% CI 0.004 to 1.36; p = 0.03). The inferences drawn from the
95% CI and p-value are different with respect to showing statistical significance; this may be because
there were low numbers of participants who had a disease flare in each group.
Number of participants in remission on and/or off medication for their juvenile
idiopathic arthritis
These outcomes will be reported in Chapter 6 because this outcome can be reported only during the
follow-up period.
Number of participants with minimum disease activity
There were 74 participants (82.2%) who had oligoarticular JIA, of whom 21 (23.3%) had extended
oligoarthritis and 53 (58.9%) had persistent oligoarthritis. Fourteen participants (15.6%) had polyarticular
JIA, of whom 12 (13.3%) had RF-positive polyarthritis and two (2.2%) had RF-negative polyarthritis.
Two participants (2.2%) had psoriatic arthritis.
Of the 74 participants who had oligoarticular JIA, 50 (68%) received adalimumab [14 (28%) out of
50 participants had extended oligoarthritis and 36 (72%) had persistent oligoarthritis] and 24 (32%)
received placebo [seven (29%) out of 24 participants had extended oligoarthritis and 17 (71%) had
persistent oligoarthritis].
Of the 14 participants who had polyarticular JIA, nine (64%) received adalimumab [eight (89%) had
RF-negative polyarthritis and one (11%) had RF-positive polyarthritis] and five (36%) received placebo
[four (80%) out of five had RF-negative polyarthritis and one (20%) had RF-positive polyarthritis).
At baseline, one (3%) participant in the placebo group and four (7%) participants in the adalimumab
group had minimum disease activity. The number of participants with minimum disease activity at each
time point is reported in Table 17. A total of 19 (32%) participants in the adalimumab group and four
participants in the placebo group had at least one case of minimum disease activity during the course of
the trial. The RR was 2.33 (95% CI 0.87 to 6.24) and the associated p-value from the chi-squared test was
0.08, indicating that there was no statistically significant difference between the two groups.
Number of participants requiring change in biological or disease-modifying
antirheumatic drugs therapy because of a failure to respond from arthritis
One (3%) participant in the placebo group and two (3%) participants in the adalimumab group required a
change in their biological drug therapy or DMARD therapy because of failure to respond from their arthritis.
This result was not statistically significant (RR 1.00, 95% CI 0.20 to 5.09; p = 0.99).
Juvenile Arthritis Disease Activity Score
The parameter estimates for each of the joint models of JADAS 10, 27 and 71 can be seen in Table 18.
The distribution of baseline JADAS scores showed that a log-transformation led to a reduction in
skewness. Therefore, the primary analysis joint models are fitted under this transformation.
CLINICAL EFFECTIVENESS RESULTS: BLINDED PHASE OF STUDY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
54
TABLE 17 Minimum disease activity by treatment group at each time point
Treatment
visit
Treatment group
TotalAdalimumab Placebo
Number with
oligoarticular
JIA or
polyarticular
JIA
Number (%)
with
minimum
disease
activity
Number with
oligoarticular
JIA or
polyarticular
JIA
Number (%)
with
minimum
disease
activity
Number with
oligoarticular
JIA or
polyarticular
JIA
Number (%)
with
minimum
disease
activity
Baseline 59 4 (7) 29 1 (3) 88 5 (6)
1 month 59 5 (8) 29 0 (0) 88 5 (6)
2 months 57 1 (2) 24 1 (4) 81 2 (3)
3 months 55 8 (15) 18 3 (17) 73 11 (15)
6 months 47 5 (10) 12 0 (0) 59 5 (8)
9 months 42 4 (10) 7 0 (0) 49 4 (8)
12 months 34 3 (9) 5 1 (20) 39 4 (10)
15 months 27 3 (11) 3 0 (0) 30 3 (10)
18 months 23 2 (9) 3 0 (0) 26 2 (8)
TABLE 18 Parameter estimates from joint modelling (random intercepts only) for JADAS 10, 27 and 71
Outcome Component Parameter Estimate 95% CI p-value
JADAS10 Longitudinal Intercept 0.62 0.24 to 1.07 0.003
Baseline 0.42 0.25 to 0.56 < 0.0001
Time –0.01 –0.03 to 0.01 0.27
Adalimumab –0.35 –0.78 to 0.01 0.07
Survival Adalimumab –2.38 –3.92 to –1.48 0.25
HR 0.09 0.02 to 0.23 0.25
Association γ0 1.11 0.11 to 2.85 0.10
JADAS27 Longitudinal Intercept 0.62 0.25 to 1.06 0.003
Baseline 0.42 0.24 to 0.57 < 0.0001
Time –0.01 –0.03 to 0.01 0.27
Adalimumab –0.34 –0.76 to 0.03 0.08
Survival Adalimumab –2.37 –3.97 to –1.47 0.25
HR 0.09 0.02 to 0.23 0.25
Association γ0 1.10 0.08 to 2.88 0.11
JADAS71 Longitudinal Intercept 0.63 0.24 to 1.08 0.003
Baseline 0.42 0.25 to 0.56 < 0.0001
Time –0.01 –0.03 to 0.01 0.26
Adalimumab –0.36 –0.78 to 0.004 0.07
Survival Adalimumab –2.38 –3.88 to –1.48 0.25
HR 0.09 0.02 to 0.23 0.25
Association γ0 1.11 0.11 to 2.81 0.0981
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The treatment effects on the longitudinal JADAS 10, 27 and 71 were all non-significant at the 5% level,
implying that there is no difference in scores between the treatments. However, all three p-values are close
to the margin of statistical significance.
Sensitivity analysis
For each outcome, a treatment–time interaction term was fitted because the treatment effect in the
longitudinal submodel was significant at the 10% level. In all cases, there was some negligible increase in
likelihood, and the corresponding AICs were slightly higher for the models with interaction, which did not
support selection of the models with interaction terms. The estimated treatment effect on the longitudinal
JADAS 10 and 71 also had p-values slightly below the 5% level.
The second model-specification sensitivity analysis considered a random-intercepts and random-slopes
model. The log-likelihood values for the primary analysis (random-intercepts only) and the sensitivity
analysis model (random intercepts and random slopes) showed that the likelihood is increased for the
random-intercepts and random-slopes model. Trading off the improvement in goodness of fit against
model complexity, the AIC confers evidence of model fit improvement. The treatment effects on all three
longitudinal JADAS scores are marginally significant, with p-values just above 5%.
When the sensitivity analysis was conducted examining the effects of missing data, the treatment effects for
each outcome in the longitudinal submodel were statistically significant (p < 0.05). Moreover, the association
parameters are also significant (p < 0.05), implying that high JADAS values lead to a significantly high risk of
treatment failure. This would suggest that the additional data have led to an increased power to detect the
treatment effects and latent association parameters.
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Chapter 6 Clinical effectiveness results:
open-label phase
The results reported in this chapter are based on the integrated analysis of the blinded and open-labelphase for participants in the adalimumab group compared with the results from the blinded phase
for participants in the placebo group. The last participant visit in the open-label phase took place on
29 June 2016.
Primary outcome
During the course of the open-label phase of the trial, there were three additional treatment failures
that occurred in the adalimumab arm. One participant was classified as having a treatment failure because
they had taken permitted concomitant medications against the acceptable criteria and two participants
had sustained scores (as recorded at entry grade) that were still present after 6 months of therapy (see
Appendix 3, Table 50).
There were a total of 17 (28.3%) treatment failures for the 60 participants in the adalimumab group and
17 (56.7%) failures for the 30 participants in the placebo group. Median time to treatment failure was
24.1 weeks (95% CI 14.7 weeks to 81 weeks) in the placebo group and not reached in the adalimumab
group within the 18-month treatment period because fewer than half of the subjects experienced
treatment failure at the conclusion of the study (Figure 8).
The results of the log-rank test from SAS PROC LIFETEST (SAS Institute In, Cary, NC, USA) offered
strong statistical evidence that the placebo and adalimumab groups differed with respect to time to
treatment failure.
The HR indicated that treatment with adalimumab significantly decreased the hazard of treatment failure
by 74% (HR 0.26, 95% CI 0.13 to 0.51; p < 0.0001), relative to placebo.
0.0
0 2010 4030 6050 80 9070
Time to treatment failure (weeks)
60
30
Adalimumab (n)
Placebo (n)
54
17
59
24
51
9
45
6
47
8
42
4
38
4
0
0
3
1
0.2
0.4
Pr
o
b
ab
ili
ty
 o
f 
re
m
ai
n
in
g
 f
ai
lu
re
 f
re
e
0.6
0.8
1.0
Allocation
+ Censored
Log-rank p < 0.0001
Adalimumab
Placebo
FIGURE 8 Primary outcome Kaplan–Meier plot for blinded and open-label phase.
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Test of proportional hazards assumption
The assumption of proportional hazards was tested by including an interaction between time and
treatment group in the Cox proportional hazards model. There was no evidence (p = 0.1371) that the
interaction was not zero and, therefore, no evidence that the HR was not constant over time.
Sensitivity analyses
There were no losses to follow-up during the course of the trial and, therefore, sensitivity analysis 8 was
not conducted. The results of the other sensitivity analyses indicate that the original conclusion from the
primary analysis was robust with regard to the changes that were made. The overall statistical significance
of the sensitivity analyses did not change.
Additional analyses
Development of uveitis in non-study eye
There were no additional occurrences of this outcome during the open-label phase of the trial.
Time to treatment failure in both eyes
This analysis was not possible because only one participant (in the placebo group) failed in both eyes at
different times.
Development of comorbidity from treatment failure
There were no additional occurrences of this outcome during the open-label phase of the trial. There were
so few numbers in the two treatment groups of those who developed a comorbidity that any modelling,
including the development of a comorbidity, was not possible.
Post hoc analyses
Time-to-treatment response
During the open-label phase of the trial, there were three participants in the adalimumab group who
achieved treatment response, meaning that, overall, during the blinded and open-label phases, a total
of 47 participants in the adalimumab group were classified as having a treatment response. The difference
between the two groups was statistically significant (log-rank p-value = 0.003). The HR indicated that
participants on adalimumab were just under three times more likely to achieve a treatment response than
those on placebo (HR 2.96, 95% CI 1.40 to 6.27).
Proportion of responders/failures/no change
Proportion of responders/failures/no change at 3 months
During the open-label phase of the trial, there were no further occurrences of response at 3 months and
the overall conclusion showed a significant difference between the treatment groups at 6 months.
Proportion of responders/failures/no change at 6 months
During the open-label phase of the trial, there were no further occurrences of response at 6 months and
the overall conclusion showed a significant difference between the treatment groups at 6 months.
Area under the curve of anterior chamber cells in eligible eye
There was a significant difference in the median number of AC cells between the two groups from the
overall data of –0.81 (95% CI –0.99 to –0.64; p < 0.0001) (results from eye level favouring the adalimumab
group), with similar results obtained when the best or worst score was used for participants with two
eligible eyes.
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Secondary outcomes
Number of participants failing treatment
Seventeen participants in the adalimumab group (28.33%) and 17 participants in the placebo group
(56.67%) were classified as having treatment failures. The risk of having a treatment failure was
statistically significantly reduced by 54% (RR 0.46, 95% CI 0.26 to 0.83; p = 0.01) in the adalimumab
group compared with placebo.
Safety, tolerability and compliance
Adverse events and serious adverse events
During the open-label phase of the trial, 63 AEs occurred in 12 participants and two SAEs occurred in two
participants (one SAE was reported outside the 30-day window of treatment cessation). For completeness,
the SAE that was reported outside the reporting time window has been reported in Appendix 3 (see Table 43)
only and is not included in any of the total numbers. The SAE that was reported during follow-up was in
relation to joint swelling of the right knee and the severity was classified as mild and judged ‘unlikely’ to be
related to the study drug.
A total of 86 participants (out of 90) experienced at least one AE. A total of 682 AEs were reported in
60 participants (100%) in the adalimumab group and 114 AEs reported in 26 participants (86.7%) in the
placebo group. The rate of AEs in the adalimumab group (9.86 per patient-year) was greater than that in
the placebo group (7.21 per patient-year).
The most common AEs in the adalimumab group were classified as infections and infestations (85.0%);
general disorders and administration-site conditions (55%); respiratory, thoracic and mediastinal disorders
(55.0%); gastrointestinal disorders (48.3%); investigations (35.0%); nervous system disorders (31.7%);
eye disorders (28.3%); musculoskeletal and connective tissue disorders (26.7%); and injury, poisoning and
procedural complications (23.3%) (Table 19).
Laboratory parameters (haematological, biochemical analysis and urinalysis)
When the data from the open-label period were combined with the data from the blinded phase of the
trial, there were no changes to the clinical conclusions of the analyses of the haematological, biochemical
and urinalysis data.
Participant diaries and dosing records
On average, treatment compliance for the adalimumab group during the open-label phase of the study,
was 84%, according to the participant diaries, and 87%, according to the accountability logs. Overall,
treatment compliance for the adalimumab group during the blinded phase of the trial and the open-label
phase of the study combined was 83%, according to the participant diaries, and 94%, according to the
accountability logs.
The average compliance with MTX for the adalimumab group during the open-label phase of the trial
(according to participant diaries) was 74%; the average compliance with MTX for the adalimumab group
overall for both phases of the trial was 61%.
Use of corticosteroids over duration of study period
Total oral corticosteroid dose
One participant in the placebo group and five participants in the adalimumab group received oral
corticosteroids during the course of the study. The five participants in the adalimumab group were on study
treatment for a total of 6.03 years and the placebo participant was on study treatment for 0.17 years.
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The total oral dose for the placebo group was 640 mg (which was 3767.74mg standardised per patient-year)
and 4267.5 mg for the adalimumab group (which was 707.70mg standardised per patient-year). A rate ratio
of 0.19 (95% CI 0.17 to 0.20) indicated that participants on placebo required more oral corticosteroids per
patient-year than those on adalimumab and there was evidence at the 5% level of a statistically significant
difference between the two groups (p < 0.0001).
Reduction in and rate of systemic corticosteroid dose from entry dose
Reduction in systemic corticosteroid dose from entry dose
Reduction in systemic corticosteroid dose from entry dose to 0mg This analysis was not able to be
performed because the statistical algorithm did not converge.
TABLE 19 Adverse events by treatment group (an integrated analysis of the blinded and open-label phases)
System Organ Class
Treatment group
TotalAdalimumab Placebo
Events
(n)
Patients
(n)
% of
patients
Events
(n)
Patients
(n)
% of
patients
Events
(n)
Patients
(n)
% of
patients
Blood and lymphatic system
disorders
5 5 8.3 0 0 0.0 5 5 5.6
Ear and labyrinth disorders 1 1 1.7 0 0 0.0 1 1 1.1
Eye disorders 21 17 28.3 9 8 26.7 30 25 27.8
Gastrointestinal disorders 87 29 48.3 14 9 30.0 101 38 42.2
General disorders and
administration-site conditions
135 33 55.0 15 8 26.7 150 41 45.6
Immune system disorders 4 4 6.7 1 1 3.3 5 5 5.6
Infections and infestations 164 51 85.0 30 14 46.7 194 65 72.2
Injury, poisoning and
procedural complications
18 14 23.3 5 3 10.0 23 17 18.9
Investigations 43 21 35.0 6 4 13.3 49 25 27.8
Metabolism and nutrition
disorders
3 3 5.0 0 0 0.0 3 3 3.3
Musculoskeletal and
connective tissue disorders
32 16 26.7 8 7 23.3 40 23 25.6
Neoplasms benign,
malignant and unspecified
(including cysts and polyps)
5 5 8.3 0 0 0.0 5 5 5.6
Nervous system disorders 36 19 31.7 10 4 13.3 46 23 25.6
Psychiatric disorders 5 2 3.3 2 1 3.3 7 3 3.3
Reproductive system and
breast disorders
11 3 5.0 0 0 0.0 11 3 3.3
Respiratory, thoracic and
mediastinal disorders
95 33 55.0 9 6 20.0 104 39 43.3
Skin and subcutaneous
tissue disorders
14 9 15.0 5 4 13.3 19 13 14.4
Surgical and medical
procedures
3 3 5.0 0 0 0.0 3 3 3.3
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Reduction in systemic corticosteroid dose from entry dose to < 5 mg This analysis was not able to
be performed because the statistical algorithm did not converge.
Rate of systemic corticosteroid dose from entry dose
The result of this analysis was the same as that of the total oral corticosteroid analysis.
Topical corticosteroid use (frequency) compared with entry use
Time to reduction to fewer than two drops in topical corticosteroid
The time to reduction to fewer than two drops per day was statistically significant in favour of adalimumab
(HR 4.25, 95% CI 1.26 to 14.31; p = 0.02).
Time to reduction to zero drops in topical steroid (post hoc analysis)
The time to reduction to zero drops per day was statistically significant in favour of adalimumab (HR 4.26,
95% CI 1.49 to 12.2; p = 0.01).
Need for pulsed corticosteroid
During the open-label phase of the trial, there were no additional participants who required pulsed
steroids. In total, one participant in the placebo group (3.33%) and two participants in the adalimumab
group (3.33%) required pulsed corticosteroids during the course of the study. The RR showed that there
was no evidence of a difference in the risk of requiring pulsed corticosteroids between the two treatment
groups (RR 1.00, 95% CI 0.09 to 10.59; p > 0.99).
Optic and ocular
Number of participants having disease flares (as defined by worsening on
Standardisation of the Uveitis Nomenclature criteria) following 3 months’ disease control
All events of disease flare following disease control took place in the blinded phase of the trial (i.e. there
were no further events within the open-label phase).
Number of participants having disease flares within the first 3 months
One participant in the adalimumab arm failed treatment within the open-label phase of the study.
Overall, three participants in the placebo group (10%) and one participant in the adalimumab group (3%)
had a disease flare in the first 3 months of treatment. There was no statistically significant evidence at the
5% level (p = 0.11) of a difference (RR 0.17, 95% CI 0.02 to 1.54) between the two groups.
Visual acuity measured by age-appropriate logarithm of the minimum angle of
resolution assessment
The integrated analysis for the data on the logMAR score for participants in the trial split by treatment
group and time point can be found in Table 20.
The parameter estimates from the joint modelling for analyses 1 and 2 (for the blinded and open-label
phase of the trial combined) are shown in Table 21.
The results for integrated analyses 1 and 2 for the treatment effects (adalimumab) on the longitudinal
logMAR are 0.01 (95% CI –0.06 to 0.02) and –0.02 (95% CI –0.07 to 0.02), respectively, implying that
there is no significant difference between the treatments on logMAR.
These estimates are adjusted for the failure caused by treatment dropout from the trial.
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TABLE 20 The logMAR results for best/worst score by treatment group for each time point
Visit
Treatment group
Adalimumab Placebo Total
Best score Worst score Best score Worst score Best score Worst score
n Mean (SD)
Median
(Range) n Mean (SD)
Median
(Range) n
Mean
(SD)
Median
(Range) n
Mean
(SD)
Median
(Range) n Mean (SD)
Median
(Range) n
Mean
(SD)
Median
(Range)
Baseline 60 0.04 (0.15) 0.00
(–0.23 to 0.56)
60 0.05 (0.16) 0.00
(–0.23 to 0.56)
30 0.06 (0.12) 0.05
(–0.13 to 0.40)
30 0.08 (0.12) 0.06
(–0.10 to 0.40)
90 0.04 (0.14) 0.00
(–0.23 to 0.56)
90 0.06 (0.14) 0.03
(–0.23 to 0.56)
1 month 60 0.03 (0.17) 0.00
(–0.30 to 0.80)
60 0.04 (0.18) 0.00
(–0.30 to 0.80)
30 0.02 (0.16) 0.00
(–0.28 to 0.38)
30 0.06 (0.17) 0.04
(–0.28 to 0.38)
90 0.02 (0.17) 0.00
(–0.30 to 0.80)
90 0.05 (0.18) 0.00
(–0.30 to 0.80)
2 months 58 0.02 (0.17) 0.00
(–0.20 to 0.56)
58 0.04 (0.19) 0.00
(–0.20 to 0.75)
25 0.05 (0.18) 0.00
(–0.15 to 0.76)
25 0.06 (0.18) 0.02
(–0.15 to 0.76)
83 0.03 (0.17) 0.00
(–0.20 to 0.76)
83 0.04 (0.19) 0.00
(–0.20 to 0.76)
3 months 57 0.00 (0.16) 0.00
(–0.20 to 0.80)
57 0.02 (0.19) 0.00
(–0.20 to 0.88)
19 0.01 (0.11) 0.00
(–0.13 to 0.24)
19 0.03 (0.12) 0.00
(–0.13 to 0.28)
76 0.00 (0.14) 0.00
(–0.20 to 0.80)
76 0.02 (0.18) 0.00
(–0.20 to 0.88)
6 months 51 0.02 (0.19) –0.02
(–0.20 to 0.88)
51 0.02 (0.19) 0.00
(–0.20 to 0.88)
12 0.05 (0.16) 0.02
(–0.18 to 0.30)
12 0.07 (0.19) 0.02
(–0.18 to 0.38)
63 0.02 (0.18) 0.00
(–0.20 to 0.88)
63 0.03 (0.19) 0.00
(–0.20 to 0.88)
9 months 48 –0.01 (0.14) 0.00
(–0.25 to 0.40)
48 –0.01 (0.14) 0.00
(–0.25 to 0.40)
7 0.00 (0.17) –0.08
(–0.10 to 0.36)
7 0.04 (0.20) –0.08
(–0.10 to 0.36)
55 –0.01 (0.14) 0.00
(–0.25 to 0.40)
55 0.00 (0.14) 0.00
(–0.25 to 0.40)
12 months 43 –0.02 (0.14) –0.02
(–0.23 to 0.34)
43 –0.01 (0.14) 0.00
(–0.23 to 0.34)
5 0.03 (0.14) 0.02
(–0.10 to 0.26)
5 0.08 (0.17) 0.03
(–0.10 to 0.26)
48 –0.02 (0.14) –0.01
(–0.23 to 0.34)
48 0.00 (0.14) 0.00
(–0.23 to 0.34)
15 months 38 –0.01 (0.12) 0.00
(–0.25 to 0.40)
38 0.00 (0.12) 0.00
(–0.25 to 0.40)
3 0.00 (0.26) –0.10
(–0.20 to 0.30)
3 0.00 (0.26) –0.10
(–0.20 to 0.30)
41 –0.01 (0.13) 0.00
(–0.25 to 0.40)
41 0.00 (0.13) 0.00
(–0.25 to 0.40)
18 months 34 0.00 (0.13) 0.00
(–0.22 to 0.28)
34 0.01 (0.12) 0.00
(–0.22 to 0.28)
3 0.02 (0.21) –0.10
(–0.10 to 0.26)
3 0.02 (0.21) –0.10
(–0.10 to 0.26)
37 0.00 (0.13) 0.00
(–0.22 to 0.28)
37 0.01 (0.12) 0.00
(–0.22 to 0.28)
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Sensitivity analysis
The inferences of the sensitivity analyses for the data from the blinded phase of the trial combined with
the open-label data were the same as those from the blinded phase alone.
Number of participants with resolution of associated optic nerve or macular oedema (as
assessed by slit lamp biomicroscopy or optical coherence tomography, where available)
There were no further occurrences of optic nerve resolution or macular oedema in the open-label phase of
the study.
Number of participants with disease control (defined as zero cells, with topical treatment
for 3 and 6 months)
Three months
There were four participants in the adalimumab group who achieved disease control for 3 months during
the open-label phase in at least one eligible eye. This meant that, overall, two participants in the placebo
group (7%) and 27 in the adalimumab group (45%) had disease control for at least 3 months (RR 6.75,
95% CI 1.72 to 26.51; p = 0.0002).
The inferences for disease control in all eligible eyes were the same as those for disease control in one
eligible eye.
TABLE 21 Model parameters for joint modelling of logMAR analyses 1 and 2
Analysis Component Parameter Estimate 95% CI p-value
1 Longitudinal Intercept 0.01 –0.03 to 0.04 0.76
Baseline 0.70 0.51 to 0.92 < 0.0001
Time –0.002 –0.004 to 4 × 10–4 0.17
Adalimumab –0.01 –0.06 to 0.02 0.53
Survival Adalimumab –1.33 –2.25 to –0.73 0.001
HR 0.26 0.11 to 0.48 0.001
Association γ0 2.86 –2.41 to 10.37 0.41
2 Longitudinal Intercept 0.02 –0.02 to 0.05 0.37
Baseline 0.81 0.60 to 1.06 < 0.0001
Time –0.002 –0.004 to 3 × 10-4 0.17
Adalimumab –0.02 –0.07 to 0.02 0.37
Survival Adalimumab –1.32 –2.23 to –0.70 0.001
HR 0.27 0.11 to 0.50 0.001
Association γ0 3.31 –2.14 to 8.43 0.27
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Six months
There were five participants in the adalimumab group who achieved disease control for 3 months during
the open-label phase in at least one eligible eye meaning that, overall, one participant (3%) in the placebo
group and 22 participants in the adalimumab group (36.67%) had disease control in at least one of their
eligible eyes (RR 11.00, 95% CI 1.56 to 77.74; p = 0.0003).
The inferences for disease control in all eligible eyes were the same as those for disease control in one
eligible eye.
Number of participants entering disease remission (defined as zero cells, without topical
treatment for 3 and 6 months)
Three months
There were no further cases of disease remission in the open-label phase.
Six months
There were no further cases of disease remission in the open-label phase.
Duration of sustaining inactive disease (zero cells in the anterior chamber, with or
without topical treatment)
The difference in the total number of days that participants sustained inactive disease was statistically
significant between the two treatment groups [16.31 days (SE 25.69 days) for the placebo group and
225.43 days (SE 18.15 days) for the adalimumab group], with participants in the adalimumab group
spending approximately 209 (mean difference 208.80, 95% CI 143.91 to 273.69) more days with inactive
disease than those in the placebo group (p < 0.0001).
Quality-of-life assessment
Childhood Health Questionnaire
The treatment effect on the longitudinal CHQ-PsS score (blinded and open-label phases) was 2.37 (95% CI
–0.41 to 5.47), which implies that there is no difference between the treatments on the score (Table 22).
The treatment effect on the longitudinal CHQ-PhS score (blinded and open-label phases) was 1.23 (95% CI
–2.31 to 5.28), which implies that there is no difference between the treatments on this score (see Table 22).
This estimate is adjusted for the failure due to dropout from the trial.
Sensitivity analysis
The inferences of the sensitivity analyses for the data from the blinded phase of the trial combined with
the open-label data were the same as those from the blinded phase alone.
Childhood Health Assessment Questionnaire
The overall treatment effect (blinded and open-label phases) on the longitudinal CHAQ was –0.14 (95% CI
–0.32 to 0.003), which implies that there is no difference between the treatments on CHAQ (Table 23).
This estimate is adjusted for the failure due to dropout from the trial. However, the p-value (0.08) is close
to the margin of statistical significance.
Sensitivity analysis
The inferences of the sensitivity analyses for the data from the blinded phase of the trial combined with
the open-label data were the same as those from the blinded phase alone.
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American College of Rheumatology Pedi core set criteria at ACR 30, 50, 70, 90 and 100
The results for the joint modelling of ACR Pedi and time to treatment failure can be seen in Table 24.
None of the improvements on ACRs is significantly different between treatments. All estimates are
adjusted for the failure caused by dropout from the trial.
Sensitivity analysis
The inferences of the sensitivity analyses for the data from the blinded phase of the trial combined with
the open-label data were the same as those from the blinded phase alone.
TABLE 23 Random intercepts model (overall data): CHAQ
Component Parameter Estimate 95% CI p-value
Longitudinal Intercept 0.20 0.05 to 0.35 0.01
Baseline 0.65 0.49 to 0.76 < 0.0001
Time –0.01 –0.01 to 4 × 10–4 0.01
Adalimumab –0.14 –0.32 to 0.01 0.08
Survival Adalimumab –1.42 –2.19 to –0.73 0.0001
HR 0.24 0.11 to 0.48 0.0001
Association γ0 0.43 –1.29 to 1.70 0.54
TABLE 22 Joint modelling results (random intercepts only) for the PsS and PhS summary score
Outcome Component Parameter Estimate 95% CI p-value
PsS Longitudinal Intercept 15.37 6.54 to 22.59 0.0004
Baseline 0.69 0.55 to 0.85 < 0.0001
Time 0.08 –0.10 to 0.23 0.34
Adalimumab 2.37 –0.41 to 5.47 0.14
Survival Adalimumab –1.56 –2.45 to –0.85 0.0002
HR 0.21 0.09 to 0.43 0.0002
Association γ0 –0.11 –0.24 to –0.01 0.07
PhS Longitudinal Intercept 20.68 12.17 to 30.70 < 0.0001
Baseline 0.58 0.38 to 0.75 < 0.0001
Time 0.04 –0.11 to 0.16 0.56
Adalimumab 1.23 –2.31 to 5.28 0.53
Survival Adalimumab –1.34 –2.30 to –0.67 0.001
HR 0.26 0.10 to 0.51 0.001
Association γ0 –0.05 –0.15 to 0.03 0.24
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Number of participants undergoing disease flare, in remission on and/or
off medication for their juvenile idiopathic arthritis, and with minimum
disease activity
Number of participants undergoing disease flare
During the open-label phase of the trial, there were no additional occurrences of participants undergoing
a disease flare; therefore, the results of the combined analyses are the same as those reported during the
blinded phase.
TABLE 24 Parameter estimates for ACR 30, 50, 70, 90 and 100
Outcome Component Parameter Estimate 95% CI p-value
ACR30 Longitudinal Intercept –1.35 –2.54 to –0.25 0.02
Time 0.04 –0.01 to 0.09 0.11
Adalimumab 0.01 –1.37 to 1.49 0.99
Survival Adalimumab –1.98 –2.97 to –1.07 < 0.001
HR 0.14 0.05 to 0.34 < 0.001
Association γ0 –0.21 –0.50 to 0.03 0.10
ACR50 Longitudinal Intercept –1.69 –2.97 to –0.50 0.01
Time 0.07 0.01 to 0.13 0.02
Adalimumab –0.71 –2.20 to 0.78 0.34
Survival Adalimumab –2.12 –3.15 to –1.24 < 0.001
HR 0.12 0.04 to 0.29 < 0.001
Association γ0 –0.26 –0.58 to –0.02 0.04
ACR70 Longitudinal Intercept –2.72 –4.10 to –1.54 < 0.001
Time 0.08 0.01 to 0.14 0.02
Adalimumab –1.11 –2.68 to 0.42 0.16
Survival Adalimumab –2.34 –4.06 to –1.18 < 0.001
HR 0.10 0.02 to 0.31 < 0.001
Association γ0 –0.38 –0.99 to –0.04 0.02
ACR90 Longitudinal Intercept –4.74 –6.48 to –3.21 < 0.001
Time 0.11 0.04 to 0.18 0.004
Adalimumab –0.48 –2.47 to 1.44 0.62
Survival Adalimumab –2.55 –4.21 to –1.30 < 0.001
HR 0.08 0.015 to 0.27 < 0.001
Association γ0 –0.38 –0.85 to –0.07 0.01
ACR100 Longitudinal Intercept –5.13 –6.38 to –3.92 < 0.001
Time 0.10 0.01 to 0.18 0.03
Adalimumab –0.43 –1.91 to 1.04 0.57
Survival Adalimumab –2.37 –4.52 to –1.15 < 0.001
HR 0.09 0.01 to 0.32 < 0.001
Association γ0 –0.44 –1.18 to 0.15 0.18
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Number of participants in remission on and/or off medication for their juvenile
idiopathic arthritis
Number of participants in remission on medication for their juvenile idiopathic arthritis
Seven participants (12%) in the adalimumab group and 17 (57%) participants in the placebo group could
not be included in the analysis because they had not been on medication for the required amount of time
(6 months).
Ten (19%) of those in the adalimumab analysis population achieved remission; none of the placebo
participants did. The risk of having remission while on medication in the adalimumab group was greater
than for those on placebo but was not statistically significant (RR 5.40, 95% CI 0.30 to 87.40; p = 0.19).
Number of participants in remission off medication for their juvenile idiopathic arthritis
There were 45 (75%) participants in the adalimumab group and 21 (70%) in the placebo group who
could not be included in the analysis because they had not been off medication for the required amount
of time (12 months).
No participants in either the adalimumab group or the placebo group achieved remission off medication
for their JIA.
Number of participants with minimum disease activity
During the open-label phase of the trial, 22 (37%) participants in the adalimumab group (this was three
more than the result from the blinded phase alone) and four participants in the placebo group had at least
one case of minimum disease activity during the course of the trial. The RR was 2.70 (95% CI 1.03 to 7.12)
and the associated p-value from the chi-squared test was 0.03, indicating that there was a statistically
significant difference between the two groups.
Number of participants requiring change in biological or disease-modifying
antirheumatic drug therapy as a result of failure to respond from arthritis
There were no further cases of participants requiring a change in biological or DMARD therapy as a result
of failure to respond from arthritis in the open-label phase.
Juvenile Arthritis Disease Activity Score
The parameter estimates for each of the joint models of JADAS 10, 27 and 71 can be seen in Table 25.
The treatment effect on the longitudinal JADAS 10, 27 and 71 was non-significant at the 5% level,
implying that there is no difference between the treatments on the scores. However, all three p-values are
close to the margin of statistical significance.
Sensitivity analysis
The inferences of the sensitivity analyses for the data from the blinded phase of the trial combined with
the open-label data were the same as those from the blinded phase alone.
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TABLE 25 Parameter estimates from joint modelling (random intercepts only) for JADAS 10, 27 and 71
Outcome Component Parameter Estimate 95% CI p-value
JADAS10 Longitudinal Intercept 0.61 0.22 to 1.07 0.004
Baseline 0.43 0.24 to 0.57 < 0.0001
Time –0.01 –0.02 to 0.007 0.26
Adalimumab –0.35 –0.76 to 0.02 0.08
Survival Adalimumab –2.25 –3.65 to –1.37 0.15
HR 0.11 0.03 to 0.25 0.15
Association γ0 1.07 –0.02 to 2.56 0.09
JADAS27 Longitudinal Intercept 0.60 0.21 to 1.04 0.004
Baseline 0.42 0.24 to 0.57 < 0.0001
Time –0.01 –0.02 to 0.01 0.28
Adalimumab –0.33 –0.75 to 0.04 0.09
Survival Adalimumab –2.24 –3.67 to –1.35 0.15
HR 0.11 0.03 to 0.26 0.15
Association γ0 1.05 –0.01 to 2.54 0.09
JADAS71 Longitudinal Intercept 0.62 0.22 to 1.08 0.004
Baseline 0.43 0.24 to 0.57 < 0.0001
Time –0.01 –0.02 to 0.01 0.26
Adalimumab –0.35 –0.77 to 0.01 0.07
Survival Adalimumab –2.25 –3.63 to –1.37 0.15
HR 0.11 0.03 to 0.25 0.15
Association γ0 1.07 –0.03 to 2.49 0.09
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Chapter 7 Clinical effectiveness results:
follow-up phase
The corticosteroid data results reported in this chapter are based on the integrated analysis of theblinded, open-label and follow-up phases for participants in the adalimumab group compared with the
results from the blinded and follow-up phases for participants in the placebo group.
The laboratory data results reported in this chapter are from the follow-up period of the trial only.
The follow-up period for the trial was reduced from 18 months (six follow-up visits) to 6 months
(two follow-up visits) in the revision to version 3.0 of the protocol, following the advice of the funders
(HTA and Arthritis Research UK; 1 March 2013). The last participant visit took place on 14 December 2016.
Laboratory parameters (haematological, biochemical analysis
and urinalysis)
The reduced follow-up period meant that only a small proportion of participants had data at six time points.
Therefore, only data from the first two follow-up visits have been presented in this report.
Haematological
Overall, statistically significant changes from baseline to follow-up visits 1 and 2 were not observed
in haematological assessments. None of the mean changes to either follow-up visit in haematological
assessments was considered to be clinically significant.
Biochemical
Overall, statistically significant changes from baseline to follow-up visits 1 and 2 were not observed in
biochemical assessments. None of the mean changes to either follow-up visit in biochemical assessments
was considered to be clinically significant.
Urinalysis
l Follow-up visit 1:
¢ There were nine abnormal assessments from five participants (the results were greater than a trace, and
so they needed microscopic urinalysis) in the placebo group. The results of the microscopic urinalysis
showed that one was normal and four were abnormal (one of these four was clinically significant).
¢ There were 19 abnormal assessments from 12 participants (the results were greater than a trace,
and so they needed microscopic urinalysis) in the adalimumab group. The results of the microscopic
urinalysis showed that five were normal and five were abnormal (two of these five were clinically
significant); two were classified as not applicable.
l Follow-up visit 2:
¢ There were 10 abnormal assessments from seven participants (the results were greater than a trace,
and so they needed microscopic urinalysis) in the placebo group. The results of the microscopic urinalysis
showed that four were normal and three were abnormal (one of these three was clinically significant).
¢ There were seven abnormal assessments from six participants (the results were greater than a trace, and
so they needed microscopic urinalysis) in the adalimumab group. The results of the microscopic urinalysis
showed that four were normal and two were abnormal (none of these two was clinically significant).
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Use of corticosteroids over duration of study period (blinded, open-label
and follow-up phases)
Total oral corticosteroid dose
One participant in the placebo group and five participants in the adalimumab group were receiving oral
corticosteroids at the start of the study. The five participants in the adalimumab group were in the study
for a total of 8.65 years and the placebo participant was in the study for 0.17 years.
The total oral dose for the placebo group was 640 mg (standardised per patient-year, 3767.74 mg) and
6837.5 mg in the adalimumab group (standardised per patient-year, 790.27 mg). A rate ratio of 0.21
(95% CI 0.19 to 0.23) indicated that participants on placebo required more oral corticosteroids per
patient-year than those on adalimumab; there was evidence at the 5% level of a statistically significant
difference between the two groups.
Reduction in and rate of systemic corticosteroid dose from entry dose
Reduction in systemic corticosteroid dose from entry dose
Reduction in systemic corticosteroid dose from entry dose to 0 mg
This analysis was not able to be performed because the statistical algorithm did not converge.
Reduction in systemic corticosteroid dose from entry dose to < 5 mg
This analysis was not able to be performed because the statistical algorithm did not converge.
Rate of systemic corticosteroid dose from entry dose
The result of this analysis was the same as that of the total oral corticosteroid analysis.
Topical corticosteroid use (frequency) compared with entry use
Time to reduction to fewer than two drops in topical corticosteroid
The time to reduction to fewer than two drops per day was statistically significant, in favour of
adalimumab (HR 4.74, 95% CI 1.41 to 16; p = 0.01).
Time to reduction to zero drops in topical steroid (post hoc analysis)
The time to reduction to zero drops per day was statistically significant, in favour of adalimumab (HR 5.24,
95% CI 1.82 to 15.1; p = 0.002).
Need for pulsed corticosteroid
During the follow-up period of the trial, two participants required pulsed corticosteroids. One participant in
the placebo group (3%) and four participants in the adalimumab group (7%) required pulsed corticosteroids
during the course of the study. There was no evidence (p = 0.66) of a difference in the risk of requiring pulsed
corticosteroids between the two treatment groups (RR 2.00, 95% CI 0.23 to 17.12).
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Chapter 8 Economic evaluation
Methods
The economic analysis adopted the perspective of the NHS and Personal Social Services providers in England.
A trial-based evaluation was extrapolated by 10 years using a Markov model in order to assess the costs and
consequences of adalimumab treatment over an appropriate analytical time horizon. The primary outcome
of the economic evaluation is the incremental cost per QALY with adalimumab in addition to MTX versus
MTX alone.
Resource use and costs
Within-trial costs were estimated by measuring health-care resource use associated with both arms of the
trial during the study period, including (1) adalimumab, MTX and other concomitant medication costs;
(2) outpatient and accident and emergency (A&E) visits and contact with health-care professionals,
including general practitioners (GPs) and school nurses; (3) hospitalisations; and (4) management of AEs.
The measurement of resource use required complementary approaches using data collected as part of the
trial and as part of routine care. Trial participants’ use of health-care services was obtained from:
l Medication forms. All medication use from 3 months before randomisation was recorded by trial
physicians at each trial visit and was supplemented by participant diary records.
l Baseline forms. Research nurses completed the relevant sections of the baseline forms to identify
participant contact with hospital and health-care professionals in the 3 months before randomisation.
l Three-monthly patient questionnaires. Research nurses completed the relevant sections of the patient
questionnaires during face-to-face interviews with trial participants to identify overnight hospital stays,
number of nights, reason for admission and type of ward. The patient questionnaires were also used to
identify contacts with health-care professionals including GPs, consultants, nurses, psychologists and
rheumatologists, as well as the places and/or means of contact (i.e. A&E, outpatient, GP practice, home
visits, telephone, text and e-mail).
l Electronic PLICS data and/or patient administration systems (PAS) data. These were accessed via the
participating hospitals’ finance departments to identify inpatient stays, use of intensive care or
high-dependency units, and outpatient visits.
l AE or SAE forms. Research nurses completed the AE and SAE forms when trial participants were
admitted to hospital for events considered possibly related to the study drug, which included
bronchopneumonia, herpes simplex infection, pharyngitis and pneumonia.
l Participant diaries recorded GP, social worker, district nurse and hospital visits.
In addition, for the estimation of long-term costs, longitudinal data for patients with JIA-associated and
idiopathic uveitis were obtained from the Bristol Regional Tertiary Paediatric Uveitis clinic. This cohort provided
data on the number and nature of surgeries performed from diagnosis with follow-up at 1, 3, 5 and 10 years.
Unit costs
All resource use was valued in monetary terms using appropriate UK unit costs estimated at the time of
analysis (cost year: 2016). The costs of adalimumab, MTX and all other concomitant medications were
based on the cost of items dispensed by Pharmacy and Appliance Contractors in England,66 supplemented
by the British National Formulary67 and retail pharmacy prices when necessary (Table 26). The cost of
adalimumab, which is not dose sensitive, was based on a once-per-fortnight subcutaneous injection. The
formulation of MTX used, which is available in injectable, oral tablet or oral solution form, was recorded
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in the concomitant medication forms during follow-up. The cost of MTX was based on a once-weekly
schedule; oral tablets were costed following best practice of all doses being made up as a multiple of a
2.5-mg dose tablet to avoid potential errors with combining different tablet strengths. All other medication
costs were based on duration of use as recorded in the concomitant medication forms and participant
diaries. All tablets and oral liquids were costed on a unit dose basis, whereas eye drops, creams, lotions
and inhalers were costed on a per pack basis.
Healthcare Resource Groups (HRGs) were used as the main currency of the economic analysis for hospital
episodes (Tables 27 and 28). These most closely reflect actual payments, with cost codes allocated based
on the latest available National Tariff68 (these are bundled care packages, reimbursed at a national level on
the basis of the NHS Payment by Results Scheme)69 and, for unbundled care packages, the latest National
Schedule,70 including A&E and outpatient contacts with time spent on consultations estimated through
discussions with research nurses. Personal Social Services Research Unit71 unit costs were applied to all
other primary health-care resource use items (Table 29).
The costs of surgery were based on the NHS National Schedule of Reference Costs70 paediatric
ophthalmology and outpatient procedures (Table 30). Clinical opinion was used to assign the most
relevant HRG code for each type of surgery.
Cost analysis
All medication, patient questionnaire and baseline form-reported hospital stays were costed irrespective of
whether or not they were condition related or not.
Bundled National Tariff costs were based on the hospital spell and incorporated excess ward days and
whether the case was elective or an emergency.72 Tariff codes were obtained primarily from PLICS and PAS
data, but if unavailable, were assigned an appropriate HRG code based on reason for admission, condition
and any complications, by referring to AEs, SAEs, baseline forms and patient questionnaires. Locally
negotiated unbundled costs were similarly identified and costs were assigned directly from the National
TABLE 26 Unit costs of trial medications
Medication Formulation Cost per unit (£) Source
Adalimumab Humira® 40 mg or 80 mg pre-filled syringea 352.14 BNF67
MTX Metoject® PEN (medac GmbH, Stirling, UK) 7.5 mg/0.15 mlb 14.85 PCA66
MTX Metoject PEN 10mg/0.2 ml 15.29 PCA66
MTX Metoject PEN 12.5 mg/0.25 ml 16.50 PCA66
MTX Metoject PEN 15mg/0.3 ml 16.57 PCA66
MTX Metoject PEN 17.5 mg/0.35 ml 17.50 PCA66
MTX Metoject PEN 20mg/0.4 ml 17.84 PCA66
MTX Metoject PEN 22.5 mg/0.45 ml 18.45 PCA66
MTX Metoject PEN 25mg/0.5 ml 18.48 PCA66
MTX MTX tablet 2.5 mg 0.06 PCA66
MTX MTX oral solution 2 mg/ml, S/F 2.65 PCA66
BNF, British National Formulary; PCA, Prescription Cost Analysis; S/F, sugar free.
a At the time of writing, there was no generic version of Humira® on the market. Both 20mg and 40mg of Humira
(Adalimumab) were manufactured by AbbVie Inc., Ludwigshafen, Germany.
b MTX (Abbvie Inc., Ludwigshafen, Germany).
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Schedule of Reference Costs.70 Reported health-care professional contacts in the patient questionnaires
and baseline forms were multiplied by unit costs to estimate total costs.
Medication and hospitalisation use were costed for the trial-based analysis period of baseline to 18 months.
If a medication administration spanned the period preceding randomisation, or beyond the 18-month time
horizon, an adjustment was made to apportion costs to only those administered during the 0- to 18-month
time horizon. Participants admitted to hospital were included if the hospital episode start date commenced
within the 0- to 18-month time horizon.
TABLE 27 Unit costs of outpatient attendances
Service
code
HRG
code HRG name Attendance
Cost per
episode (£) Source
130 BZ22Z Intermediate Vitreous
Retinal Procedures
OP procedure 142 National Tariff68
130 BZ23Z Minor Vitreous Retinal
Procedures
OP procedure 109 National Tariff68
130 WF01B Ophthalmology OP first attendance – single
professional
113 National Tariff68
130 WF02B Ophthalmology OP first attendance – multi
professional
125 National Tariff68
130 WF01A Ophthalmology OP follow-up attendance –
single professional
64 National Tariff68
130 WF02A Ophthalmology OP follow-up attendance –
multiprofessional
94 National Tariff68
216 WF01B Paediatric
Ophthalmology
OP first attendance – single
professional
136 National Tariff68
216 WF01A Paediatric
Ophthalmology
OP follow-up attendance –
single professional
82 National Tariff68
262 WF01A Paediatric Rheumatology OP attendance 203 NHS Reference Costs
2015 to 201670
410 WF01A Rheumatology OP follow-up attendance –
single professional
103 National Tariff68
410 WF01B Rheumatology OP first attendance – single
professional
225 National Tariff68
410 WF02B Rheumatology OP first attendance – multi
professional
246 National Tariff68
410 WF02A Rheumatology OP follow-up attendance –
multiprofessional
165 National Tariff68
420 WF01B Paediatrics OP first attendance – single
professional
222 National Tariff68
420 WF01A Paediatrics OP follow-up attendance –
single professional
135 National Tariff68
420 WF02A Paediatrics OP follow-up attendance –
multiprofessional
156 National Tariff68
650 WF01A/
WF01B
Physiotherapy OP attendance 48 NHS Reference Costs
2015 to 201670
OP, Outpatient.
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Outcomes
The health outcome for the economic evaluation was the QALY, calculated from utilities measured from
responses to the Health Utilities Index (HUI) questionnaire administered at baseline and at 3, 6, 9, 12 and
18 months. This was selected in preference to the EuroQol-5 Dimensions (EQ-5D) for its validity in
paediatric populations. The HUI is a 40-item questionnaire that assesses health-related quality of life
on eight single attributes: vision, hearing, speech, ambulation, dexterity, emotion, cognition and pain.
Each HUI level code is estimated from responses to single questions or from a pattern of responses to a
specific series of questions. Single attribute utility functions supply scores that express the morbidity for
a person for each attribute. The health-related quality of life for a subject was determined by applying a
multiattribute utility function to estimate HUI3 scores.73
TABLE 28 Unit costs of inpatient attendances, including day case
Service
code
HRG
code HRG name Attendance
Cost per
episode (£) Source
262/410 – Rheumatology Day case 246 National Tariff68
262/410 HB29Z Minimal knee procedures for non-trauma,
with length of stay 1 day or less
Day case 356 National Tariff68
262/410 PA64A Non-surgical ophthalmology, with length of
stay 0 days
Day case 552 National Tariff68
262/410 PH34D Paediatric, musculoskeletal or connective
tissue disorders, with CC score 0
Day case 590 NHS Reference Costs
2015 to 201670
262/410 HB39Z Minimal foot procedures for non-trauma,
with length of stay 1 day or less
Day case 672 National Tariff68
262/410 PA34B Musculoskeletal or connective tissue
disorders, without CC
Day case 688 National Tariff68
262/410 PH34C Paediatric, musculoskeletal or connective
tissue disorders, with CC score 1–2
Day case 696 NHS Reference Costs
2015 to 201670
262/410 PA34A Musculoskeletal or connective tissue
disorders, with CC
Day case 988 National Tariff68
CC, complication or comorbidity.
TABLE 29 Unit costs of health-care practitioner attendances
Profession
Unit cost (£)
Surgery Home Telephone E-mail Text message(s) A&E
Outpatient
visits
Additional
visits
GP 44.00 65.00 26.98 19.00 7.60 44.00 44.00 44.00
Nurse 14.42 14.42 8.82 7.35 2.94 29.40 44.10 44.10
Consultant 36.34 69.00 16.33 11.50 4.60 46.00 69.00 69.00
Optometrist 79.19 79.19 16.33 11.50 4.60 79.19 79.19 79.19
Psychologist 26.10 26.10 6.18 4.35 1.74 26.10 26.10 26.10
Note
Item costs are based on pro rata Personal Social Services Research Unit costs,71 according to the estimated time spent
on consultations.
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Modelled extrapolation
The Markov model was informed by a patient-level longitudinal data set of patients with idiopathic
and JIA-associated uveitis. The only outcome recorded in both SYCAMORE and the Bristol data set74
(see Resource use and costs), and which is expected to directly affect patients’ health-related quality of life,
was visual acuity, based on logMAR scores. To align with the model framework, the Bristol data74 were
stratified as no visual impairment (VI) (logMAR < 0.3) and VI (logMAR ≥ 0.3). Health states were defined by
patients’ vision in the worst eye as this was deemed the most clinically relevant. For trial participants, visual
logMAR scores were recorded during all protocol-based visits and at unscheduled clinic visits. Data were
ordered chronologically for each participant and time in each visual state (no VI, VI) was interpolated. The
proportion of time in each state (no VI, VI) for each arm of the trial was used to determine the initial
distribution of participants across the states of the Markov model (Figure 9). The cycle length was specified
as 1 year, and a half-cycle correction applied.
The Bristol cohort provided logMAR scores at diagnosis and at 1, 3, 5 and 10 years. This provided four
time periods over which transitions among states may occur. Transitions between visual states, or to the
same visual state, were defined as being either with or without surgery, which, along with transitions to
the death state, resulted in 11 possible transitions. Annual transition probabilities were estimated by
converting pooled transition probabilities over the 10-year time horizon into rates and back into
transition probabilities.
The cost of surgery was taken as being the mean cost of a transition with surgery according to the
longitudinal data set, as some transitions were associated with multiple surgery costs.
Published all-cause mortality data75 were adjusted for age but not sex because of the mixed cohort.
A standardised mortality ratio of 3.9 (95% CI 0.8 to 11.3) for non-systematic JIA was applied.76
TABLE 30 Unit costs applied to surgeries in longitudinal data
Recorded surgery Code Description in schedule Unit cost (£) Source
Cataract BZ32B Intermediate, cataract or lens
procedures, with CC score 0–1
208 NHS Reference Costs
2015 to 201670
Vitrectomy BZ85Z Very major or major, vitreous retinal
procedures, 18 years and under
334 NHS Reference Costs
2015 to 201670
Trabeculectomy BZ94B Intermediate, glaucoma or iris
procedures, with CC score 0
401 NHS Reference Costs
2015 to 201670
Iridectomy BZ94B Intermediate, glaucoma or iris
procedures, with CC score 0
401 NHS Reference Costs
2015 to 201670
Capsulotomy BZ33Z Minor, cataract or lens procedures 140 NHS Reference Costs
2015 to 201670
Glaucoma tube BZ93B Major, glaucoma or iris procedures,
with CC score 0–1
106 NHS Reference Costs
2015 to 201670
CC, complication or comorbidity.
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Incremental analysis
Base-case analysis
The cost-effectiveness of adalimumab plus MTX compared with MTX alone was evaluated by its ICER,
calculated by the formula:
ICER = ΔCosts /ΔQALY, (1)
where ΔCosts is the difference in mean total costs between intervention groups and ΔQALY is the
difference in mean QALYs between intervention groups.
The base-case analysis was defined as pertaining to the 18-month trial period plus the 10-year extrapolation,
based on an imputed data set to account for missing data and adjusting for the crossover of participants in
the placebo arm who had access to adalimumab after the end of the blinded phase.
The base-case assumptions were that participants in the adalimumab arm of the trial had access to
adalimumab for a further 3 years beyond the 18-month trial and then continued with MTX monotherapy
[Michael Beresford (University of Liverpool), Andrew Dick (Bristol Eye Hospital), Athimalaipet Ramanan (Bristol
Royal Hospital for Children), Eifiona Wood (Bangor University), Giovanna Culeddu (Bangor University) and
Dyfrig Hughes (Bangor University), personal communication, 2017]. Trial drug costs are based on full
adherence to adalimumab and MTX, in accordance with doses as defined in the protocol. Costs and QALYs
beyond the first year were discounted at an annual rate of 3.5%.
Missing data and crossover
There were missing utility values at baseline and at 3, 6, 9, 12 and 18 months, and missing data for assessing
the duration of time in visual impairment. Missing values were imputed using multiple imputation by chained
equations.77 Ten imputed data sets were created using predictive mean matching from a set of imputation
models constructed from all potential prognostic factors (trial arm, age, sex, baseline visual impairment) and
outcome variables (cost and exposure to adalimumab during the open-label phase).
The instrumental variable method was used to limit the bias that would result from participants randomised to
placebo having access to adalimumab during post-trial closure follow-up.78 Instrumental variable regressions
for total costs and QALYs were calculated over the 18-month time horizon, considering received treatment
(adalimumab), sex and age as covariates. For the 10-year modelled extrapolation, state-specific costs
(excluding trial drug costs, which were added into the Markov model separately) and QALYs were derived
using instrumental variable regressions, with treatment (adalimumab) and time in visual state as covariates.
Sensitivity analyses
Univariate sensitivity analysis
A number of sensitivity analyses were conducted to assess the robustness of the analysis. These included
exploration of the impact of different time horizons of analysis and a series of sensitivity analyses relating
to medication adherence, which tested assumptions based on the number of vials issued, accountability
logs and recordings in participant diaries.
Separately, sensitivity analyses were conducted to assess the impact of participants having access to adalimumab
for only the trial period (18 months) or for the duration of the model (18 months plus 10 years), based on the
proportion of participants in the adalimumab arm who had access to adalimumab beyond the 18-month trial
period in the open-label phase of the trial.
Owing to uncertainty in the proportion of participants who entered the Markov model with visual impairment,
sensitivity analyses were conducted based on the CIs of these proportions. The Markov model was estimated
with the proportions generated from upper to lower (H : L) and lower to upper (L : H) values of the CIs for
both arms of the trial.
Finally, a sensitivity analysis was conducted without the discounting of future costs and QALYs.
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Probabilistic sensitivity analysis
Mean costs and QALYs and differences between intervention groups in costs and QALYs were based on a
bootstrapped analysis using 10,000 replicates. The 95% central range was based on the 2.5 and 97.5
percentiles of the bootstrap values.
A probabilistic sensitivity analysis of the base case was performed using a Monte Carlo simulation with
10,000 replicates, sampling each parameter simultaneously within its distribution. Probability distributions
for regression-based analyses were generated using Cholesky decomposition.
Uncertainty in the ICER was represented as a cost-effectiveness plane and cost-effectiveness acceptability
curves, which present the probability of adalimumab being cost-effective for given ceiling thresholds of
costs per QALY.79 Estimates of ICERs were compared with the £20,000- to £30,000-per-QALY threshold of
cost-effectiveness set by NICE.80
Scenario analyses
Complete-case data
Scenario analyses were conducted for complete-case data over 18 months. This was also extended to the
10-year extrapolation by specifying an ordinary least squares regression, using complete-case resource use,
non-trial drug costs and QALYs to determine state-specific costs and utilities for both the adalimumab and
placebo arms, based on time in visual state.
Disregarding crossover
A further analysis was conducted without regard for post-trial closure crossover from placebo to adalimumab.
This was based on the imputed data set over 18 months and the 10-year extrapolation phase. Seemingly
unrelated regressions for total costs and QALYs predicted by trial arm were conducted for imputed data over
the 18-month time horizon. For the corresponding extrapolation, resource use, non-trial drug costs and
QALYs were generated by seemingly unrelated regressions with trial arm and time in visual state as covariates.
Trial drug costs were added afterwards.
All summary data and regression-based analyses were conducted using Stata version 13. The Markov model
was analysed in Microsoft Excel® 2013 (Microsoft Corporation, Redmond, WA, USA) and reported in
accordance with the Consolidated Health Economic Evaluation Reporting Standards.81
Results
Resource use and cost analysis
Participants’ use of health-care resources and the corresponding NHS costs were comparable at baseline in
both intervention groups for the 3 months prior to randomisation (Table 31). Only resource use associated
with concomitant medications (excluding MTX) was statistically different between groups. However, the
costs of the concomitant medications were not major cost drivers and accounted for only 3% of the total
costs for the adalimumab arm and 1% of total costs for the placebo arm. The main cost drivers for the
3 months prior to randomisation were inpatient admissions (52% of the total) and outpatient visits
(35% of total costs).
Each trial participant had available a level of resource use data that was costed and treated as complete
from baseline to 18 months’ follow-up. Tables 32 and 33 present the disaggregated health-care resource
use and costs, respectively, over this period. Mean total costs were £15,980 (95% CI £14,213 to £17,943;
n = 60) for adalimumab plus MTX and £6248 (95% CI £3922 to £8889; n = 30) for placebo plus MTX.
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TABLE 31 Baseline costs in the 3 months prior to randomisation, by intervention group
Item of resource use
Treatment group, mean, (£) (95% CI)
Difference in mean, (£)
(95% CI)Adalimumab (n= 60) Placebo (n= 30)
MTX 153 (127 to 179) 168 (131 to 200) –14 (–56 to 31)
Other concomitant
medications
51 (31 to 78) 19 (12 to 26) 32 (11 to 61)
Inpatient admissions 867 (542 to 1239) 768 (549 to 973) 100 (–299 to 525)
Outpatient visits 570 (450 to 705) 534 (345 to 759) 37 (–221 to 272)
GP visits 100 (66 to 143) 97 (56 to 147) 3 (–59 to 64)
Nurse visits 80 (54 to 109) 87 (49 to 126) –7 (–53 to 40)
Other 166 (103 to 238) 184 (103 to 277) –19 (–129 to 91)
Total costs 1614 (1312 to 1946) 1526 (1072 to 2047) 88 (–510 to 652)
TABLE 32 Disaggregated health-care resource use, including the most frequently observed HRGs over 18 months
from randomisation, by intervention group
Item of resource use
Treatment group, mean count (range if > 0)
[number of participants]
Difference in meansAdalimumab Placebo
GP visits 3.5 (1–14) [35] 2.75 (1–6) [12] 0.75
Nurse visits 3.3 (1–12) [22] 3.5 (1–10) [4] –0.20
Physiotherapist 2.9 (1–7) [10] 3.7 (3–4) [3] –0.80
Optician 2.0 (1–3) [8] 0.0 (0) [0] 2.00
Psychologist 1.4 (1–3) [5] 1.75 (1–4) [4] –0.35
OP – HRG BZ22B 2.0 (1–3) [4] 1.0 (1) [1] 1.00
OP – HRG BZ23Z 1.25 (1–2) [4] 1.0 (1) [1] 0.25
OP – HRG WF01A 6.07 (1–18) [26] 5.7 (1–15) [10] 0.37
OP – HRG WF01B 1.4 (1–2) [10] 1.16 (1–2) [6] 0.24
OP – HRG WF02A 3.6 (1–10) [5] 3.0 (1–5) [3] 0.60
IP – HRG PA34A 8.5 (1–31) [11] 5.25 (1–19) [8] 3.25
IP – HRG PA34B 10 (4–18) [3] 1.5 (1–3) [4] 8.50
IP – HRG PA64A 2.0 (1–3) [2] 2.0 (2–2) [1] 0.00
IP – HRG PH34C 1.2 (1–2) [5] 4.0 (3–5) [3] –2.80
IP – HRG PH34D 3.4 (1–7) [5] 1.4 (1–3) [5] 2.00
IP, inpatient; OP, outpatient.
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Adalimumab use was the main driver of the differences in costs between groups, contributing to 88% of the
difference in total costs. The cost of concomitant medications and optician visits differed between arms, but
these were not major cost drivers, accounting for 3% and 0.2% of the difference in total costs, respectively.
There was no statistical difference in resource use between the other items. The annualised cost of the trial
medications (adalimumab and MTX) differed by £8720 between groups (£11,118 adalimumab plus MTX vs.
£2398 MTX alone).
The Bristol cohort provided data from 91 patients with JIA-associated uveitis and 66 with idiopathic uveitis
(Table 34). The mean age of the patients was 8 years (SD 3.8 years) and 60% were female, which is
comparable with the SYCAMORE cohort. Thirty-seven surgeries in 25 patients were recorded in the Bristol
data set,74 corresponding to 7.87 per 100 patient-years of follow-up. The frequency of surgeries per
patient in a single time period are summarised in Table 35. Drug data were not dated and were, therefore,
TABLE 33 Disaggregated and total 18-month costs from randomisation, by intervention group
Item of resource use
Treatment group, mean, (£) (95% CI)
Difference in means, (£) (95% CI)Adalimumab (n= 60) Placebo (n= 30)
Adalimumab 10340 (9392 to 11,245) 1761 (722 to 2951) 8579 (7065 to 9978)
MTX 778 (638 to 910) 637 (462 to 816) 141 (–80 to 364)
Concomitant medications 540 (379 to 743) 249 (92 to 471) 291 (11 to 549)
Inpatient HRGs 2522 (1195 to 4135) 2549 (1166 to 4267) –27 (–2198 to 2158)
Outpatient HRGs 700 (434 to 1011) 692 (294 to 1191) 8 (–559 to 510)
GP visits 91 (64 to 122) 48 (23 to 79) 43 (2 to 84)
Optician 21 (8 to 37) 0 21 (8 to 37)
Nurse visits 18 (9 to 27) 7 (0 to 18) 11 (–3 to 23)
Physiotherapist 12 (4 to 21) 9 (0 to 20) 3 (–10 to 15)
Psychologist 3 (0 to 6) 6 (1 to 14) –3 (–12 to 4)
Total cost 15,980 (14,213 to 17,943) 6248 (3922 to 8889) 9732 (6562 to 12,793)
TABLE 34 Characteristics of patients included in the Bristol cohort
Characteristics Patients
Age at diagnosis (years)
Mean (SD) [range] 7.9 (3.8) [1–15]
Sex, n (%)
Male 60 (38.2)
Ethnicity, n (%)
Caucasian 122 (78.2)
Asian 6 (3.9)
African 1 (0.6)
Other 6 (3.9)
Unknown 22 (14.1)
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TABLE 34 Characteristics of patients included in the Bristol cohort (continued )
Characteristics Patients
Aetiology, n (%)
JIA 91 (58.3)
Idiopathic 66 (42.3)
Type of uveitis, n
Anterior 120
Intermediate 28
Panuveitis 8
Posterior 1
Year of diagnosis, n (%)
1997–2000 10 (6.4)
2001–5 37 (23.6)
2005–10 61 (38.9)
2011–15 48 (30.6)
Biologics received, n (%) (abatacept, adalimumab, etanercept, infliximab, tocilizumab)
None 104 (66.2)
One 41 (26.1)
Two 9 (5.7)
Three 2 (1.3)
Five 1 (0.6)
Adalimumab 47 (30.0)
LogMAR > 0.3 at diagnosis, n (%)a
Best eye 12 (9.5)
Worst eye 47 (37.3)
Surgical procedures, nb
Capsulotomy 3
Cataract 15
Glaucoma tube 1
Iridectomy 2
Trabeculotomy 10
Vitrectomy 6
a LogMAR data at diagnosis were available for 126 patients.
b A total of 37 procedures out of 268 observations.
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not used to stratify the data, as it was assumed that, following a standard care pathway, only patients
whose disease had progressed furthest would be prescribed biologics, which would bias the model against
adalimumab. For the Bristol cohort, the mean cost of surgeries between any two points of follow-up
was £419.
Outcomes
Utility and quality-adjusted life-years
Health Utility Index questionnaires were not completed for all participants, meaning that baseline utilities
were missing for 12 participants in the adalimumab group and nine participants in the placebo group.
For participants with complete baseline responses to the HUI questionnaire, mean utility values were
0.83 (95% CI 0.76 to 0.89; n = 48) for the adalimumab group and 0.87 (95% CI 0.78 to 0.96; n = 21)
for the placebo group (Table 36). No significant differences in utility scores were noted at baseline;
however, differences were reported for the 18-month utility scores, with a mean difference of 0.06
(95% CI 0.01 to 0.11) in favour of placebo.
Visual acuity
Quality-adjusted life-year scores were calculated for both the complete-case and imputed analyses. Owing to
missing data, QALY values were calculated only for three participants randomised to placebo and 25 participants
randomised to adalimumab. In the complete-case analysis, QALY scores were lower in the adalimumab group
[1.40 (95% CI 1.35 to 1.45)] than in the placebo group [1.45 (95% CI 1.41 to 1.5)], although the difference
was not significant. After imputation, the QALY scores were higher for adalimumab than placebo [1.35
(95% CI 1.30 to 1.41) and 1.28 (95% CI 1.15 to 1.41), respectively] but, again, not significantly different.
Figure 10 illustrates the distribution of HUI3 level scores by treatment arm, attributes and time. Fewer
participants in the placebo arm than in the adalimumab arm completed the HUI3; completion rates further
reduced in both arms over the trial period. At baseline, 82% of participants in the adalimumab group and
72% of participants in the placebo group reported level 1 vision (no visual impairment); by 18 months,
76% of participants in the adalimumab group and 75% of participants in the placebo group were in the
TABLE 35 Surgeries recorded in the Bristol data set
Surgeries in a single time period (n) Number recorded Cost per person (£)
None 243 0
Cataract 8 208
Glaucoma tube 1 106
Trabeculotomy 5 401
Vitrectomy 3 334
Capsulotomy; cataract 1 348
Capsulotomy (2), trabeculectomy (2) 1 1082
Cataract, iridectomy 1 610
Cataract (2), iridectomy 1 817
Cataract, trabeculectomy 1 610
Cataract, trabeculectomy (2) 1 1011
Cataract, vitrectomy 1 542
Vitrectomy (2) 1 667
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TABLE 36 Health outcomes 18 months from randomisation, by intervention group
Analysis Health outcomes
Treatment group, mean (95% CI)
Difference in means
(95% CI)Adalimumab Placebo
Complete casea Baseline utility 0.83 (0.76 to 0.89) 0.87 (0.78 to 0.96) –0.042 (–0.15 to 0.07)
18-month analysis,
time in VI (proportion)
0.03 (0.01 to 0.07) 0.02 (0.00 to 0.07) 0.01 (–0.04 to 0.06)
Utility at 18 months 0.94 (0.88 to 0.98) 0.99 (0.97 to 1.00) –0.06 (–0.11 to –0.01)
QALYs over 18 months 1.40 (1.35 to 1.45) 1.45 (1.41 to 1.50) –0.05 (–0.12 to 0.02)
Imputed datab Baseline utility 0.84 (0.77 to 0.90) 0.86 (0.78 to 0.95) –0.03 (–0.13 to 0.08)
18-month analysis,
time in VI (proportion)
0.05 (0.02 to 0.08) 0.11 (0.06 to 0.17) –0.06 (–0.12 to –0.01)
Utility at 18 months 0.93 (0.87 to 0.99) 0.92 (0.50 to 1.33) 0.01 (–0.18 to 0.20)
QALYs over 18 months 1.35 (1.30 to 1.41) 1.28 (1.15 to 1.41) 0.07 (–0.04 to 0.18)
a The CIs are percentile based.
b The CIs are normal based.
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FIGURE 10 Distribution of participants’ responses to each HUI3 attribute, by treatment allocated and time.
Levels range from 1 to 6, with 6 representing the most severe problem. The numbers of completed responses
are reported by treatment arm. (a) Vision; (b) hearing; (c) speech; (d) ambulation; (e) dexterity; (f) emotions;
(g) cognition; and (h) pain. (continued )
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level 1 vision category. However, at 18 months, responses to this attribute were reported for only four
participants in the placebo group, compared with 34 participants in the adalimumab group. For pain, at
baseline, 49% (29/59) of participants in the adalimumab group and 58% (17/29) of participants in the
placebo group reported level 1 pain score (no pain). At 18 months, 82% (27/33) of participants in the
adalimumab group and 100% (4/4) of participants in the placebo group reported level 1 pain score, but,
again, interpretation is hampered by low reporting rates at 18 months, especially in the placebo arm.
No participants reported hearing-related problems for the duration of the trial.
Visual acuity (logMAR) scores were available for 52 participants with complete-case data: 43 participants in
the adalimumab group and nine participants in the placebo group. Baseline logMAR scores were complete
and indicated the proportions of participants in the VI health state at baseline as 11.67% for adalimumab
and 6.67% for placebo, which was anticipated to introduce bias in the ‘time in visual impairment’
outcome. At 18 months, 36 participants in the adalimumab arm of the trial and eight participants in the
placebo arm had no time in the VI state. Mean proportion of time in the VI health state was 0.03 for
participants in the adalimumab group and 0.02 for participants in the placebo group (difference 0.01,
95% CI –0.04 to 0.06) (see Table 36).
Following imputation, participants randomised to adalimumab spent 5.3% of time in VI during the 18-month
analysis, whereas participants randomised to placebo spent 11.1% of time in VI. By including VI at baseline
and time in VI, alongside demographics, costs and utility outcomes, the imputation model corrected for
the imbalance in VI at baseline. In the imputed analyses, the rate of VI is higher in the placebo arm than in
the adalimumab arm.
Data on logMAR from the Bristol cohort were available for 126, 117, 93, 75 and 22 patients at baseline
and at 1, 3, 5 and 10 years, respectively. Based on the stratification of logMAR, 69 patients were recorded
as having VI at one or more time point, whereas 88 patients were never recorded as having VI. There were
268 observed transitions over the four periods when transition was possible.
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FIGURE 10 Distribution of participants’ responses to each HUI3 attribute, by treatment allocated and time.
Levels range from 1 to 6, with 6 representing the most severe problem. The numbers of completed responses
are reported by treatment arm. (a) Vision; (b) hearing; (c) speech; (d) ambulation; (e) dexterity; (f) emotions;
(g) cognition; and (h) pain.
DOI: 10.3310/hta23150 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 15
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Ramanan et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
87
Analysis
Base-case analysis
All Markov model inputs and their distributions are presented in Table 37.
Over the time horizon of the 18-month trial plus 10-year extrapolation, the total costs of the adalimumab
arm were £70,719. The total costs of the placebo arm were £31,403. Total QALYs were 8.60 for the
adalimumab arm and 8.29 for the placebo arm.
The incremental costs and QALYs for adalimumab were £39,316 and 0.30, respectively, resulting in an
ICER of £129,025 per QALY gained.
TABLE 37 Inputs from the Markov model
Parameter
Point
estimate
Distribution
(distribution parameters) Source
18-month data (trial based)
Cost coefficient
Adalimumab 14,374.01 Cholesky decomposition Trial data (SYCAMORE)
Age –257.72
Sex –445.89
Constant 3765.78
QALY coefficient
Adalimumab 0.11 Cholesky decomposition Trial data (SYCAMORE)
Age –0.00
Sex –0.02
Constant 1.26
Month 19–138 (Markov model): base-case model assumptions
Cost coefficients
Adalimumab arm (excluding trial
drug costs)
1437.13 Cholesky decomposition Trial data (SYCAMORE)
Time in visual impairment 2662.57
Constant 1603.05
Drug cost
Adalimumab 7411.73 Gamma∼(8.11, 1370.33) Trial data (SYCAMORE)
MTX 1598.17 Gamma∼(0.56, 4315.70) Trial data (SYCAMORE)
Surgery cost (per surgery transition) 418.71 None (fixed) Bristol data74 (see Resource
use and costs)
Discount rate: cost (per annum) 0.035 None (fixed) NICE80
QALY coefficients
Adalimumab arm (excluding trial
drug costs)
0.07 Cholesky decomposition Trial data (SYCAMORE)
Time in visual impairment –0.00
Constant 0.83
Discount rate: QALY (per annum) 0.035 None (fixed) NICE80
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Sensitivity analyses
Univariate sensitivity analysis
The results of the sensitivity analyses are presented in Table 38. These demonstrate that the model is
most sensitive to adalimumab usage. The most cost-effective scenario is based on the assumption of
adherence to MTX and adalimumab as recorded in the participant diaries over the 18-month time horizon
(incremental cost of £117,514 per QALY gained) and the 18-month plus 10-year time horizon (incremental
cost of £115,708 per QALY gained). However, participant diary recording of doses can be subject to
unreliability and does not reflect the costs to the NHS of prescriptions issued. The least cost-effective
analysis relates to adalimumab use being based on the number of vials issued, which was greater than the
base-case assumption based on time in the study (110.55%), resulting in ICERs of £149,040 and £140,576
per QALY gained over 18 months and 18-month plus 10-year time horizons, respectively.
The analysis in which the duration of adalimumab treatment was increased resulted in a lower ICER (£127,646
per QALY gained). Conversely, a shorter duration of treatment of 18 months, compared with 3 years in the
base case, reduces the incremental QALY gain and raises the ICER to £133,656 per QALY gained.
Probabilistic sensitivity analysis
Based on the results of the probabilistic sensitivity analysis applied to the base case, the mean total costs
of the adalimumab arm were £70,951 [95% credible range (CR) £45,204 to £123,764]. The mean total
costs of the placebo arm were £31,587 (95% CR £5308 to £83,320). Mean QALYs were 8.60 (95% CR
8.00 to 9.19) for the adalimumab arm and 8.29 (95% CR 7.42 to 9.17) for the placebo arm.
The mean incremental costs and QALYs for adalimumab were £39,364 (95% CR £24,728 to £58,235) and
0.31 (95% CR –0.04 to 0.66), respectively.
TABLE 37 Inputs from the Markov model (continued )
Parameter
Point
estimate
Distribution
(distribution parameters) Source
Probabilities
Proportion of VI
Adalimumab arm 0.05 Beta∼(4.75, 85.25) Trial data (SYCAMORE)
Placebo arm 0.11 Beta∼(10.04, 79.96) Trial data (SYCAMORE)
Transition probability from
No VI to no VI (no surgery) 0.95 Dirichlet∼(162, 4, 14, 2)
approximated by standardised
series of gamma distributions
Bristol data74 (see Resource
use and costs)
No VI to no VI (surgery) 0.01
No VI to VI (no surgery) 0.04
No VI to VI (surgery) 0.01
VI to no VI (no surgery) 0.33 Dirichlet∼(29, 6, 38, 13)
approximated by standardised
series of gamma distributions
Bristol data74 (see Resource
use and costs)
VI to no VI (surgery) 0.06
VI to VI (no surgery) 0.47
VI to VI (surgery) 0.14
Mortality ratea 0.000071 None (fixed) Human Mortality Database75
Standardised mortality ratio 3.9 Log-normal∼(3.9, 2.6785) Davies et al.76
a Mortality rate in the model is dependent on age. The figure presented in the table corresponds to the mortality rate of
an 8-year-old child.
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The cost-effectiveness plane (Figure 11) and the cost-effectiveness acceptability curve (Figure 12) indicate
that adalimumab is highly unlikely to be cost-effective in the £20,000- to £30,000-per-QALY threshold
range. The probability of being cost-effective at the £30,000-per-QALY threshold is < 1%. In 96% of
simulations, adalimumab was both more costly and more effective; however, in 4% of simulations,
adalimumab was seen to be less effective than placebo and remained more costly.
TABLE 38 Results of the sensitivity analyses
Sensitivity analysis
Costs (£) QALY
ICER (£)
Treatment group
Incremental
Treatment group
IncrementalAdalimumab Placebo Adalimumab Placebo
Base casea 70,719 31,403 39,316 8.60 8.29 0.30 129,025
Time horizon of analysis
18 months
Adalimumab adherence
based on vials issued
17,399 1734 15,666 1.36 1.25 0.11 149,040
Adalimumab adherence
based on accountability
logs
15,716 2095 13,621 1.36 1.25 0.11 129,587
Adalimumab and MTX
adherence based on
participant diaries
14,345 1993 12,352 1.36 1.25 0.11 117,514
18 months + 10 years
Adalimumab treatment for
18 months only
45,504 31,403 14,101 8.40 8.29 0.11 133,656
Adalimumab treatment for
18 months + 10 years
120,262 31,403 88,858 8.99 8.29 0.70 127,646
Adalimumab adherence
based on vials issued
74,011 31,175 42,835 8.60 8.29 0.30 140,576
Adalimumab adherence
based on accountability
logs
68,800 31,536 37,264 8.60 8.29 0.30 122,291
Adalimumab and MTX
adherence based on
participant diaries
59,896 24,638 36,258 8.60 8.29 0.30 115,708
No discounting 77,634 36,743 40,621 9.88 9.57 0.32 128,886
23% of participants who
were administered
adalimumab beyond
18 monthsb
51,304 31,403 19,900 8.44 8.29 0.15 131,511
Adalimumab : placebo VI
proportions H : L
70,864 31,147 39,716 8.60 8.29 0.30 130,586
Adalimumab : placebo VI
proportions L : H
70,574 31,659 38,915 8.60 8.29 0.31 127,471
H : L, high to low; L : H, low to high.
a Based on a 7-year-old female (median demographic of SYCAMORE).
b This is the observed percentage of participants randomised to the adalimumab arm who were administered adalimumab
beyond 18 months.
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Scenario analyses
The complete-case analysis was limited by sparse QALY data for participants in the placebo group (n = 3)
and should be interpreted with caution. For the imputed data, the ICER is robust to a variety of assumptions
(Table 39). Taking into account the post-trial closure crossover from placebo to adalimumab has little
impact on the ICER during the 18-month time horizon, but it has greater effect in the extrapolated phase,
as patient benefit associated with adalimumab administered to participants in the placebo group in
follow-up is adjusted away from the placebo arm to the adalimumab arm.
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TABLE 39 Results of the scenario analyses
Scenario
Costs (£) QALYs
ICER (£)
Treatment group
Incremental
Treatment group
IncrementalAdalimumab Placebo Adalimumab Placebo
Complete-case analysis
18-month time
horizon
15,891 5904 9988 1.40 1.45 –0.05 Dominated
+ 10-year time
horizon
78,331 45,622 32,710 9.55 9.60 –0.05 Dominated
Imputed data not accounting for crossover
18-month time
horizon
15,891 5904 9988 1.35 1.28 0.07 135,431
+ 10-year time
horizon
72,685 39,000 33,685 8.71 8.50 0.21 158,259
Imputed data accounting for crossover
18-month time
horizon
16,336 1962 14,374 1.36 1.25 0.11 136,751
+ 10-year time
horizon
70,719 31,403 39,316 8.60 8.29 0.30 129,025
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Chapter 9 Discussion
The objectives of SYCAMORE, a randomised, double-blind, placebo-controlled trial were to investigatethe clinical efficacy, safety and cost-effectiveness of adalimumab in combination with MTX for the
treatment of JIA-associated uveitis in patients who had active uveitis despite having been on MTX for at
least 12 weeks (with a stable dose for 4 weeks prior to the screening visit).
A total of 90 participants with active uveitis were randomised from 14 sites in the UK. No participants
were excluded from the primary analysis and, therefore, the ITT data set contained all 90 participants.
All participants received at least one dose of their allocated treatment and the safety data set also
contained all 90 participants.
The majority of participants were female (77.8%) with a mean age of 8.9 years and had one eligible eye
(72.2%). All participants had JIA-associated uveitis, with the majority of eligible eyes having mild or
moderate uveitis (66.1% had activity of 1+ and 25.2% had activity of 2+); the type of JIA that was most
common was persistent oligoarthritis (58.9%). There was no statistical testing of the baseline characteristics
but numerically the two groups were very similar.
The primary efficacy outcome was time to treatment failure between the adalimumab and placebo groups.
During the blinded phase of the study, the risk of treatment failure was significantly reduced by 75% for
participants in the adalimumab group compared with participants in the placebo group (HR 0.25, 95% CI
0.12 to 0.51; p < 0.0001 from the log-rank test).
The results of the sensitivity analyses showed that the conclusions of the primary analysis were robust to
changes that were made. These results all remained highly statistically significant.
The clinical secondary outcome variables that were both clinically and statistically significant in favour of
adalimumab included greater disease control (uveitis) at 3 months and 6 months in at least one eligible
eye and in all eligible eyes; greater disease control (uveitis) at 6 months; increased number of participants
entering disease (uveitis) remission at 3 months and 6 months in at least one eligible eye and in all eligible
eyes; increased duration of inactive disease (uveitis); ability to reduce to fewer than two corticosteroid
drops and zero drops; and reduced total oral corticosteroid use.
As expected, the greatest proportion of uveitis patients have the oligoarticular subtype form of JIA. Therefore,
measures of disease activity that look at articular disease did not show statistically significant differences.
The AE profile was consistent with the safety profile established across the approved indications of
adalimumab. There were no deaths during the course of the trial. There were two AEs in the adalimumab
group and one SAE in the placebo group, which led to the withdrawal of the participant.
As adalimumab is a potent immunosuppressive agent, as noted in previous literature,82 children treated with
adalimumab in combination with MTX in this trial (integrated analysis of double-blind and open-label data)
had a greater rate of AEs per year than placebo-treated children (9.86 vs. 7.21, respectively). The majority of
these AEs were viral infections, which is consistent with published literature.41 There was also a greater
incidence of SAEs in the adalimumab group than the placebo group (21.7% vs. 6.7%, respectively). The
most frequently reported SAEs were infections and infestations (11 events in 9 participants in the
adalimumab group). The majority of the SAEs were mild or moderate in severity. There were no cases of
malignancies, demyelinating events or deaths during the course of this study.
The economic analysis has strength in that it estimates the cost-effectiveness of adalimumab over a time
period beyond that of SYCAMORE, up until the participants reach the age of 18 years. However, key
limitations included incomplete data on health utilities and crossover effects resulting from early trial closure.
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These were addressed using robust methods (multiple imputation and instrumental variable regression) but,
nevertheless, might have introduced bias to the analysis. We also deviated from the protocol by using HUI3
[instead of the Health Utility Index Mark 2 (HUI2)] utilities. This was carried out for two justifiable reasons,
which had not become apparent (or which we had not appreciated) during the writing of the protocol. First,
the attributes of the two HUIs are different, the HUI2 does not include an attribute specific to vision, which,
given the context of SYCAMORE, would be a major disadvantage. Second, HUI3 yields more information
than HUI2 when there are missing data. Taking the HUI2 sensation attribute as an example, any single
missing response to one of the three subattributes (e.g. speech) would result in the whole sensation score
being classed as missing in HUI2, whereas in HUI3 it would only affect the speech attribute but vision and
hearing could still be counted as they are single attributes. It is acknowledged that one consequence of this
change is that although there is UK health state valuation for the HUI2 there is none for HUI3, and so this is
based on Canadian values.73
A further limitation, related to the outcome measure for the analysis being VI, that differs from the primary
outcome measure in SYCAMORE was time to treatment failure. This was necessary in order to model the
impact of adalimumab over a time frame valid for JIA-associated uveitis and given the need to link to the
Bristol cohort data. Regarding the generalisability of the Bristol cohort, both age and sex were representative
of those in SYCAMORE; however, the Bristol cohort included idiopathic uveitis and patients experienced
more VI than SYCAMORE participants. Moreover, there were probably differences in treatment plans,
such as the choice of DMARDs and thresholds for initiating biologics. Bristol also pioneered combined
(ophthalmology and rheumatology) clinics, which needed to be developed during SYCAMORE in many
centres or optimised in many others to aid successful delivery of the trial to time and target.
The extrapolation model has several limitations, mainly because of a paucity of data. The structure of the
model was limited by the number of participants and the incompleteness of the Bristol data set.74 The
model structure reflects visual acuity in a patient’s worst eye, which was deemed to be most clinically
relevant. A further stratification of logMAR ≥ 1 as severe VI may have added to the interpretation of the
progression of uveitis; however, within SYCAMORE, a logMAR score of 1 was recorded only once in over
900 recorded visits, and transitioning to severe VI from either no VI or VI in the Bristol data set74 was
recorded in < 3% of transitions.
It was assumed that the transition probabilities in the model were independent of trial arm. Although
the longitudinal (Bristol) data set74 included information on adalimumab prescription, it appeared that
adalimumab was only prescribed to those patients in a worse health state (confounding by indication),
which would bias the results, hence a single set of transition probabilities were derived based on data
from all patients.
A further limitation is acknowledged: 15 participants from the SYCAMORE cohort are included in the
longitudinal data set, contributing to 26 out of 268 total recorded transitions. To retain as much power
as possible, these participants were not removed; however, this could be considered double counting.
This approach to modelling the long-term costs and consequences of adalimumab might have been
structured differently. The model considered the progression of uveitis and associated complications
requiring surgery, but does not explicitly reflect the impact of treatment on the progression of JIA.
However, health state costs and QALYs determined from the trial implicitly included the benefits of
treatment on mobility and pain, which are captured within the HUI3 utilities. The model also did not
include the state of severe VI or blindness. A model based on the association between AC cell count and
blindness might have offered an alternative approach, although this would not have reduced the need
for considerable assumptions relating to the magnitude of long-term treatment benefits. Expected rates
of blindness may be low in SYCAMORE participants as they had mild or moderate uveitis, with 91% of
participants having AC cell counts of 1+ or 2+ at baseline. It may, alternatively, have been possible to
calculate utilities and costs for the states of treatment failure and no treatment failure, and project the
survival curves relating to the primary clinical end point of time to treatment failure, with the differences
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in costs and QALYs between treatment groups being driven by the survival function. This would have
required an assumption that all the health-related quality-of-life benefits and costs (other than those of
adalimumab) are driven by treatment success/failure, which might not necessarily be the case.
Despite these limitations, the analysis is robust to several assumptions. In an extreme scenario of every
participant randomised to the placebo group moving to the state of VI in the modelled extrapolation,
the ICER reduces only to £78,524 per QALY gained, which still exceeds the cost-effectiveness threshold.
In order to demonstrate cost-effectiveness, participants receiving adalimumab would need to experience
1.00 additional QALY gain over the 10-year extrapolation, which seems unlikely, given that the QALY gain
over the course of the trial was only 0.11.
In summary, this is the first large, randomised, double-blind, placebo-controlled trial of children with
MTX-refractory JIA-associated uveitis, which shows that treatment with adalimumab combined with MTX
is both effective and safe but, at £129,025 per QALY gained, is unlikely to be cost-effective in the UK
NHS setting.
Implications for practice
This trial provides robust evidence regarding the use of adalimumab in the management of children and
adolescents with JIA-associated uveitis refractory to MTX. The results show that adalimumab therapy in
combination with MTX controlled inflammation and had a lower rate of treatment failure than placebo in
this patient group. This finding, taken alongside the expected increased incidence of AEs in the adalimumab
group and the economic analysis, can potentially inform current clinical practice with the aim of reducing
uveitis-related ocular morbidity, including VI.
Recommendations for research
This trial answered some key questions for the management of JIA-associated uveitis refractory to MTX.
However, it also identified a number of crucial next-step research challenges. These include the following:
1. defining the optimum time after control of uveitis to withdraw/stop adalimumab
2. defining the development and clinical utility of testing for antidrug antibodies in patients with waning
of response to adalimumab
3. consideration of the option of increasing the frequency of administration of adalimumab for those with
a suboptimal response
4. developing biomarkers for predicting early and complete response to adalimumab so that patients can
be stratified more quickly to the appropriate treatment.
Overall conclusion
Adalimumab in combination with MTX is safe and effective in the management of JIA-associated uveitis.
However, the likelihood of cost-effectiveness is < 1% at the £30,000-per-QALY threshold. Several limitations
of the trial are noted. However, overall, this trial is, to our knowledge, the first randomised, double-blind,
placebo-controlled, multicentre trial with an integrated economic evaluation comparing the efficacy, safety
and cost-effectiveness of adalimumab in combination with MTX versus placebo with MTX alone, with regard
to controlling disease activity in refractory uveitis associated with JIA. It also notes important future research
priorities, including a future clinical trial to define the most effective time to stop therapy and to identify
prognostic biomarkers of early and complete response.
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Everyone should be able to find out about how patient data are used. #datasaveslives You can find out
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Professor Athimalaipet Vaidyanathan Ramanan* (Co-Chief Investigator), Consultant Paediatric Rheumatologist,
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Liverpool, UK.
Dr Ashley P Jones, Senior Statistician, CTRC, University of Liverpool, Liverpool, UK.
Professor Andrew Dick, Professor of Ophthalmology, Department of Clinical Sciences, University of Bristol,
Bristol, UK.
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Independent Data and Safety Monitoring Committee
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Trial Management Group
Professor Athimalaipet Vaidyanathan Ramanan (Co-Chief Investigator), Consultant Paediatric Rheumatologist,
Bristol Royal Hospital for Children & Royal National Hospital for Rheumatic Diseases, UK.
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Evaluation, Bangor University, Bangor, UK.
Debbie Janson, patient representative.
Dr Ashley P Jones, Senior Statistician, CTRC, University of Liverpool, Liverpool, UK.
Dr Sandrine Lacassagne, Paediatric Rheumatologist, Great Ormond Street Hospital for Children NHS Trust,
London, UK.
Mr Andrew McKay, Trial Statistician, CTRC, University of Liverpool, Liverpool, UK.
Jennifer Oliver, Bristol Children’s Vaccine Centre, Bristol, UK.
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Appendix 2 Differences between The New
England Journal of Medicine manuscript63 and
Chapter 5 results of this report
Outcome NEJM paper63 results Chapter 5 results Notes
Time to treatment
failure
HR 0.25, 95% CI 0.12 to
0.49; p < 0.0001
HR 0.25, 95% CI 0.12 to
0.51; p < 0.0001
Three participants who were
classified as treatment failures
in the first snapshot were
classified incorrectly and,
therefore, should have been
withdrawals (participants from
the adalimumab group,
anonymised identification
numbers: 0249031, 0249040;
placebo: 0243049).
Additionally, in the treatment
failure line listings, 0133058’s
further details changed from
‘No follow up, consent to use
collected data’ to ‘Continue
follow up’ and 0116008’s
first of the consecutive visits
changed from ‘Visit 3 –
3 months’ treatment: 2+ on
31 May 2012’ to ‘Unscheduled
visit: 2+ on 12 July 2012’
Number of participants
failing treatment
RR 0.40, 95% CI 0.22 to
0.73; p = 0.002
RR 0.40, 95% CI 0.23 to
0.72; p = 0.002
See above for an explanation
of the reclassification of the
three treatment failures
AEs 588 AEs in 53 participants in
the adalimumab group and
103 AEs in 25 participants in
the placebo group
Rate (95% CI) in the
adalimumab group 10.07,
95% CI 9.26 to 10.89
Rate in the placebo group
6.51, 95% CI 5.26 to 7.77
619 AEs in 59 participants
in the adalimumab
group and 114 AEs in
26 participants in the
placebo group
Rate (95% CI) in the
adalimumab group 10.60,
95% CI 9.77 to 11.44
Rate in the placebo group
7.21, 95% CI 5.89 to 8.53
The number of AEs increased
owing to responses to data
queries that were received
in relation to concomitant
medications. When
concomitant medications
were queried, extra rows of
concomitant medications that
were not expected were
submitted, which then
indicated that there were
further AEs (as they had AE
numbers indicated on the
form that had not been
received)
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Outcome NEJM paper63 results Chapter 5 results Notes
SAEs 17 SAEs in 13 participants in
the adalimumab group and
3 SAEs in two participants in
the placebo group
Rate (95% CI) in the
adalimumab group 0.29,
95% CI 0.15 to 0.43
Rate in the placebo group
0.19, 95% CI 0.00 to 0.40
No change N/A
Compliance Participant diaries:
IMP –
Adalimumab, 82.87%;
placebo, 74.11%
MTX –
Adalimumab, 60.46%;
placebo, %
Accountability logs:
IMP –
Adalimumab, 94.00%;
placebo, 90.24%
Participant diaries:
IMP –
Adalimumab, 84.00%;
placebo, 74.00%
MTX –
Adalimumab, 62.50%;
placebo, %
Accountability logs:
IMP –
Adalimumab, 94.00%;
placebo, 90.00%
Minor differences between
two sets of result
Total oral corticosteroid
dose
The analysis of this outcome
was not reported in the NEJM
manuscript or supplementary
table
N/A N/A
Reduction in systemic
corticosteroid dose from
entry dose to 0 mg
Analyses of these data were
not possible owing to the
statistical algorithm not
converting
No change N/A
Reduction in systemic
corticosteroid dose from
entry dose to < 5mg
Analyses of these data were
not possible owing to the
statistical algorithm not
converting
No change N/A
Time to reduction to
fewer than two drops in
topical corticosteroid
HR 3.72, 95% CI 1.09 to
12.71; p = 0.04
HR 3.99, 95% CI 1.18 to
25.20; p = 0.03
00243049: originally failure
code 2 and now failure code 1.
Changed from 49 days to
147 days owing to incorrect
treatment failure. Placebo
participant
00249040: originally failure
code 2 and now failure code 1.
Changed from 202 days to
343 days owing to incorrect
treatment failure. Adalimumab
participant
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Outcome NEJM paper63 results Chapter 5 results Notes
Time to reduction to
zero drops in topical
steroid (post hoc
analysis)
HR 3.58, 95% CI 1.24 to
10.32; p = 0.02
HR 4.02, 95% CI 1.40 to
11.50; p = 0.01
00243049: originally failure
code 2 and now failure code 1.
Changed from 49 days to
147 days owing to incorrect
treatment failure. Placebo
participant
00249040: originally failure
code 2 and now failure code 1.
Changed from 202 days to
475 days owing to incorrect
treatment failure. Adalimumab
participant
00249048: originally failure
code 0 and now failure code 1.
Changed from 504 days to
483 days. One concomitant
medication added. Originally,
the last entry had a missing
end date, so this was imputed
as the PO date, but now one
concomitant medication has
been added, which has an end
date and so the participant
reached zero drops before
their PO date. Adalimumab
participant
Number of participants
requiring pulsed therapy
RR 0.50, 95% CI 0.03 to
7.72; p > 0.99
RR 1.00, 95% CI 0.09 to
10.59, p > 0.99
Two participants required
pulsed therapy during the
blinded phase in the
adalimumab group; only one
was reported in the NEJM
manuscript
Number of participants
having uveitis disease
flares following
3 months of disease
control
The analysis of this outcome
was not reported in the NEJM
manuscript or supplementary
table
N/A
Number of participants
having disease flares
within the first 3 months
RR 0.07, 95% CI 0.00 to 1.36 No change N/A
Visual acuity measured
by age-appropriate
logMAR assessment
Best case: –0.01, 95% CI
–0.06 to 0.03; p = 0.59
Worst case: –0.02, 95% CI
–0.07 to 0.03; p = 0.53
Best case: –0.01, 95% CI
–0.07 to 0.02; p = 0.51
Worst case: –0.02, 95% CI
–0.07 to 0.02; p = 0.36
An incorrect assumption
had been made with
regard to how premature
discontinuations were handled
in the analysis. In the NEJM
manuscript, these were
incorrectly handled as
treatment failures
Number of participants
with resolution of
associated optic nerve or
macular oedema
Analysis of the optic nerve
data was not possible owing
to the low number of
participants who had this
Macular oedema: RR 5.00,
95% CI 0.34 to 74.52
No changes N/A
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Outcome NEJM paper63 results Chapter 5 results Notes
Number of participants
with disease control
(in all eligible eyes)
3 months: RR 11.00, 95% CI
1.56 to 77.74; p < 0.001
6 months: RR 8.50, 95% CI
1.19 to 60.87; p = 0.005
3 months: RR 5.75, 95% CI
1.45 to 22.78; p = 0.001
6 months: no change
One more participant in the
adalimumab arm had disease
control for 3 months
Number of participants
entering disease
remission (in all eligible
eyes)
3 months: RR 7.50, 95% CI
1.04 to 54.12; p = 0.02
6 months: RR 13.72, 95% CI
0.84 to 223.26; p = 0.004
3 months: no change
6 months: no change
N/A
Duration of sustaining
inactive disease
MD 164.79, 95% CI 104.41
to 225.16; p < 0.0001
MD 164.55, 95% CI
104.41 to 224.69;
p < 0.0001
Very minor difference in MD
CHQ PsS 2.69, 95% CI
–0.26 to 5.86; p = 0.06
PhS 1.36, 95% CI
–2.28 to 5.05; p = 0.49
PsS 2.31, 95% CI –0.44 to
5.40; p = 0.15
PhS 1.16, 95% CI –2.41 to
5.05; p = 0.55
An incorrect assumption
had been made with
regard to how premature
discontinuations were handled
in the analysis. In the NEJM
manuscript, these were
incorrectly handled as
treatment failures
CHAQ –0.14, 95% CI
–0.32 to 0.01; p = 0.08
–0.14, 95% CI –0.31 to
0.02; p = 0.09
An incorrect assumption
had been made with
regard to how premature
discontinuations were handled
in the analysis. In the NEJM
manuscript these were
incorrectly handled as
treatment failures
ACR ACR30: –0.70, 95% CI
–1.86 to 0.52; p = 0.23
ACR50: –0.65, 95% CI
–1.74 to 0.44; p = 0.25
ACR70: –0.61, 95% CI
–1.89 to 0.74; p = 0.34
ACR90: –0.46, 95% CI
–3.38 to 2.46; p = 0.76
ACR100: –1.23, 95% CI
–2.34 to –0.14; p = 0.03
ACR30: –0.04, 95% CI
–1.37 to 1.59; p = 0.98
ACR50: –0.70, 95% CI
–2.15 to 0.77; p = 0.37
ACR70: –1.08, 95% CI
–2.70 to 0.46; p = 0.16
ACR90: –0.33, 95% CI
–2.22 to 1.39; p = 0.72
ACR100: –0.32, 95% CI
–1.85 to 1.17; p = 0.65
An incorrect assumption
had been made with
regard to how premature
discontinuations were handled
in the analysis. In the NEJM
manuscript, these were
incorrectly handled as
treatment failures
The significance of ACR100
did change, but this is
not regarded as clinically
important because there were
such small numbers in the
analysis
Number of participants
undergoing arthritis
disease flare, in
remission on and/or off
medication for their JIA,
and with minimum
disease activity
Disease flare: RR 0.07, 95% CI
0.00 to 1.36; p = 0.03
Remission: this outcome was
only reportable during the
follow-up phase and,
therefore, was not reported in
the NEJM paper
Minimum disease activity: RR
2.33, 95% CI 0.87 to 6.24;
p = 0.08
Disease flare: no change
Remission: N/A
Minimum disease activity:
no change
N/A
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Outcome NEJM paper63 results Chapter 5 results Notes
Number of participants
requiring change in
biologics or DMARD
therapy owing to failure
to respond from arthritis
RR 1.00, 95% CI 0.20 to
5.09; p = 0.99
No change N/A
JADAS JADAS10: –0.35, 95% CI
–0.79 to –0.01; p = 0.07
JADAS27: –0.34, 95% CI
–0.78 to 0.03; p = 0.08
JADAS71: –0.36, 95% CI
–0.80 to –0.0004; p = 0.07
JADAS10: –0.35, 95% CI
–0.78 to 0.01; p = 0.07
JADAS27: –0.34, 95% CI
–0.76 to 0.03; p = 0.08
JADAS71: –0.36, 95% CI
–0.78 to 0.004; p = 0.07
An incorrect assumption had
been made with regard to how
premature discontinuations
were handled in the analysis.
In the NEJM manuscript these
were incorrectly handled as
treatment failures
MD, mean difference; N/A, not applicable; NEJM, New England Journal of Medicine; PO, primary outcome.
Parts of this table are from The New England Journal of Medicine, Ramanan AV, Dick AD, Jones AP, McKay A, Williamson PR,
Compeyrot-Lacassagne S, Hardwick B, et al. for the SYCAMORE Study Group. Adalimumab plus methotrexate for uveitis
in juvenile idiopathic arthritis, vol. 376, pp. 1637–46.63 Copyright © (2017) Massachusetts Medical Society. Reprinted
with permission.
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Appendix 3 Additional clinical effectiveness data
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TABLE 40 Screening overview (by centre)
Site
Patients, n (n visits)
Not consented (n) Randomised (n)Screened Eligible Non-eligible
Eligibility
unclear
University Hospitals Bristol NHS
Foundation Trust
43 (59) 28 (28) 26 (30) 1 (1) 0 28
Great Ormond Street Hospital
for Children NHS Trust
26 (34) 22 (24) 10 (10) 2 22
Alder Hey Children’s NHS
Foundation Trust Hospital
30 (33) 12 (13) 20 (20) 6 7
The Newcastle upon Tyne
Hospitals NHS Foundation Trust
18 (23) 9 (9) 13 (14) 4 5
Norfolk and Norwich University
Hospitals NHS Foundation Trust
25 (49) 7 (8) 24 (41) 3 5
Central Manchester University
Hospitals NHS Foundation Trust
8 (15) 6 (6) 6 (9) 2 4
University Hospital
Southampton NHS Foundation
Trust
8 (13) 6 (6) 3 (6) 1 (1) 2 4
Sheffield Children’s NHS
Foundation Trust
33 (52) 11 (13) 25 (39) 9 3
Royal Belfast Hospital for Sick
Children
11 (37) 4 (4) 10 (33) 1 3
University Hospitals of Leicester
NHS Trust
5 (5) 3 (3) 2 (2) 0 2
The Leeds Teaching Hospitals
NHS Trust
17 (29) 9 (9) 13 (20) 7 1
Birmingham Children’s Hospital
NHS Foundation Trust
90 (151) 8 (11) 87 (137) 3 (3) 10 1
Hull and East Yorkshire
Hospitals NHS Trust
3 (4) 1 (1) 3 (3) 0 1
Royal Hospital for Sick Children
Edinburgh – NHS Lothian
6 (6) 2 (2) 4 (4) 1 0
Royal Hospital for Sick Children,
Glasgow – NHS Greater
Glasgow and Clyde
9 (9) 2 (2) 7 (7) 2 2
Total 332 (519) 130 (139) 253 (375) 5 (5) 49 90
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TABLE 41 Reasons for receiving no consent
Site Total (N) Reason n
Percentage
of total
The Leeds Teaching Hospitals NHS Trust 7 Does not like injections 1 14.3
Wanted alternative treatment 3 42.9
Could not comply with trial 1 14.3
Clinician did not think appropriate 1 14.3
Wanted to start adalimumab outside trial 1 14.3
Norfolk and Norwich University Hospitals
NHS Foundation Trust
3 Other family commitments 2 66.7
Declined; no reason 1 33.3
The Newcastle upon Tyne Hospitals NHS
Foundation Trust
4 Declined; no reason 4 100.0
University Hospital Southampton NHS
Foundation Trust
2 Declined; no reason 1 50.0
Did not want placebo 1 50.0
Birmingham Children’s Hospital 10 Declined; no reason 3 30.0
Did not want placebo 2 20.0
Does not like injections 1 10.0
Wanted to start adalimumab outside trial 1 10.0
Other 3 30.0
Alder Hey Children’s NHS Foundation Trust
Hospital
6 Declined; no reason 3 50.0
Did not want placebo 1 16.7
Does not like injections 1 16.7
Other 1 16.7
Central Manchester University Hospitals NHS
Foundation Trust
2 Did not want placebo 1 50.0
Could not comply with trial 1 50.0
Sheffield Children’s NHS Foundation Trust 9 Other family commitments 4 44.4
Declined; no reason 3 33.3
Did not want placebo 1 11.1
Other 1 11.1
Great Ormond Street Hospital for Children
NHS Trust
2 Other 2 100.0
Royal Hospital for Sick Children Edinburgh –
NHS Lothian
1 Did not want placebo 1 100.0
Royal Hospital for Sick Children, Glasgow –
NHS Greater Glasgow and Clyde
2 Declined; no reason 1 50.0
Did not want placebo 1 50.0
Royal Belfast Hospital for Sick Children 1 Does not like injections 1 100.0
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TABLE 42 Reasons for treatment failure
Participant ID Site Treatment
Date of
randomisation
Date of treatment
failure
Time to fail
(days/months) Reason for treatment failure Further details
Participant unblinded
at time of treatment
failure (date)
Eye treatment
failure
occurred in
0116003 Bristol Children’s
Hospital
Placebo 23 November 2011 19 January 2012 57/1.87 Intermittent or continuous suspension of
trial treatment (placebo)
Continue follow-up No Right
0116008 Bristol Children’s
Hospital
Placebo 15 March 2012 16 August 2012 154/5.06 Sustained scores as recorded at entry
grade, measured over two consecutive
readings (grades 1 to 2) still present after
6 months of therapy
Continue follow-up:
Baseline visit – (1+)
Previous visit = SYCAMORE
Unscheduled visit – (2+ on
12 July 2012)
Failure visit = SYCAMORE
Premature withdrawal – (1+ on
16 August 2012)
No Left
0249019 Great Ormond
Street Hospital
Placebo 27 July 2012 27 September 2012 62/2.04 Non-permitted used No follow-up, consent to use
collected data
Yes; 1 October 2012 Left
0114011 Southampton
General Hospital
Adalimumab 11 April 2012 2 January 2013 266/8.74 Permitted concomitant medications used
against acceptable criteria
Continue follow-up Yes; 3 January 2013 Left
0036018 Norfolk and
Norwich University
Hospitals
Placebo 17 July 2012 21 January 2013 188/6.18 Sustained scores as recorded at entry
grade, measured over two consecutive
readings (grades 1 to 2) still present after
6 months of therapy
Continue follow-up:
Baseline visit – (2+)
Previous visit = SYCAMORE
Treatment visit 3 – 3-months’
treatment (3+ on 16 October 2012)
Failure visit = SYCAMORE
Premature withdrawal – (2+ on
21 January 2013)
Yes; 11 March 2013 Right
0249025 Great Ormond
Street Hospital
Placebo 2 November 2012 13 February 2013 103/3.38 Non-permitted concomitant medications
used
No follow-up, consent to use
collected data
Yes; 20 November 2013 Both
0116006 Bristol Children’s
Hospital
Adalimumab 26 January 2012 14 March 2013 413/13.57 Permitted concomitant medications used
against acceptable criteria
Continue follow-up Yes; 15 March 2013 Left
0114033 Southampton
General Hospital
Placebo 13 February 2013 11 April 2013 57/1.87 Permitted concomitant medications used
against acceptable criteria
Continue follow-up Yes; 17 April 2013 Left
0246030 Royal Manchester
Children’s Hospital
Placebo 29 January 2013 24 April 2013 85/2.79 Non-permitted concomitant medications
used
Continue follow-up Yes; 26 April 2013 Both
continued
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TABLE 42 Reasons for treatment failure (continued )
Participant ID Site Treatment
Date of
randomisation
Date of treatment
failure
Time to fail
(days/months) Reason for treatment failure Further details
Participant unblinded
at time of treatment
failure (date)
Eye treatment
failure
occurred in
0116026 Bristol Children’s
Hospital
Adalimumab 8 November 2012 25 April 2013 168/5.52 Permitted concomitant medications used
against acceptable criteria
Continue follow-up Yes; 5 April 2013 Both
0243023 Alder Hey
Children’s Hospital
Adalimumab 12 October 2012 19 October 2013 250/8.21 Non-permitted concomitant medications
used
Continue follow-up Yes; 19 June 2013 Left
0249024 Great Ormond
Street Hospital
Adalimumab 16 October 2012 21 June 2013 248/8.15 Permitted concomitant medications used
against acceptable criteria
Continue follow-up No Right
0116005 Bristol Children’s
Hospital
Placebo 15 December 2011 4 July 2013 567/18.63 Sustained scores as recorded at entry
grade, measured over two consecutive
readings (grades 1 to 2) still present after
6 months of therapy
Continue follow-up:
Baseline visit – (1+)
Previous visit = SYCAMORE
End of treatment – follow-up visit 2
(1+ on 2 May 2013)
Failure visit = SYCAMORE
Unscheduled visit – (2+ on 4 July
2013)
Yes; 16 November 2012 Right
0243032 Alder Hey
Children’s Hospital
Placebo 11 February 2013 17 July 2013 156/5.13 Non-permitted concomitant medications
used
Continue follow-up No Right
0540037 Royal Belfast
Hospital for Sick
Children
Placebo 30 April 2013 24 July 2013 85/2.79 Non-permitted concomitant medications
used
Continue follow-up Yes; 24 July 2013 Both
0249043 Great Ormond
Street Hospital
Adalimumab 16 August 2013 28 October 2013 73/2.4 Non-permitted concomitant medications
used
Continue follow-up No Right
0249029 Great Ormond
Street Hospital
Placebo 25 January 2013 20 December 2013 329/10.81 Sustained scores as recorded at entry
grade, measured over two consecutive
readings (grades 1 to 2) still present after
6 months of therapy
Continue follow-up:
Baseline visit – (1+)
Previous visit = SYCAMORE
Treatment visit 5 – 9 months’
treatment (2+ on 27 September
2013)
Failure visit = SYCAMORE
Treatment visit 6 – 12 months’
treatment (1+ on 20 December
2013)
Yes; 26 June 2014 Left
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Participant ID Site Treatment
Date of
randomisation
Date of treatment
failure
Time to fail
(days/months) Reason for treatment failure Further details
Participant unblinded
at time of treatment
failure (date)
Eye treatment
failure
occurred in
0069039 Great North
Children’s Hospital
Adalimumab 2 May 2013 27 January 2014 270/8.87 Intermittent or continuous suspension of
study treatment (adalimumab)
Continue follow-up Yes; 16 January 2014 Right
0249047 Great Ormond
Street Hospital
Placebo 12 September 2013 28 February 2014 169/5.55 Sustained scores as recorded at entry
grade, measured over two consecutive
readings (grades 1 to 2) still present after
6 months of therapy
Continue follow-up:
Baseline visit – (1+)
Previous visit = SYCAMORE
Treatment visit 2 – 2 months’
treatment (1+ on 15 November
2013)
Failure visit = SYCAMORE
End of treatment – follow-up visit 1
(3+ on 28 February 2014)
Yes; 18 November 2013 Right
0133058 Birmingham
Children’s Hospital
Adalimumab 31 December 2013 24 February 2014 83/2.73 Non-permitted concomitant medications
used
Continue follow-up Yes; 30 May 2014 Right
0116051 Bristol Children’s
Hospital
Placebo 31 October 2013 17 April 2014 168/5.52 Sustained scores as recorded at entry
grade measured over two consecutive
readings (grades 1 to 2) still present after
6 months of therapy
Continue follow-up:
Baseline visit – (1+)
Previous visit = SYCAMORE
Treatment visit 3 – 3 months of
treatment (1+ on 23 January 2014)
Failure visit = SYCAMORE
Treatment visit 4 – 6 months of
treatment (1+ on 17 April 2014)
No Left
0246055 Royal Manchester
Children’s Hospital
Adalimumab 5 December 2013 23 April 2014 139/4.57 Sustained scores as recorded at entry
grade measured over two consecutive
readings (grades 1 to 2) still present after
6 months of therapy
Continue follow-up:
Baseline visit – (2+)
Previous visit = SYCAMORE
End of treatment – follow-up visit 1
(1+ on 7 March 2014)
Failure visit = SYCAMORE
Unscheduled visit (1+ on
23 April 2014)
No Left
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TABLE 42 Reasons for treatment failure (continued )
Participant ID Site Treatment
Date of
randomisation
Date of treatment
failure
Time to fail
(days/months) Reason for treatment failure Further details
Participant unblinded
at time of treatment
failure (date)
Eye treatment
failure
occurred in
0249059 Great Ormond
Street Hospital
Placebo 2 January 2014 20 June 2014 169/5.55 Sustained scores as recorded at entry
grade measured over two consecutive
readings (grades 1 to 2) still present after
6 months of therapy
No follow-up, consent to use
collected data:
Baseline visit – (1+)
Previous visit = SYCAMORE
Unscheduled visit – (2+ on
16 May 2014)
Failure visit = SYCAMORE
Treatment visit 4 – 6 months of
treatment (3+ on 20 June 2014)
No Left
0116067 Bristol Children’s
Hospital
Placebo 5 June 2014 24 July 2014 49/1.61 Permitted concomitant medications used
against acceptable criteria
Continue follow-up No Both
0030035 Leeds General
Infirmary
Adalimumab 19 April 2013 5 September 2014 504/16.56 Permitted concomitant medications used
against acceptable criteria and intermittent
or continuous suspension of study
treatment (adalimumab)
Continue follow-up Yes; 28 August 2014 Both
0393075 Royal Hospital for
Sick Children
(Edinburgh)
Placebo 21 August 2014 16 October 2014 56/1.84 Non-permitted concomitant medications
used
Continue follow-up No Right
0030073 Leeds General
Infirmary
Adalimumab 30 July 2014 17 November 2014 110/3.61 Permitted concomitant medications used
against acceptable criteria
Continue follow-up Yes; 3 December 2014 Both
0069076 Great North
Children’s Hospital
Adalimumab 28 August 2014 17 February 2015 173/5.68 Sustained scores as recorded at entry
grade measured over two consecutive
readings (grades 1 to 2) still present after
6 months of therapy
Continue follow-up:
Baseline visit – (1+)
Previous visit = SYCAMORE
Unscheduled visit (1+ on 6 January
2015)
Failure visit = SYCAMORE
Treatment visit 4 – 6 months of
treatment (1+ on 17 February
2015)
Yes; 25 February 2015 Right
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Participant ID Site Treatment
Date of
randomisation
Date of treatment
failure
Time to fail
(days/months) Reason for treatment failure Further details
Participant unblinded
at time of treatment
failure (date)
Eye treatment
failure
occurred in
0249086 Great Ormond
Street Hospital
Placebo 5 January 2015 2 April 2015 87/2.86 Non-permitted concomitant medications
used
Continue follow-up Yes; 8 May 2015 Left
0116062 Bristol Children’s
Hospital
Adalimumab 17 February 2014 9 April 2015 416/13.67 Intermittent or continuous suspension of
study treatment (adalimumab)
Continue follow-up Yes; 10 April 2015 Right
0116066 Bristol Children’s
Hospital
Adalimumab 25 April 2014 9 April 2015 349/11.47 Intermittent or continuous suspension of
study treatment (adalimumab)
Continue follow-up Yes; 30 March 2015 Right
ID, identification.
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TABLE 43 Line listings of SAEs
Subject
number
Age at onset
(years)/sex Onset date Resolution date MedDRA PT Severity
Relationship to
adalimumab/
placebo (per the
investigator)
Adalimumab
0114011 4.89/female 9 June 2012 13 June 2012 Varicella Moderate Possibly/possibly
0114016 3.56/female 23 July 2012 15 August 2012 Streptococcal
infection
Moderate Possibly/possibly
0249021 7.63/male 21 October 2012 25 October 2012 Diarrhoea Moderate Possibly/possibly
Syncope Moderate Possibly/possibly
0116015 5.14/female 14 November
2012
15 November
2012
Viral infection Moderate Possibly/possibly
0116004 9/male 24 March 2013 3 April 2013 Scarlet fever Moderate Possibly/possibly
0246022 9.22/female 9 August 2013 20 August 2013 Cellulitis Mild Possibly/possibly
Infected bites Mild Possibly/possibly
0116015 5.85/female 1 August 2013 1 September 2013 Lower respiratory
tract infection
Moderate Probably/possibly
0116026 9.43/female 24 April 2013 1 May 2013 Cataract Moderate Unrelated/unrelated
0243056 5.05/female 25 January 2014 28 January 2014 Varicella Moderate Possibly/possibly
0116044 14.37/male 27 February 2014 15 June 2014 Testes exploration Moderate Unrelated/unrelated
0248064 6.17/male 7 July 2014 9 July 2014 Streptococcal
infection
Moderate Probably/possibly
0030035 7.47/female 25 August 2014 27 August 2014 Viral infection Mild Possibly/possibly
0116068 8.31/female 18 October 2014 18 October 2014 Antiviral
prophylaxis
Mild Unrelated/unrelated
0116052 7.56/male 9 November 2014 17 November
2014
Food poisoning Moderate Unrelated/unrelated
0248064 6.76/male 6 February 2015 7 February 2015 Tonsillar
hypertrophy
Moderate Possibly/possibly
0116061a 5.34/female 30 June 2015 1 July 2015 Tonsillitis Mild Possibly/possibly
0540060b 12.82/female 13 May 2015 14 May 2015 Joint swelling Mild Unlikely/unlikely
Placebo
0249025 7.07/female 13 February 2013 13 February 2013 Anterior chamber
flare
Mild Possibly/unrelated
Anterior chamber
flare
Mild Possibly/unrelated
0248070 6.24/male 7 July 2014 20 August 2014 Uveitis Severe Possibly/unrelated
MedDRA, Medical Dictionary for Regulatory Activities; PT, preferred term.
a A SAE that occurred during the open-label phase.
b A SAE that occurred during follow-up (i.e. outside the reporting timelines as stated in the SYCAMORE protocol).
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TABLE 44 Study drug compliance data for participants in the adalimumab group
Participant
ID Date of first dose
Date of expected
last dose
Reason for expected last
dose
Treatment diaries Accountability logs
Expected
number of
study drug
doses
Recorded
number of
study drug
doses
Compliance
(%)
Missing
entry in
diary
(n)
Number
of vials
issued
Number
of vials
returned
used
Number
of vials
returned
unused
Missing
vials (n)
Compliance
(%)
Additional information
on vials returned unused
0030035 19 April 2013 5 September 2014 Failed treatment: permitted
concomitant medications used
against acceptable criteria and
intermittent or continuous
suspension of study treatment
(adalimumab)
37 32 86.49 5 36 31 4 1 88.89
0030073 1 August 2014 17 November 2014 Failed treatment: permitted
concomitant medications used
against acceptable criteria
8 7 87.50 1 8 7 0 1 100.00
0031078 1 October 2014 15 September 2015 Last treatment visit in blinded
phase
25 25 100.00 0 30 0 0 30 100.00
0031079 16 October 2014 26 November 2015 Last treatment visit in blinded
phase
30 26 86.67 4 38 0 0 38 100.00
0036038 2 May 2013 13 October 14 Completed 18 months of
treatment
38 34 89.47 4 38 26 2 10 94.74
0036053 11 November 2013 7 April 2014 Withdrew 11 11 100.00 0 14 11 3 0 78.57
0036081 21 November 2014 11 January 2016 Last treatment visit in blinded
phase
30 24 80.00 6 30 20 0 10 100.00
0069020 30 July 2012 10 February 2014 Completed 18 months of
treatment
41 40 97.56 1 42 20 0 22 100.00
0069039 8 May 2013 27 January 2014 Failed treatment: intermittent or
continuous suspension of study
treatment (adalimumab)
19 13 68.42 6 18 0 6 12 66.67
0069076 2 September 2014 17 February 2015 Failed treatment: sustained
scores as recorded at entry
grade, measured over two
consecutive readings (grades 1
to 2) still present after 6 months
of therapy
13 13 100.00 0 18 13 5 0 72.22 Four vials were issued on
10 February 2015. One vial
was used prior to the
participant failing treatment
on 17 February 2015.
The remaining three were
returned unused
0078071 3 July 2014 21 August 2014 Withdrew 4 2 50.00 2 4 0 0 4 100.00
0114011 11 April 2012 2 January 2013 Failed treatment 20 19 95.00 1 22 9 1 12 95.45
0114016 4 July 2012 15 August 2012 Withdrew 4 1 25.00 3 4 0 0 4 100.00
0114041 22 May 2013 13 February 2014 Withdrew 20 19 95.00 1 24 20 0 4 100.00
continued
D
O
I:10.3310/hta23150
H
EA
LTH
TECH
N
O
LO
G
Y
A
SSESSM
EN
T
2019
VO
L.23
N
O
.15
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2019.This
w
ork
w
as
produced
by
Ram
anan
et
al.under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth
and
SocialC
are.This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,the
fullreport)m
ay
be
included
in
professional
journals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:N
IH
R
Journals
Library,N
ationalInstitute
for
H
ealth
Research,Evaluation,Trials
and
Studies
C
oordinating
C
entre,A
lpha
H
ouse,U
niversity
of
Southam
pton
Science
Park,Southam
pton
SO
16
7N
S,U
K
.
123
TABLE 44 Study drug compliance data for participants in the adalimumab group (continued )
Participant
ID Date of first dose
Date of expected
last dose
Reason for expected last
dose
Treatment diaries Accountability logs
Expected
number of
study drug
doses
Recorded
number of
study drug
doses
Compliance
(%)
Missing
entry in
diary
(n)
Number
of vials
issued
Number
of vials
returned
used
Number
of vials
returned
unused
Missing
vials (n)
Compliance
(%)
Additional information
on vials returned unused
0116001 27 October 2011 14 March 2013 Completed 18 months of
treatment
37 34 91.89 3 36 19 0 17 100.00
0116002 10 November 2011 28 March 2013 Completed 18 months of
treatment
37 33 89.19 4 36 32 0 4 100.00
0116004 15 December 2011 2 May 2013 Completed 18 months of
treatment
37 35 94.59 2 36 0 0 36 100.00
0116006 26 January 2012 14 March 2013 Failed treatment 30 30 100.00 0 30 0 0 30 100.00
0116007 8 February 2012 27 June 2013 Completed 18 months of
treatment
37 36 97.30 1 36 33 0 3 100.00
0116013 21 June 2012 7 November 2013 Completed 18 months of
treatment
37 36 97.30 1 38 2 0 36 100.00
0116014 28 June 2012 14 November 2013 Completed 18 months of
treatment
37 36 97.30 1 36 33 0 3 100.00
0116015 28 June 2012 14 November 2013 Completed 18 months of
treatment
37 34 91.89 3 42 17 0 25 100.00
0116026 8 November 2012 25 April 2013 Failed treatment 13 11 84.62 2 14 0 0 14 100.00
0116034 18 April 2013 11 September 2014 Completed 18 months of
treatment
37 36 97.30 1 36 1 0 35 100.00
0116044 23 August 2013 15 January 2015 Completed 18 months of
treatment
37 24 64.86 13 36 0 0 36 100.00
0116052 7 November 2013 18 November 2014 Withdrew 27 23 85.19 4 30 20 3 7 90.00
0116061 14 February 2014 18 June 2015 Completed 18 months of
treatment
35 34 97.14 1 38 30 2 6 94.74
0116062 18 February 2014 9 April 2015 Failed treatment: intermittent or
continuous suspension of study
treatment (adalimumab)
30 27 90.00 3 32 24 4 4 87.50
0116066 28 April 2014 9 April 2015 Failed treatment: intermittent or
continuous suspension of study
treatment (adalimumab)
25 15 60.00 10 28 21 6 1 78.57
0116068 5 June 2014 30 July 2015 Last treatment visit in blinded
phase (unscheduled)
31 17 54.84 14 32 13 3 16 90.63
0116069 5 June 2014 17 September 2015 Last treatment visit in blinded
phase (unscheduled)
34 29 85.29 5 36 0 0 36 100.00
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Participant
ID Date of first dose
Date of expected
last dose
Reason for expected last
dose
Treatment diaries Accountability logs
Expected
number of
study drug
doses
Recorded
number of
study drug
doses
Compliance
(%)
Missing
entry in
diary
(n)
Number
of vials
issued
Number
of vials
returned
used
Number
of vials
returned
unused
Missing
vials (n)
Compliance
(%)
Additional information
on vials returned unused
0116072 10 July 2014 26 November 2015 Completed 18 months of
treatment
37 36 97.30 1 36 2 0 34 100.00
0116088 5 February 2015 15 October 2015 Last treatment visit in blinded
phase
19 12 63.16 7 24 3 0 21 100.00
0133058 31 December 2013 24 March 2014 Failed treatment: non-permitted
concomitant medications used
6 1 16.67 5 12 2 0 10 100.00
0243009 26 March 2012 31 July 2013 Completed 18 months of
treatment
36 34 94.44 2 36 35 1 0 97.22
0243023 12 October 2012 19 June 2013 Failed treatment: non-permitted
concomitant medications used
18 17 94.44 1 18 18 0 0 100.00
0243042 17 August 2013 17 December 2014 Completed 18 months of
treatment
35 28 80.00 7 36 36 0 0 100.00
0243056 16 December 2013 6 May 2015 Completed 18 months of
treatment
37 34 91.89 3 36 36 0 0 100.00
0243089 11 February 2015 13 January 2016 Last treatment visit in blinded
phase
25 23 92.00 2 24 24 0 0 100.00
0246022 11 September 2012 14 February 2014 Completed 18 months of
treatment
38 34 89.47 4 38 22 0 16 100.00
0246054 4 December 2013 8 May 2015 Completed 18 months of
treatment
38 36 94.74 2 38 34 1 3 97.37
0246055 10 December 2013 19 February 2014 Withdrew 6 3 50.00 3 4 3 1 0 75.00
0248050 10 October 2013 9 March 2015 Completed 18 months of
treatment
37 15 40.54 22 36 33 1 2 97.22
0248064 10 April 2014 16 March 2015 Withdrew 25 22 88.00 3 26 23 3 0 88.46
0248087 5 January 2015 7 December 2015 Last treatment visit in blinded
phase
25 13 52.00 12 24 18 0 6 100.00
0249021 24 August 2012 10 January 2014 Completed 18 months
treatment
37 35 94.59 2 36 36 0 0 100.00
0249024 18 October 2012 21 June 2013 Failed treatment: permitted
concomitant medications used
against acceptable criteria
18 16 88.89 2 24 16 8 0 66.67 On 11 June 2013, six vials
were issued; all were
returned unused as the
participant withdrew on
21 June 2013
0249028 23 November 2012 28 March 2014 Completed 18 months of
treatment
36 34 94.44 2 36 36 0 0 100.00
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TABLE 44 Study drug compliance data for participants in the adalimumab group (continued )
Participant
ID Date of first dose
Date of expected
last dose
Reason for expected last
dose
Treatment diaries Accountability logs
Expected
number of
study drug
doses
Recorded
number of
study drug
doses
Compliance
(%)
Missing
entry in
diary
(n)
Number
of vials
issued
Number
of vials
returned
used
Number
of vials
returned
unused
Missing
vials (n)
Compliance
(%)
Additional information
on vials returned unused
0249031 1 February 2013 9 May 2014 Failed treatment: permitted
concomitant medications used
against acceptable criteria
34 4 11.76 30 36 29 5 2 86.11 On 19 March 2014, six vials
were issued. One vial was
used prior to the participant
failing treatment on 9 May
2016; the rest were returned
unused
0249036 26 April 2013 12 September 2014 Completed 18 months of
treatment
37 34 91.89 3 36 36 0 0 100.00
0249040 17 May 2013 5 December 2013 Failed treatment: permitted
concomitant medications used
against acceptable criteria
15 12 80.00 3 18 12 6 0 66.67 On 28 October 2013, six
vials were issued. All six
vials were returned unused
0249043 16 August 2013 28 October 2013 Failed treatment: non-permitted
concomitant medications used
6 4 66.67 2 12 6 6 0 50.00 On 18 October 2013, six
vials were issued. All six
vials were returned unused
0249046 12 September 2013 30 January 2015 Completed 18 months of
treatment
37 36 97.30 1 40 35 3 2 92.50
0249048 13 September 2013 30 January 2015 Completed 18 months of
treatment
37 32 86.49 5 36 36 0 0 100.00
0249065 25 April 2014 11 September 2015 Completed 18 months of
treatment
37 35 94.59 2 36 36 0 0 100.00
0249077 5 September 2014 16 January 2015 Last treatment visit in blinded
phase (unscheduled)
10 5 50.00 5 12 9 0 3 100.00
0249083 5 December 2014 6 November 2015 Last treatment visit in blinded
phase
25 18 72.00 7 28 9 0 19 100.00
0249091 27 March 2015 4 December 2015 Last treatment visit in blinded
phase
19 18 94.74 1 18 12 0 6 100.00
0540060 31 January 2014 7 January 2015 Withdrew 25 14 56.00 11 24 0 5 19 79.17 On 7 October 2014, six vials
were issued. Five of these
vials were returned unused.
Participant withdrew as a
result of missing MTX doses
before failing treatment for
missing adalimumab doses
0540080 21 October 2014 9 December 2015 Last treatment visit in blinded
phase
30 29 96.67 1 28 0 0 28 100.00
Mean compliance 81.01% 93.91%
ID, identification.
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TABLE 45 Study drug compliance data for participants in the placebo group
Participant
ID Date of first dose
Date of expected
last dose Reason for expected last dose
Treatment diaries Accountability logs
Expected
number of
study drug
doses
Recorded
number of
study drug
doses
Compliance
(%)
Missing
entry in
diary (n)
Number
of vials
issued
Number
of vials
returned
used
Number
of vials
returned
unused
Compliance
(%)
Missing
vials (n)
Additional
information on vials
returned unused
0031074 14 August 2014 5 May 2015 Last treatment visit in blinded
phase (unscheduled)
19 18 94.74 1 20 0 0 100.00 20
0036018 18 July 2012 21 January 2013 Failed treatment: sustained scores
as recorded at entry grade
measured over two consecutive
readings (grades 1 to 2), still
present after 6 months of therapy
14 15 107.14 0 14 13 1 92.86 0
0036057 16 December 2013 31 March 2014 Withdrew 8 8 100.00 0 12 8 4 66.67 0 Six vials were issued on
6 March 2014. Two vials
were used prior to the
participant withdrawing
on 31 March 2014. The
remaining four vials
were returned unused
0069017 5 July 2012 13 January 2014 Completed 18 months of
treatment
40 39 97.50 1 44 6 2 95.45 36
0069092 31 March 2015 5 May 2015 Last treatment visit in blinded
phase (unscheduled)
3 2 66.67 1 4 2 0 100.00 2
0114033 13 February 2013 11 April 2013 Failed treatment 5 3 60.00 2 6 4 0 100.00 2
0116003 24 November 2011 19 January 2012 Failed treatment 5 1 20.00 4 6 0 0 100.00 6
0116005 15 December 2011 15 November 2012 Withdrew 25 22 88.00 3 30 16 0 100.00 14
0116008 15 March 2012 16 August 2012 Failed treatment: sustained scores
as recorded at entry grade
measured over two consecutive
readings (grades 1 to 2), still
present after 6 months of therapy
12 11 91.67 1 16 1 6 62.50 9 Six vials were issued on
16 August 2012 prior
to the participant failing
treatment (on the same
day). These vials were
all returned unused
0116012 17 May 2012 10 October 2013 Completed 18 months of
treatment
37 35 94.59 2 36 27 1 97.22 8
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TABLE 45 Study drug compliance data for participants in the placebo group (continued )
Participant
ID Date of first dose
Date of expected
last dose Reason for expected last dose
Treatment diaries Accountability logs
Expected
number of
study drug
doses
Recorded
number of
study drug
doses
Compliance
(%)
Missing
entry in
diary (n)
Number
of vials
issued
Number
of vials
returned
used
Number
of vials
returned
unused
Compliance
(%)
Missing
vials (n)
Additional
information on vials
returned unused
0116027 8 November 2012 17 January 2013 Withdrew 6 2 33.33 4 4 0 0 100.00 4
0116051 31 October 2013 17 April 2014 Failed treatment 13 12 92.31 1 14 9 0 100.00 5
0116063 27 February 2014 12 February 2015 Withdrew 26 24 92.31 2 34 19 9 73.53 6 Two vials were issued
on 6 May 2014 and a
further six were issued
on 21 May 2014. The
extra two vials issued in
error were returned
unused
Six vials were issued on
28 January 2015 and all
six were returned
unused; one of these
vials should have been
used
0116067 5 June 2014 24 July 2014 Failed treatment: permitted
concomitant medications used
against acceptable criteria
4 4 100.00 0 6 1 2 66.67 3
0116085 18 December 2014 29 January 2015 Withdrew 4 2 50.00 2 4 2 0 100.00 2
0243032 12 February 2013 18 December 2013 Withdrew 23 22 95.65 1 26 22 4 84.62 0 Two extra vials issued
on 3 December 2013
were returned unused
0243049 24 September 2013 6 November 2013 Failed treatment: permitted
concomitant medications used
against acceptable criteria
4 3 75.00 1 4 3 1 75.00 0
0246030 30 January 2013 24 April 2013 Failed treatment: non-permitted
concomitant medications used
7 6 85.71 1 12 0 0 100.00 12
0248070 10 June 2014 7 July 2014 Withdrew 2 2 100.00 0 4 2 2 50.00 0
0249019 2 August 2012 27 September 2012 Failed treatment: non-permitted
concomitant medications used
5 4 80.00 1 6 4 2 66.67 0
0249025 2 November 2012 13 February 2013 Failed treatment: non-permitted
concomitant medications used
8 5 62.50 3 12 4 4 66.67 4 On 29 January 2013,
six vials were issued;
two were used prior
to participant failing
treatment on
13 February 2013 and
the remaining four
were returned unused
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Participant
ID Date of first dose
Date of expected
last dose Reason for expected last dose
Treatment diaries Accountability logs
Expected
number of
study drug
doses
Recorded
number of
study drug
doses
Compliance
(%)
Missing
entry in
diary (n)
Number
of vials
issued
Number
of vials
returned
used
Number
of vials
returned
unused
Compliance
(%)
Missing
vials (n)
Additional
information on vials
returned unused
0249029 25 January 2013 20 December 2013 Failed treatment: sustained scores
as recorded at entry grade
measured over two consecutive
readings (grades 1 to 2), still
present after 6 months of therapy
24 9 37.50 15 30 22 6 80.00 2 On 16 December 2013,
six vials were issued, all
were returned unused
as participant failed
treatment on
20 December 2013
0249045 13 September 2013 30 January 2015 Completed 18 months of
treatment
37 14 37.84 23 40 35 1 97.50 4
0249047 12 September 2013 15 November 2013 Withdrew 5 2 40.00 3 6 3 2 66.67 1
0249059 3 January 2014 20 June 2014 Failed treatment: sustained scores
as recorded at entry grade
measured over two consecutive
readings (grades 1 to 2), still
present after 6 months of therapy
13 1 7.69 12 18 12 6 66.67 0 On 16 June 2014, six
vials were issued. All six
vials were returned
unused
0249082 28 November 14 31 July 2015 Last treatment visit in blinded
phase (unscheduled)
18 20 111.11 0 20 9 0 100.00 11
0249086 5 January 2015 2 April 2015 Failed treatment: non-permitted
concomitant medications used
7 6 85.71 1 10 6 4 60.00 0 On 5 February 2015,
six vials were issued; a
further two vials were
issued on 6 March 2015.
Four vials were used
prior to the participant
failing treatment on
2 April 2014. The
remaining four vials
were returned unused
0249090 13 February 2015 8 May 2015 Last treatment visit in blinded
phase
7 6 85.71 1 6 4 0 100.00 2
0393075 21 August 2014 16 October 2014 Failed treatment: non-permitted
concomitant medications used
5 3 60.00 2 6 1 1 83.33 4
0540037 1 May 2013 24 July 2013 Failed treatment: non-permitted
concomitant medications used
7 6 85.71 1 12 0 6 50.00 6 On 24 July 2013, six
vials were issued prior
to the participant failing
treatment. All six vials
were returned unused
Mean compliance 74.61% 83.40%
ID, identification.
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TABLE 46 The logMAR score by treatment group at each time point
Visit
Treatment group
TotalAdalimumab Placebo
Best score Worst score Best score Worst score Best score Worst score
n Mean (SD)
Median
(range) n Mean (SD)
Median
(range) n Mean (SD)
Median
(range) n Mean (SD)
Median
(range) n Mean (SD)
Median
(range) n Mean (SD)
Median
(range)
Baseline 60 0.04 (0.15) 0.00
(–0.23 to 0.56)
60 0.05 (0.16) 0.00
(–0.23 to 0.56)
30 0.06 (0.12) 0.05
(–0.13 to 0.40)
30 0.08 (0.12) 0.06
(–0.10 to 0.40)
90 0.04 (0.14) 0.00
(–0.23 to 0.56)
90 0.06 (0.14) 0.03
(–0.23 to 0.56)
1 month 60 0.03 (0.17) 0.00
(–0.30 to 0.80)
60 0.04 (0.18) 0.00
(–0.30 to 0.80)
30 0.02 (0.16) 0.00
(–0.28 to 0.38)
30 0.06 (0.17) 0.04
(–0.28 to 0.38)
90 0.02 (0.17) 0.00
(–0.30 to 0.80)
90 0.05 (0.18) 0.00
(–0.30 to 0.80)
2 months 57 0.02 (0.17) 0.00
(–0.20 to 0.56)
57 0.04 (0.19) 0.00
(–0.20 to 0.75)
25 0.05 (0.18) 0.00
(–0.15 to 0.76)
25 0.06 (0.18) 0.02
(–0.15 to 0.76)
82 0.03 (0.17) 0.00
(–0.20 to 0.76)
82 0.05 (0.19) 0.00
(–0.20 to 0.76)
3 months 56 0.00 (0.16) 0.00
(–0.20 to 0.80)
56 0.02 (0.20) 0.00
(–0.20 to 0.88)
19 0.01 (0.11) 0.00
(–0.13 to 0.24)
19 0.03 (0.12) 0.00
(–0.13 to 0.28)
75 0.00 (0.14) 0.00
(–0.20 to 0.80)
75 0.02 (0.18) 0.00
(–0.20 to 0.88)
6 months 47 0.02 (0.20) –0.02
(–0.20 to 0.88)
47 0.03 (0.20) 0.00
(–0.20 to 0.88)
12 0.05 (0.16) 0.02
(–0.18 to 0.30)
12 0.07 (0.19) 0.02
(–0.18 to 0.38)
59 0.03 (0.19) 0.00
(–0.20 to 0.88)
59 0.03 (0.19) 0.00
(–0.20 to 0.88)
9 months 42 –0.01 (0.14) 0.00
(–0.25 to 0.40)
42 –0.01 (0.14) 0.00
(–0.25 to 0.40)
7 0.00 (0.17) –0.08
(–0.10 to 0.36)
7 0.04 (0.20) –0.08
(–0.10 to 0.36)
49 –0.01 (0.14) 0.00
(–0.25 to 0.40)
49 0.00 (0.15) 0.00
(–0.25 to 0.40)
12 months 34 –0.01 (0.14) –0.01
(–0.23 to 0.34)
34 0.00 (0.14) 0.00
(–0.23 to 0.34)
5 0.03 (0.14) 0.02
(–0.10 to 0.26)
5 0.08 (0.17) 0.03
(–0.10 to 0.26)
39 –0.01 (0.14) 0.00
(–0.23 to 0.34)
39 0.01 (0.14) 0.00
(–0.23 to 0.34)
15 months 27 0.00 (0.14) 0.00
(–0.25 to 0.40)
27 0.00 (0.13) 0.00
(–0.25 to 0.40)
3 0.00 (0.26) –0.10
(–0.20 to 0.30)
3 0.00 (0.26) –0.10
(–0.20 to 0.30)
30 0.00 (0.15) –0.02
(–0.25 to 0.40)
30 0.00 (0.15) –0.02
(–0.25 to 0.40)
18 months 23 0.02 (0.13) 0.00
(–0.20 to 0.28)
23 0.04 (0.11) 0.02
(–0.20 to 0.28)
3 0.02 (0.21) –0.10
(–0.10 to 0.26)
3 0.02 (0.21) –0.10
(–0.10 to 0.26)
26 0.02 (0.13) 0.00
(–0.20 to 0.28)
26 0.04 (0.12) 0.01
(–0.20 to 0.28)
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FIGURE 14 Mean profile plot for logMAR best score.
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FIGURE 15 Mean profile plot for logMAR worst score.
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TABLE 47 The CHQ PsS: summary statistics by treatment by time point
Visit
Treatment group
TotalAdalimumab Placebo
n Missing Mean (SD) Median (range) n Missing Mean (SD) Median (range) n Missing Mean (SD) Median (range)
Baseline 53 7 51.17 (9.53) 52.74 (30.69–65.85) 22 8 49.48 (7.55) 49.67 (37.25–60.76) 75 15 50.68 (8.98) 51.99 (30.69–65.85)
1 month 53 7 51.06 (10.36) 53.41 (18.72–65.19) 27 3 50.01 (10.27) 50.58 (20.75–63.60) 80 10 50.71 (10.28) 53.24 (18.72–65.19)
2 months 49 9 53.02 (10.00) 54.62 (24.01–64.52) 19 6 50.20 (10.75) 52.42 (30.57–64.29) 68 15 52.23 (10.21) 54.47 (24.01–64.52)
3 months 50 6 54.12 (9.02) 57.52 (26.86–64.30) 16 3 54.21 (8.57) 55.38 (38.63–64.47) 66 9 54.14 (8.85) 57.32 (26.86–64.47)
6 months 40 8 53.94 (9.79) 57.00 (15.14–65.20) 11 1 49.68 (11.56) 54.18 (23.16–61.32) 51 9 53.02 (10.23) 56.19 (15.14–65.20)
9 months 35 7 55.82 (6.84) 58.04 (39.68–65.82) 7 0 50.26 (13.72) 56.14 (25.06–62.08) 42 7 54.89 (8.41) 56.93 (25.06–65.82)
12 months 33 1 54.08 (9.22) 57.61 (27.32–65.30) 4 1 54.18 (8.83) 55.36 (42.61–63.39) 37 2 54.09 (9.06) 57.61 (27.32–65.30)
15 months 25 2 53.56 (7.76) 53.61 (36.75–65.35) 3 0 53.27 (11.83) 55.45 (40.50–63.87) 28 2 53.53 (8.00) 54.53 (36.75–65.35)
18 months 20 3 53.58 (11.71) 55.14 (10.02–64.60) 3 0 47.25 (18.64) 55.49 (25.91–60.35) 23 3 52.76 (12.44) 55.49 (10.02–64.60)
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FIGURE 16 The PsS mean profile plot.
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TABLE 48 The CHQ PhS: summary statistics by treatment by time point
Visit
Treatment group
TotalAdalimumab Placebo
n Missing Mean (SD) Median (range) n Missing Mean (SD) Median (range) n Missing Mean (SD) Median (range)
Baseline 53 7 43.20 (11.84) 46.39 (–3.81 to 59.97) 22 8 40.48 (16.36) 43.54 (6.44 to 58.87) 75 15 42.40 (13.26) 46.28 (–3.81 to 59.97)
1 month 53 7 45.54 (11.29) 47.61 (1.97 to 61.07) 27 3 44.73 (12.10) 49.02 (7.47 to 59.60) 80 10 45.27 (11.50) 47.69 (1.97 to 61.07)
2 months 49 9 47.54 (10.69) 52.06 (10.96 to 59.65) 19 6 43.65 (15.56) 46.85 (–2.61 to 59.65) 68 15 46.46 (12.25) 51.81 (–2.61 to 59.65)
3 months 50 6 46.50 (13.13) 50.76 (3.62 to 60.76) 16 3 47.35 (7.97) 48.89 (31.61 to 59.65) 66 9 46.70 (12.03) 49.70 (3.62 to 60.76)
6 months 40 8 47.16 (11.84) 52.06 (9.30 to 58.64) 11 1 41.95 (15.79) 43.69 (1.20 to 59.65) 51 9 46.03 (12.80) 50.40 (1.20 to 59.65)
9 months 35 7 47.50 (11.26) 51.57 (11.12 to 59.00) 7 0 45.20 (14.77) 51.67 (22.56 to 57.01) 42 7 47.12 (11.74) 51.62 (11.12 to 59.00)
12 months 33 1 47.29 (13.06) 52.92 (3.54 to 59.53) 4 1 53.09 (4.79) 54.07 (46.83 to 57.40) 37 2 47.92 (12.53) 52.92 (3.54 to 59.53)
15 months 25 2 42.85 (15.88) 48.98 (6.03 to 60.05) 3 0 55.75 (2.48) 54.86 (53.83 to 58.55) 28 2 44.23 (15.53) 49.97 (6.03 to 60.05)
18 months 20 3 45.92 (12.06) 51.93 (17.26 to 55.79) 3 0 53.77 (9.71) 59.09 (42.56 to 59.65) 23 3 46.94 (11.89) 52.78 (17.26 to 59.65)
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FIGURE 17 The PhS mean profile plot.
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TABLE 49 The CHAQ score by treatment group, by time point
Visit
Treatment group
TotalAdalimumab Placebo
n Missing Mean (SD) Median (range) n Missing Mean (SD) Median (range) n Missing Mean (SD) Median (range)
Baseline 59 1 0.52 (0.64) 0.21 (0.00–2.49) 28 2 0.48 (0.49) 0.45 (0.00–1.57) 87 3 0.51 (0.59) 0.33 (0.00–2.49)
1 month 59 1 0.41 (0.56) 0.13 (0.00–2.29) 30 0 0.60 (0.55) 0.55 (0.00–1.61) 89 1 0.47 (0.56) 0.22 (0.00–2.29)
2 months 57 1 0.38 (0.53) 0.11 (0.00–1.96) 24 1 0.54 (0.59) 0.45 (0.00–2.32) 81 2 0.43 (0.55) 0.20 (0.00–2.32)
3 months 54 2 0.36 (0.58) 0.03 (0.00–2.49) 18 1 0.37 (0.47) 0.19 (0.00–1.50) 72 3 0.36 (0.55) 0.05 (0.00–2.49)
6 months 45 3 0.36 (0.61) 0.02 (0.00–2.49) 12 0 0.46 (0.63) 0.11 (0.00–2.00) 57 3 0.38 (0.61) 0.05 (0.00–2.49)
9 months 39 3 0.35 (0.63) 0.06 (0.00–2.28) 7 0 0.36 (0.57) 0.09 (0.00–1.58) 46 3 0.35 (0.62) 0.06 (0.00–2.28)
12 months 34 0 0.33 (0.60) 0.02 (0.00–2.04) 4 1 0.09 (0.15) 0.02 (0.00–0.31) 38 1 0.31 (0.57) 0.02 (0.00–2.04)
15 months 26 1 0.43 (0.58) 0.11 (0.00–2.00) 3 0 0.03 (0.04) 0.01 (0.00–0.07) 29 1 0.39 (0.56) 0.10 (0.00–2.00)
18 months 22 1 0.30 (0.48) 0.02 (0.00–1.55) 3 0 0.03 (0.05) 0.01 (0.00–0.09) 25 1 0.27 (0.46) 0.02 (0.00–1.55)
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FIGURE 18 Mean profile plots for CHAQ score by treatment group.
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TABLE 50 Treatment failures during the open-label phase
Participant
ID Site
Date of
randomisation
Date of treatment
failure
Time to failure
(days/months) Reason for treatment failure Further details
Patient unblinded at
time of treatment
failure (date)
Eye
failed
0116068 Bristol
Children’s
Hospital
5 June 2014 18 June 2015 378/12.42 Permitted concomitant medications
used against acceptable criteria
Continue follow-up Already in open-label
phase
Left
0116069 Bristol
Children’s
Hospital
5 June 2014 20 August 2015 441/14.49 Sustained scores as recorded at
entry grade measured over two
consecutive readings (grades 1
to 2), still present after 6 months
of therapy
Continue follow-up:
Base – (1+)
Previous = SYCAMORE
Treatment visit 7 – 15 months’
treatment (1+ on 30 July 2015)
Fail = SYCAMORE
Unscheduled visit – (1+ on
20 August 2015)
Already in open-label
phase
Right
0249091 Great Ormond
Street Hospital
27 March 2015 11 September 2015 168/5.52 Sustained scores as recorded at
entry grade measured over two
consecutive readings (grades 1
to 2), still present after 6 months
of therapy
Continue follow-up:
Base – (2+)
Previous = SYCAMORE
Treatment visit 3 – 3 months’
treatment (1+ on 19 June 2015)
Fail = SYCAMORE
Treatment visit 4 – 6 months’
treatment (2+ on
11 September 2015)
Already in open-label
phase
Left
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Appendix 4 Trial management team
A ll trial management was conducted by the CTRC, University of Liverpool, Liverpool, UK.
Senior statisticians
Professor Paula Williamson.
Dr Ashley P Jones.
Head of trial management
Ms Helen Hickey.
Senior data manager
Mrs Clare Jackson.
Information systems manager
Dr Duncan Appelbe.
Trial co-ordinator
Mr Ben Hardwick.
Statisticians, database developers and administration
Mrs Anna Rosala-Hallas.
Miss Naomi Rainford.
Dr Graeme Hickey.
Dr Ruwanthi Kolamunnage-Dona.
Miss Elizabeth Conroy.
Dr Kerry Dawn.
Mrs Michaela Brown.
Mr Meirion Thomas.
Mrs Janet Harrison.
Miss Catherine Forrest.
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